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Abstract	  
Atrial fibrillation (AF) is the commonest disorder of cardiac rhythm. Following coronary 
artery surgery approximately 1 in 3 patients will develop de novo post-operative AF (POAF) 
leading not only to prolonged hospital stay but also to increased morbidity and mortality. The 
pathophysiology of this arrhythmia is highly complex, and combines factors such as ion 
channel dysfunction, inflammation, oxidative stress, fibrosis and autonomic dysfunction that 
through electrical and structural remodelling promote both triggering and maintenance of this 
arrhythmia. For many years POAF has been regarded as a reactive phenomenon, occurring in 
response to post surgical inflammatory stressors and electrolyte imbalance. However, it is 
also possible that in a proportion of patients, prior cardiomyocyte remodelling predisposes to 
atrial arrhythmogenesis when exposed to surgical stress.   
 
Understanding the genomic and metabolic mechanisms that underlie this substrate may not 
only provide novel diagnostic biomarkers to identify at risk patients, but also isolate 
previously unrecognised therapeutic targets for prevention and treatment. In this work, a 
clinical observational study was utilised to obtain microRNA, gene expression and metabolic 
profiles of patients developing POAF after coronary artery bypass graft (CABG) surgery. 
Based on these results, a network of genomic and subsequent downstream pathway 
interactions was established to characterise the atrial substrate of post-operative AF.  
Furthermore, analysis of pre-operative blood was performed in order to identify novel 
microRNA that may provide a platform for biomarker development. Finally, the metabolic 
signature of the atrial myocardium and its relationship with the surrounding epicardial 
adipose were investigated to complete a comprehensive overview of the central mechanisms 
thought to underlie POAF pathogenesis. 
 
This work demonstrates that prior to surgery and the onset of arrhythmia, several distinct 
genomic and post-translational characteristics are evident in the both the myocardium and 
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circulating blood of patients going on to develop POAF. Analysis of right atrial biopsies 
highlights a characteristic microRNA profile associated with POAF, and identifies target 
genes regulating intracellular signalling pathways, leukocyte recruitment, and ion channel 
remodelling. Furthermore, selected gene expression analysis demonstrates a de-differentiated 
phenotype similar to that seen in chronic AF, whilst at the same time establishing that 
disordered cardiomyocyte calcium handling is apparent at the time of surgery. Finally, 
analysis of the pre-operative circulating blood serum highlights microRNA selectively 
upregulated in POAF and establishes the potential for future biomarker development. 
 
In summary, the results presented here support the presence of a pre-existing atrial substrate 
in POAF, suggesting the potential exists for high-risk patients to be identified prior to surgery 
and the onset of arrhythmia. Furthermore, for the first time a number of similarities have been 
made apparent between post-operative and chronic AF, implying a common mechanistic 
spectrum of structural and electrical remodelling. As a consequence, the results presented in 
this thesis have not only improved our understanding of the complex interplay of factors 
leading to the pathogenesis of AF, but also provide a platform for both the development of a 
unique clinical biomarker and the identification of novel therapeutic targets. 
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Chapter	  1	  
Introduction	  
	  
1.1	  Atrial	  Fibrillation:	  Definition	  
Atrial fibrillation is the commonest sustained disorder of cardiac rhythm.(1) It is characterised 
by fast, irregular and uncoordinated atrial depolarization and a loss of atrial mechanical 
function. Electrocardiography (ECG) typically demonstrates loss of ‘P’ waves with a 
fibrillatory baseline, and where atrioventricular conduction is intact there is an irregular, often 
fast, ventricular response (‘QRS’ depolarization). Clinically, AF may be asymptomatic, 
however acute paroxysms often present as palpitations and may be associated with dizziness, 
chest pain or even loss of consciousness in severe cases. Atrial fibrillation also leads to 
pooling and stasis of blood within the atria, which may subsequently lead to thrombo-
embolism and stroke and associated increases in morbidity and mortality.(2)   
 
1.2	  Classification	  	  
Atrial fibrillation may be classified into 3 subtypes according to its duration and pattern of 
recurrence. Atrial fibrillation is classified as ‘recurrent’ when 2 or more episodes have 
occurred. Recurrent AF self-terminating within 7 days is classified as ‘paroxysmal AF’, 
however the frequency and symptomatology of these paroxysms may be variable. Multiple 
paroxysms over a short time period may degenerate into persistent AF when episodes no 
longer self terminate. Persistent AF is defined as recurrent AF lasting for more than 7 days 
which does not self terminate but requires medical or electrical cardioversion to terminate 
within 1 year. Permanent established AF is reserved for those cases where AF remains for 
longer than 1 year and medical or chemical cardioversion have failed or are not attempted. 
Previously terminated AF that has relapsed may also be considered in this category. It is 
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notable that ‘permanent AF’ may be reversed in some cases whereby surgical or catheter 
ablation techniques are used to alter the conduction properties of the myocardium and restore 
sinus rhythm.(1) A summary of atrial fibrillation subtypes is shown in Table 1-1.(1, 3) 
 
Classification Definition 
Recurrent AF 2 or more episodes. Includes paroxysmal and persistent AF  
Paroxysmal AF 
2 or more episodes which are self-terminating and last less than 
7 days in duration 
Persistent AF 
Atrial fibrillation lasting more than 7 days but terminating 
within 1 year either spontaneously or by means of electrical or 
chemical cardioversion 
Permanent AF 
Atrial fibrillation lasting more than 1 year where electrical or 
chemical cardioversion have been unsuccessful or not 
attempted.  
 
Table 1-1: Classification of Atrial Fibrillation 
	  
1.3	  The	  Burden	  of	  Atrial	  Fibrillation	  
Based on 38-year follow up from the Framingham Heart Study, the lifetime risk of atrial 
fibrillation is estimated at 1 in 4 individuals.(4) In their 1998 study of 211 general practice 
(GP) surgeries (1.4 Million patients), Majeed et al. found a prevalence of AF of 12.1/1000 
men and 12.7/1000 women across England and Wales.(5) A further UK-wide assessment in 
1995 estimated the total number of patients living with AF to be approximately 534 000.(6) In 
the United States, results from the Framingham study identified 2.2 Million adults suffering 
from AF, with the prevalence doubling with every decade of age (Figure 1-1 (a)).(4) 
Furthermore, Atrial fibrillation was also more common in men than women, even when 
adjusting for AF risk factors and co-morbidities (Figure 1-1 (b)).  
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Figure 1-1: (a) Age related increase in prevalence of AF in men and women; (b) Sex related 
differences in AF with increasing age. Data from Framingham heart study database. Images taken from 
Kannel et al. 1998.(4) 
 
The global burden of AF is increasing, and it is likely that the current prevalence is now 
substantially higher than these figures taken from large historical epidemiological studies. In 
their aforementioned study, Majeed et al. were able to demonstrate an increase in AF 
prevalence of 22% between the start of their study in 1994 and its conclusion in 1998.(5) This 
echoes earlier findings from the US Framingham report whereby retrospective analysis of 
national hospital discharge survey data demonstrated an increase in the age-standardized 
prevalence of AF from 3.2% to 9.1% in men and 2.8% to 4.7% in women between 1968 and 
1989.(4) In 2006 NICE estimated that when applied to the 2006 national population, the work 
by Majeed et al would give an estimate of 639,000 cases of AF in England, resulting in a 
national prevalence rate of 1.28%.(7)  
 
The US retrospective Medicare Beneficiary Study gives a recent estimate of AF prevalence in 
433, 123 patients between 1993 and 2007. Whilst AF incidence was 1.94% and 7.3% in 1993 
in 66-69 year olds and 85-89 year olds respectively, this increased to 3.61 and 16.25% in 
2007 (Figure 1-2).(8) In Europe, one recent Spanish multicenter observational study of 1043 
patients >60 years suggested an overall prevalence of AF of 10.9%, 20.1% of which was 
undiagnosed.(9) Furthermore, 14% of patients 75-79 years of age suffered from the condition, 
increasing to 19.6% and 24.4% at 80-84 and ≥85 years respectively.  
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Figure 1-2: The point prevalence of AF with age demonstrating increases from 1993 to 2007. Data 
taken from the Medicare Beneficiary Study, Piccini et al. 2012. (8) 
 
A number of risk factors and co-morbidities pre-dispose to an increased risk of atrial 
fibrillation within the general population (Table 1-2). 
 
Table 1-2: Relative risk of factors contributing to the incidence of Atrial Fibrillation. LA – Left 
Atrium, LV – Left Ventricle, FS – Fractional Shortening. 
 
The most significant of these are Valvular heart disease, heart failure, acute coronary 
syndrome and hypertension.(4, 10) Studies have also indicated an association of chronic 
Risk Factor Relative Risk Odds Ratio 95% Confidence Interval 
Data taken from meta-analysis by Ball et al. 2013 (10) 
Hypertension 73% 1.73 1.31, 2.28 
Male sex 64% 1.64 1.45, 1.86 
Acute Coronary 
Syndrome 77% 1.77 1.44, 2.19 
Diabetes 44% 1.44 1.07, 1.94 
Hyperthyroidism 68% 1.68 1.29, 2.18 
Obesity (BMI≥30) 22% 1.22 1.14, 1.30 
Smoking  47% 1.47 1.22, 1.78 
Data taken from Kannel et al. 1998 (4) 
Heart Failure Men: 4.5x Women: 5.9x 
Valvular heart disease Men: 1.8x Women: 5.9x 
LA enlargement 39% per 5 mm increase in diameter 
LV fractional shortening 34% per 5% reduction in FS 
LV wall thickness 28% per 4 mm increase in thickness 
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conditions such as pulmonary disease, renal dysfunction, rheumatoid arthritis and coeliac 
disease with an increase in the incidence of AF. Furthermore, both obesity (BMI≥30) and 
sleep apnoea may also increase AF prevalence. Bearing in mind the emerging global 
epidemic of obesity and given that overall more than 10% of the world’s population are now 
obese,(11) it is possible that this association may contribute to rises in AF prevalence over 
forthcoming decades, particularly in younger age groups.  
 
1.3.1	  The	  economic	  cost	  of	  AF	  
In their economic analysis of atrial fibrillation in the general population, Stuart et al. estimate 
the "direct" cost of health care for patients suffering from AF to be £244 Million, which 
accounted for 0.62% of total NHS expenditure in 1995. Furthermore, due to the aging 
population and increasing prevalence of AF, they predicted an increase in this figure to £459 
Million by 2000, accounting for 0.97% of total NHS expenditure. In 2006 the National 
Institute for Clinical Excellence (NICE) produced a detailed cost analysis of for all AF across 
England based upon the number of cases of AF, the cost of diagnosis and treatment and 
taking into account savings made by avoidance of stroke due to therapeutic anticoagulation. 
(7)The total cost of fully implementing clinical guidelines on the diagnosis and management 
of AF was calculated at £21.86 Million per annum (table 1-3).  
 
Table 1-3: Total cost analysis of significant resource impact recommendations for Atrial Fibrillation in 
England (Taken from NICE CG036 costings report, 2006).(7) 
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The specific cost of post-operative AF (POAF) has been estimated to range from $2574 - 
$6356 per patient.(12, 13) As described in the above analysis of all cause AF this expenditure 
reflects increased resource utilisation in several areas but also includes increased hospital 
stay, use of ward and ITU consumables, nursing care, laboratory fees, imaging, 
pharmacotherapy and anaesthetic support.(13)  
 
1.4	  Atrial	  Fibrillation	  Pathophysiology	  
Atrial fibrillation is a multi-system disease with a complex underlying pathophysiology. 
Established AF requires a combination of triggering factors acting to initiate rhythm 
disturbance, and maintaining factors, which allow the arrhythmia to become sustained. 
Broadly there are two distinct concepts as to the propagation of electrical activity in atrial 
fibrillation: the single and multiple wavelet theories. The former suggests that atrial 
fibrillation involves a single macro re-entrant circuit that may originate from either a fixed or 
variable site of rapidly firing atrial myocardium. As this single re-entrant circuit propagates, it 
meets areas of refractory myocardium thus leading to fibrillatory contraction. The latter 
multiple wavelet theory describes AF as a number of irregular, dysynchonous re-entrant 
circuits which may either self propagate or initiate each other. As with the single wavelet 
theory, these circuits are disrupted by areas of refractoriness and conduction block within the 
myocardium producing fibrillatory contraction.(14-16) 
 
In their seminal 1998 work, Haissaguerre and colleagues mapped the site of electrical triggers 
for atrial fibrillation to predominate from the region of the left atrium surrounding the 
pulmonary veins.(17) However, it is also recognised that non-pulmonary vein triggers may 
initiate AF, including the autonomic ganglionic plexi and other regions of atrial myocardium 
exhibiting complex fractionated atrial electrograms.(18) Triggering of AF from within these 
regions relies on a number of factors that produce changes in the cellular properties of the 
myocardium enhancing excitability, increasing automaticity and reducing the refractory 
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period. Once initiated, maintenance of atrial fibrillation requires changes to the atrial substrate 
such that multiple re-entrant circuits may be set up. This atrial re-modelling may be a 
combination between electrical, mechanical and structural changes that vary in contribution 
according to the underlying cause and duration of AF. 
 
1.4.1	  Electrical	  Remodelling:	  ‘AF	  begets	  AF’	  
Once AF is established, tachycardia produces further atrial electrical remodelling 
perpetuating the maintenance of the arrhythmia. Increased inducibility of depolarization and 
shortening of the effective refractory period (ERP) leads to increased susceptibility to 
repeated depolarization. In this way ‘AF begets AF’ and progression from an initial triggering 
insult may result in sustained arrhythmia.(19, 20)  
 
A number of ion flux changes associated with electrical remodelling both in the triggering 
and maintenance of AF. These are summarised as follows: 
 
Calcium 
Changes in intracellular calcium handling play a role in both the initiation and maintenance of 
AF. The commonest cause of electrical triggering (focal ectopic discharge) is 
afterdepolarizations which may occur before (early) or subsequent to (late) full 
repolarization.(21) Early afterdepolarization occurs secondary to prolongation of the action 
potential duration and recovery of the L-type calcium current (ICaL) allowing Ca2+ influx into 
the cell. This then depolarizes surrounding myocardium leading to ectopic discharge. 
Conversely, late afterdepolarization and subsequent spontaneous action potential generation 
occurs due to a transient rise in intracellular Ca2+ generated by the sodium-calcium exchange 
current (NCX, figure 1-4) during diastole.(21)  
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Furthermore, calcium handling is also implicated in the maintenance of AF. Atrial stretch 
occurring secondary to impaired diastolic function increases intracellular Ca2+ via stimulation 
of stretch activated calcium channels, producing Ca2+ mediated Ca2+ release from the 
sarcoplasmic reticulum.(22) Animal models of AF utilising rapid atrial pacing demonstrate a 
reduction in transient outward (Ito) and L-type calcium currents (ICaL), with a subsequent 
shortening of action potential duration (APD). In studies of human atrial cardiomyocytes, this 
reduction in ICaL has been shown to be as much as 73% in chronic AF, with slowed ICa,L 
inactivation, decreasing Ca2+ influx during tachycardia.(23) This shortening of APD allows a 
larger number of re-entrant circuits to be set up and sustained, increasing the likelihood of 
fibrillatory contraction.  
 
Sodium 
Pacing induced tachycardia has been associated with a reduction in the sodium current (INa) in 
animal models. This slows conduction velocity and shortens the action potential duration in 
turn facilitating re-entry as previously described. Furthermore, patch clamp studies of isolated 
human right atrial myocytes demonstrate a shift in voltage-dependent inactivation of INa 
towards more positive potentials in chronic AF thus potentially increasing AP amplitude and 
facilitating its propagation.(23) However, despite these findings the role of INa in human atrial 
fibrillation remains uncertain. Recent evidence suggests that a loss of function mutation in the 
voltage gated sodium channel SCN5A may contribute to lone familial AF although the 
mechanism by which this occurs is yet to be determined.(24) 
 
Potassium  
Increases in the inward rectifying potassium current (IK1) have been demonstrated in patients 
with chronic AF when compared to those in sinus rhythm.(25-27) This results in heightened 
repolarization and thus reduces the ERP and prolongs the APD allowing for the setting up of 
re-entrant circuits. Changes in IKACh have also been associated with AF and may be in the 
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form of a protective down-regulation of IKACh in an attempt to balance other ion flux changes 
producing a reduction in ERP,(26) or as a primary cause of ERP shortening secondary to 
increased autonomic activity. In the latter instance, vagal stimulation releases Acetylcholine 
and activates the atrial ACh regulated potassium current leading to a reduction in the duration 
of phase 3 (repolarization) of the action potential and thus ERP shortening (Figure 1-4).(28) 
Finally, a reduction in the transient outward potassium current (Ito) is also demonstrated 
during AF electrical remodelling. This is thought to subsequently encourage AP propagation 
by increasing the amplitude of the action potential.(29)  
 
Defects in ion channels (or ‘channelopathies’) can therefore predispose to AF through the 
alteration of ion channel activation and atrial conduction properties. In familial AF, single 
nucleotide polymorphisms at the chromosome 4q25 locus (notably the rs2200733 and 
rs10033464 SNPs) have been associated with dysfunction of a number of ion channels 
including the IKs potassium channel (α-subunit encoded for by the KCNQ1 gene), the IKur 
potassium channel (encoded for by KCNA5) and the sodium INa channel (encoded for by 
SCN5A). These alterations in ion channel expression have been found to be mediated through 
the paired-like homeodomain transcription factor 2 (PITX2) gene located adjacent to the 4q25 
locus.(30) Furthermore, other genewide linkage studies have also demonstrated SNPs at the 
1q21 locus (rs13376333) affecting transcription of the KCNN3 gene encoding for the voltage-
independent calcium-activated channel. In addition to these SNPs affecting promoter regions 
of genes encoding the ion channels mentioned above, familial AF has been associated with a 
number of mutations directly affecting particular ion channel genes. These include missense 
mutations in the KCNJ2 (encoding the Kir2.1 protein forming the α–subunit of the IK1 
channel), KCNE 1-5 (encoding for the β-subunit of the IKs channel), and KCNH2 (encoding 
for the α-subunit of the cardiac IKr channel) genes as well as non-sense mutations in the 
KCNA5 gene.(31) 
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Figure 1-3: The cardiomyocyte action potential and ion flux changes associated with atrial 
fibrillation 
 
 
 
1.4.2	  Structural	  Re-­‐modelling	  
Macroscopically, loss of coordinated atrial contraction in AF impairs diastolic filling and 
reduces stroke volume leading to pooling of blood in the atria, increased atrial stretch and an 
enlargement in atrial dimensions. These changes stimulate the release of naturitic peptides, 
alter intracellular calcium handling, activate the renin-angiotensin system, and promote the 
release of inflammatory cytokines and proteins such as Endothelin-1 and heat shock proteins. 
On a cellular level, this gives rise to a number of changes globally termed ‘atrial structural 
remodeling’ which include: (1) loss of perinuclear sarcoplasmic contractile structures and 
their replacement with glycogen resulting in a gradual loss of contractile function; (ii) 
Interstitial fibrosis with an increase in extracellular matrix, fibroblasts and collagen 
deposition; (iii) de-differentiation of cells to a more fetal phenotype and (iv) cellular 
apoptosis.(22, 32) Furthermore, impairment of gap junction function may also result in 
localized conduction block thus promoting re-entry and fibrillatory contraction. 
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The renin-angiotensin system 
The renin-angiotensin (RAA) system may be activated in AF both by atrial stretch and 
secondary to atrial fibrosis. Interstitial fibrosis promotes atrial fibrillation by producing areas 
of conduction block that prevent action potential propagation and promote re-entry. Atrial 
stretch may foster fibrillation by several mechanisms, and has been shown to both directly 
activate the angiotensin receptor 1 (AT1R) and to promote transcription of genes encoding 
angiotensinogen and angiotensin converting enzyme (ACE) in turn increasing angiotensin-II 
(ATII) production.(22, 29) Through binding with the AT-1 receptor, AT-II may stimulate 
fibrosis and cellular apoptosis via the Ras signaling cascade, as well as promoting 
intracellular calcium release by activating protein kinase C (via inositol 1,4,5-trisphosphate 
(IP3)).(29) 
 
Angiotensin II also activates membrane associated protein kinases (MAPKs), which 
consequently stimulate the production of pro-fibrotic mediators such as TGF-β, and 
connective tissue derived growth factor (CTGF) via signaling pathways involving tumor 
necrosis factor receptor associated factor 6 (TRAF6) and TGF-β-associated kinase 1 
(TAK1).(33) Furthermore, TGF-β itself activates angiotensin II producing a positive feedback 
mechanism leading to fibrosis, collagen deposition, and the production of extracellular 
proteins including fibronectin, and proteoglycans.(34)  
 
Atrial overload and Platelet Derived Growth Factor (PDGF) 
Atrial fibrillation is associated with a pro-inflammatory state as demonstrated by histological 
evidence of inflammatory cell infiltrate and the prevention of atrial structural remodeling in 
mast cell deficient C57BL/6 mice.(35, 36) Recently, Liao et al. have highlighted the link 
between mast cell activity and upregulation of platelet derived growth factor-A (PDGF-A), 
demonstrating abolition of atrial fibrosis with antibody blockade of the PDGF receptor 
PDGFR-α. PDGF itself promotes atrial fibrosis by stimulating tyrosine kinase receptors 
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which themselves autophosphorylate, initiating several intracellular signaling cascades 
including the MAPK and phospholipase C pathways. PDGF then exerts both autocrine and 
paracrine effects on a number of other growth factors and cytokines to promote fibroblast 
proliferation and extracellular matrix protein deposition as described above. Interestingly, 
DNA microarray and subsequent qPCR validation experiments have demonstrated significant 
increases in PDGF and PDGFR-α expression in canine atria when compared ventricular 
myocardium, suggesting that PDGF may play a role in the atrial specificity of fibrosis in 
AF.(37)  
 
Gap junctions and Connexins 
Connexins are transmembrane gap junction proteins that regulate cell-cell communication, 
forming low resistance pores that allow transmission of small molecules or ions from one cell 
to the next. Gap junctions form the key mechanism by which action potentials may be 
conducted between cardiomyocytes and disruption of these tightly regulated channels may 
produce conduction block, variable refractoriness and potentiate arrhythmogenesis.(38) 
Whilst there are 3 connexins present in atrial cardiomyocytes, Cx40, Cx43 and Cx45, it is 
Cx40 and Cx43 that have been identified to play a role in the pathophysiology of AF. 
Increased expression of these two connexins (Cx40 and Cx43), has been shown to reduce 
susceptibility to atrial fibrillation in animal models, however whether this is predominantly 
due to increased refractoriness or slowed cell-cell conduction remains to be determined.(39, 
40)  
 
Connexins also play a fundamental role in the unique anisotropic conduction properties of 
cardiac myocytes. A shift in the localization of these proteins from the intercalated disc to the 
lateral cell membrane may result in a reduction in anisotropic conduction. Indeed, analysis of 
atrial tissue biopsies from chronic AF patients has demonstrated lateralization of Cx43, 
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without changes in the absolute number of Cx43 proteins, is associated with an increase in 
action potential propagation velocity transverse to the myocyte fibers.(41)  
 
The function of connexins may also be regulated by phosphorylation of their cytoplasmic C-
terminal domains, with connexin activity being increased in the phosphorylated state.(42) 
Hypophyosphorylation of connexin 43 has been associated with chronic AF in both animal 
models and human patients, and increased phosphorylation of connexin 40 has been 
demonstrated in the right atrial appendage of mitral valve disease patients with chronic 
AF.(41, 43) It has also been recognized that AF associated increases in oxidative stress and 
inflammation play a part in the mechanism of this re-distribution of connexins by reducing 
microtubule trafficking of connexins to the intercalated discs.(44)  
 
In summary, variation in the number, localization and phosphorylation state of connexins may 
all contribute to the creation of a susceptible substrate in which AF may be set up and 
maintained. However, the exact interplay between these factors in different subgroups of 
human AF remains unclear and is the subject of extensive ongoing research. 
 
1.4.3	  Inflammation	  	  
Atrial fibrillation has been associated with a generalized pro-inflammatory state, however 
whether this inflammatory environment is produced as a consequence of or predisposes to AF 
continues to remain a subject of debate. Inflammatory mediators implicated in AF 
pathogenesis include the interleukins- 1, 2, 6, and 8 (IL-1, IL-2, IL-6 and IL-8), tumour 
necrosis factor-α (TNF-α), C-reactive protein (CRP), heat shock proteins, and matrix 
metalloproteinases.  
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Interleukins 
Interleukin-1 is the most recent of the IL family to be implicated in AF pathogenesis and 
consists of a group of 11 cytokines that have a range of pro- and anti-inflammatory properties. 
Interleukin-1 receptor antagonist (IL-1RN) is a pro-inflammatory gene located at the IL-1 
locus that has recently been implicated in lone AF. In their prospective study of 140 patients 
(70 lone AF, 70 non-AF), Gungor et al. demonstrated a significantly higher frequency of the 
allele 2 VNTR (variable number of the tandem repeat) polymorphism of IL-1RN in lone AF 
when compared to controls. Furthermore, the presence of this allele 2 polymorphism was 
found along with elevations in CRP to be an independent predictor of lone atrial fibrillation in 
multivariate regression analysis.(45) 
 
Interleukin-2 is a pro-inflammatory cytokine whose primary role is in T-cell growth and 
development. High admission serum levels of IL-2 have been shown to correlate with failure 
of medical conversion (amiodarone) in new onset AF, highlighting a role of acute 
inflammation in AF maintenance.(46) Furthermore, IL-2 has also been implicated in the 
pathogenesis of post-operative atrial fibrillation (POAF). Increased levels of Interleukin-2 
have been demonstrated pre- and at 3 hours after coronary artery bypass grafting in patients 
developing early de novo POAF when compared to those who maintain sinus rhythm. 
However, this did not remain true for those patients developing POAF between 2 and 5 days 
after surgery.(47) 
 
Interleukin-6 is an acute phase cytokine with both pro- and anti-inflammatory properties. 
Increased levels of IL-6 have been associated with both chronic and post-operative AF.(48-
51) Furthermore, high IL-6 levels may predict a worse prognosis and increased risk of 
adverse cardiovascular events in anticoagulated patients with chronic AF.(52) Increased 
levels of IL-6 at 6 months follow up were also associated with recurrence of AF in patients 
receiving valsartan pharmacotherapy in one prospective, multicentre randomised controlled 
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trial of 382 patients, although no association was found between pre-treatment IL-6 levels and 
the risk of AF recurrence.(53) Genewide association studies have demonstrated several single 
nucleotide polymorphisms in the IL-6 receptor gene that are associated with AF. Recently, 
the IL-6 -634C/G polymorphism has also been correlated with AF in a hypertensive Han 
Chinese population.(54)  
 
Interleukin-8 is a pro-inflammatory cytokine produced by macrophages, monocytes, 
endothelial cells and fibroblasts that predominantly acts to induce neutrophil chemotaxis and 
promote subsequent phagocytosis. In their study of 113 patients undergoing CABG, Wu and 
colleagues found significantly higher levels of IL-8 on post operative days 1 and 2 in patients 
developing POAF compared to those who did not. Interestingly, this group did not 
demonstrate significant differences in IL-6 between POAF and non-POAF patients.(55) 
Conversely however, Ishida et al. did not demonstrate any difference in IL-8 levels between 
patients developing POAF after off pump surgery compared to those maintaining sinus 
rhythm, whereas IL-6 levels at 3 and 6 hours were significantly higher in the POAF 
group.(56) Increased IL-8 levels have also been demonstrated in chronic AF when compared 
to controls. Furthermore, in their study of 29 patients undergoing radiofrequency catheter 
ablation, Liuba et al suggested plasma IL-8 levels were also higher in patients with permanent 
AF when compared to paroxysmal AF when taken from sites including the femoral vein, right 
atrium, and coronary sinus.(57) 
 
Tumour Necrosis Factor-α 
Tumor necrosis factor-α is a multifunctional pro-inflammatory cytokine secreted by 
macrophages, monocytes, natural killer and T-cells in response to stimulation by bacterial 
lipopolysaccharide. By acting on 2 receptors, TNFR1 and TNFR2, TNF- α activates a number 
of signaling cascades involved in inflammation, cell proliferation and apoptosis.(58) In their 
study of 67 patients undergoing cardiac surgery, Deng et al observed a significant increase in 
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TNF-αin the blood plasma and left atrial tissue of patients with chronic atrial fibrillation 
compared to those in sinus rhythm. Furthermore, the levels of soluble TNFR1 were also 
significantly higher in AF vs. non-AF patients.(59) In a mixed cohort of permanent, persistent 
and paroxysmal AF, Cheng et al. similarly demonstrated a rise in TNF-α in AF vs. non-AF 
and found TNF-α to be an independent predictor of AF multivariate analysis (OR 1.80; 95% 
CI, 1.03-3.20).(60) It is thought that TNF-α may increase susceptibility to AF by producing 
structural remodeling and atrial fibrosis. In a recent mouse model, systemic TNF-α infusion 
produced significantly more atrial fibrotic changes when compared to control animals, with a 
corresponding reduction in connexin 40 and borderline decrease in connexin 43 expression. 
Furthermore, TNF-α infusion produced up regulation of Smad3 suggesting involvement of 
the TGF-β/Smad signaling pathway which stimulates fibroblast proliferation and collagen 
deposition.(61) 
 
C-Reactive Protein 
A number of studies have correlated increased levels of CRP with an increase in the risk of 
both all cause and post-operative atrial fibrillation. However, two recent large population 
studies using a Mendelian randomization design have questioned the causative nature of this 
relationship. The Copenhagen General Population Study (CGPS) began in 2003 and is a 
cross-sectional study including a total of 36 000 individuals. In their 2010 analysis of this 
dataset, Marott et al. examined the potential causal association between elevated CRP levels 
and increased risk of AF by examining whether CRP genotype combinations correlated with 
increased atrial fibrillation risk in line with their long-term elevated plasma CRP levels.(62) 
Increased high sensitivity C-reactive protein (hsCRP) was associated with a significant 
increase in unadjusted AF (p<0.001) as well as AF after multifactorial adjustment for age, 
gender, statin use and genotype. Further adjustment for heart failure and fibrinogen reduced 
the risk of AF however this remained significant (p=0.02 and 0.03 respectively). However, 
CRP genotypes/polymorphisms known correlate with life-long increases (rs1130864 and 
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rs3091244) and decreases (rs3093077) in CRP levels did not correlate with a respective 
increased or decreased risk of AF. Furthermore, these observations were echoed in a similar 
study by Alegret et al. (n=375 controls, 249 AF) where increases in plasma CRP were found 
in patients with permanent AF when compared to controls but no difference in distribution of 
genotypes associated with elevated CRP was seen between AF and non-AF groups.(63) 
Interestingly, this study did not demonstrate a difference in plasma CRP between paroxysmal 
AF and controls and plasma CRP was not an independent predictor of AF in their risk 
adjusted multivariate model.(63)  
 
1.4.4	  Oxidative	  Stress	  
The potential role of oxidative stress in the initiation and maintenance of AF is becoming 
increasingly recognised. Not only has AF been associated with a shift in gene expression, 
promoting genes coding for reactive oxygen species (ROS),(64) but peroxynitrite and 
hydroxyl radicals have been identified in the atrial appendages of patients with chronic 
AF.(65) In their canine model of AF, Carnes and colleagues go on to link this oxidative stress 
to electrical atrial remodelling. Using rapid in vivo pacing of canine atria they observed an 
increase in markers of peroxinitrite and a reduction in effective refractory period (ERP).(66) 
 
Although the mechanisms by which ROS affect electrophysiological remodelling remain 
unclear, several factors are likely to contribute to this process. Firstly, ROS may cause 
modulation of intracellular Ca2+, resulting in cytosolic Ca2+ overload, a reduction in the L- 
type calcium current (ICa), and alterations in excitation-contraction coupling. In an initial 
attempt to counteract this Ca2+ overload, a compensatory reduction in action potential 
duration (APD) and ERP is observed, promoting re-entry and development of 
tachyarrhythmia.(67) Secondly, post- translational modifications caused by peroxynitrite and 
hydroxyl radicals may generate both structural and functional changes in myofibrillar 
proteins, potentiating arrhythmogenesis by impairment of myofibrillar contractile 
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function.(65) In particular, irreversible peroxynitrite- induced inhibition and nitration of 
monomeric myofibrillar creatinine kinase (MM-CK) may reduce the supply of high energy 
phosphate to myosin ATPase, negatively affecting myofibrillar contractile function.(68)  
Finally, oxidative stress may lead to a derangement in ion channel regulatory mechanisms in 
turn leading to the generation and perpetuation of AF. ROS may both accelerate the activation 
kinetics and reduce the inactivation of voltage gated K+ channels, resulting in a reduction in 
APD and ERP and promoting re-entry.(69) Furthermore, oxidative stress may enhance slow 
inactivating Na+ current (INa) and slow inactivation of voltage gated Na+ channels,(70, 71) 
promoting diastolic depolarisation, action potential generation and arrhythmogenesis. 
 
As mounting evidence for the role of oxidative stress in AF pathogenesis has become 
apparent, antioxidant vitamins have been explored as both preventative and therapeutic 
agents. Vitamins C and E are chain- breaking antioxidants that act on water- and lipid- 
soluble zones respectively, to scavenge free radicals and terminate the propagation of free 
radical reactions. Their differing solubility not only enables synergistic ROS scavenging but 
also regeneration of vitamin E by vitamin C at the lipid-water interface.(72, 73)  Carnes and 
colleagues demonstrated a reduction in atrial tissue levels of vitamin C reflecting increased 
consumption following rapid atrial pacing. Moreover, exogenous administration of vitamin C 
both attenuated this pacing induced reduction in ERP and blunted the production of 
peroxynitrite.(66) Aside from this ROS scavenging, several other mechanisms exist by which 
vitamins C and E reduce oxidative stress, including down-regulation of NAD(P)H oxidase 
and up-regulation of endothelial nitric oxide synthease. This results in a reduction in 
superoxide formation and increase in nitric oxide (NO) generation, and in turn has beneficial 
effects on both endothelial cell function and vascular tone regulation.(72) 
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1.5	  Post-­‐operative	  Atrial	  Fibrillation	  
Post-operative Atrial fibrillation (AF) affects approximately 30-60% of patients undergoing 
cardiac surgery despite no prior history of this arrhythmia.(74, 75) With appropriate medical 
therapy POAF is often self- limiting, however it is associated with significant post- operative 
morbidity and mortality, resulting in triple the risk of cardiac related death and quadruple the 
risk of disabling embolic events.(74) Recent evidence also demonstrates a significantly worse 
long- term survival in patients developing POAF following both valvular and coronary 
surgery,(76, 77) with a 10- year mortality up to 48% higher in patients developing POAF 
compared to those that do not.(78) In addition, POAF results in a significantly longer 
intensive care unit (ITU) and hospital stay, an increase in resource utilisation, and an increase 
in the financial cost of healthcare.(79-81) 
 
Post- operative AF is thought to result from a number of ‘triggering’ and ‘sustaining’ factors 
acting on a pre-existing pro-arrhythmogenic substrate. However, the balance of these factors 
differs from chronic atrial fibrillation with acute changes such as local and systemic 
inflammation, oxidative stress and autonomic stimulation being relatively more influential in 
the pathophysiology of post operative AF.  
 
The role of inflammation 
As previously discussed, the surge of inflammatory cytokines produced intraoperatively and 
in the immediate post operative period undoubtedly plays a role in AF pathogenesis and is 
likely to act as a key triggering factor particularly in the early post-operative days. 
Intraoperatively, contact of blood with the bypass circuit results in activation of the 
alternative complement pathway and release of TNF-alpha.(82)  
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The role of oxidative stress 
Several mechanisms of reactive oxygen species (ROS) generation within the atrial myocyte 
have been described.(65, 79, 83) Whilst a number of cellular mechanisms protect against 
oxidant damage in normal myocardium, persistent oxidative stress depletes endogenous 
antioxidants and ultimately results in oxidative damage. Ischaemia-reperfusion injury 
following coronary surgery, aortic cross clamping and cardiopulmonary bypass stimulate the 
production of nitrogen and oxygen free radicals including superoxide, peroxynitrite, hydroxyl 
and hydrogen peroxide and result in depletion of endogenous antioxidants such as 
glutathione.(79) Furthermore, oxidative damage, as demonstrated by the presence of 
glutathione disulphide, may be seen for up to 24 hours following aortic cross clamp 
removal.(79)  
 
Management and preventative strategies for post operative AF 
Guidelines currently exist in both Europe and the United States regarding the 
pharmacological prophylaxis and management of POAF following cardiac surgery.(84, 85) 
At present β blockers are recommended as first line pharmacotherapy (84, 85) with sotalol 
and amiodarone used as alternative agents.(84) However, these pharmacological therapies are 
subject to a number of limitations including treatment failure, toxicity and pro- 
arrhythmogenicity. Significant effort has therefore been placed in the development of 
alternative preventative strategies, and the identification of oxidative stress as a mechanism 
for AF development has made way for antioxidant vitamins as novel therapeutic agents. 
Vitamins C and E are chain breaking antioxidants which scavenge free radicals and terminate 
the propagation of free radical reactions.(73) Vitamin E is pivotal to maintenance of 
membrane stability, acting to prevent lipid peroxidation, whereas Vitamin C both 
independently scavenges water soluble free radicals and acts synergistically with Vitamin E, 
reducing vitamin E radicals and allowing its regeneration.(73) 
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1.6	  Thesis	  Aims	  	  
 
The aim of this thesis is to determine whether de novo post-operative atrial fibrillation 
(POAF) is associated with changes in the metabolic and microRNA profiles of patients 
undergoing coronary artery bypass grafting (CABG). 
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Chapter	  2	  
MicroRNA:	  A	  novel	  biomarker	  for	  post-­‐operative	  atrial	  
fibrillation	  
 
2.1	  Background	  
2.1.1	  The	  role	  of	  microRNA	  
First discovered in C. Elegans and published in 1993 by Victor Ambros, Rosalind Lee and 
Rhonda Feinbaum,(86) microRNA are small non-coding RNA molecules approximately 19 to 
25 nucleotides in length acting to supress their target mRNA by inhibiting its translation or 
promoting its degradation. They may therefore be considered as post-transcriptional 
regulators of mRNA expression. The miRBASE database (Release 21) currently lists a total 
of 35828 mature miRNA products in 223 species, with 2588 mature sequence human 
microRNAs. Each of these mature sequence miRNAs may in turn have several hundred 
potential mRNA targets.(87-89) 
 
In addition to miRNA found in cell and tissue lysates, these small non-coding RNAs have 
also been identified in a number of biofluids including blood serum, plasma, urine, saliva, 
semen and cerebrospinal fluid.(90-93) These circulating miRNA are most commonly derived 
from platelets, mononuclear phagocytes and endothelial cells, although low levels of tissue 
specific miRNA detected in biofluids has lead to the suggestion that miRNA can also be 
actively secreted into the plasma and may even play a role in exerting paracrine effects on 
distant targets. Furthermore, miRNA may be released in the circulation by dead or dying 
cells, either contained within apoptotic bodies or as free miRNA.(94, 95) Both apoptotic 
bodies and microvesicles enhance the stability of miRNA in the peripheral blood by 
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providing resistance to endogenous RNases. Moreover, under strict regulation microvesicles 
may act to specifically deliver miRNA to their target cells contributing to a potential 
paracrine function.(94) Free circulating miRNA identified outside microvesicles are thought 
to be shed into the circulation by apoptotic or necrotic cells. Although such free miRNA 
would be expected to be relatively unstable and undergo degradation by endogenous RNases, 
by binding to the component of the RISC complex, Argonaute 2 protein (Ago2), free miRNA 
also resist degradation and have been shown to be stable in call lysate for at least 2 
months.(95)  
 
Although these results suggest the potential for circulating miRNA to exert paracrine effects 
on target cells, the exact regulatory role played by these miRNA remains unclear. The low 
concentration of paracellular miRNA detectable in human plasma and other biofluids argues 
against a substantial paracrine function particularly given the one to one nature of microRNA-
mRNA interaction which would require high levels of intracellular microRNA (>1000 
copies/cell) in order to produce significant paracrine effects on their target.(96) Furthermore, 
common miRNA expression between blood cells and the organ/disease of interest may lead to 
difficulty in interpreting the significance of circulating miRNA particularly in the context of 
biomarker discovery.(97) 
 
2.1.2	  MicroRNA	  Biosynthesis	  
MicroRNA biosynthesis can broadly be described to follow one of two routes, the 
‘Canonical’ pathway, describing the synthesis of miRNA transcribed by non-coding regions 
of the genome; and the ‘intronic’ or ‘mirtronic’ pathway, describing the synthesis of miRNA 
coded for within the introns of their host genes.  
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The Canonical pathway 
MicroRNA biosynthesis begins in the nucleus with transcription of the primary miRNA 
transcript (or pri-miRNA) by either RNA polymerase II (the most common) or RNA 
polymerase III (where the miRNA is associated with Alu repeats). The pri-miRNA is a 
hairpin structure, made up of a terminal loop attached to a stem region of approximately 33 
base pairs with 2 single stranded flanking regions at each end (Figure 2-1). This pri-miRNA 
is cleaved by the microprocessor RNase III enzyme complex of Drosha (RNASEN) and 
Pasha (DGCR8 or DiGeorge critical region 8), to form pre-miRNA,(98) a precursor hairpin 
structure that can subsequently be exported from the nucleus by the Exportin-5-Ran-GTP 
complex. Once in the cytoplasm, the pre-miRNA is bound by a group of proteins including 
Dicer RNase, Tar RNA binding protein (TRBT), protein activator of PKR (PACT) and 
Argonaute 2 protein (Ago2), which form the RISC loading complex and later facilitate 
binding to RISC. During binding of the RISC loading complex, the pre-miRNA hairpin is 
cleaved by Dicer to form a double stranded miRNA duplex. This duplex contains both a 
functional strand, which acts to guide the RISC (RNA silencing complex) to its 
complementary mRNA target, and an antisense passenger strand (denoted by * in RNA 
nomenclature), which is then degraded. It is thought that the unwinding of the duplex and 
degradation of the passenger strand is mediated by either a specific helicase or helicase 
complex associated with RISC formation, or by the Ago2 protein associated with the RISC 
complex, which may itself promote cleavage of the passenger strand.(98) The guide strand 
itself is though to be selected due to a difference in thermodynamic stability of the base pairs 
at the 5’ end of the helix. The guide strand exhibits less stable base pairing at the 5’ end.(99) 
The final step of the canonical pathway is the binding of the functional strand to the RISC 
complex which may then in turn regulate the target mRNA. This functions to guide the RISC 
complex to its target by imperfect base pairing within the 5-8 nucleotide ‘seed’ region at the 
5’ end of the strand. The target RNA is then inhibited, either by destabilization of the mRNA-
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target interaction, cleavage and degradation of the mRNA strand or by deadenylation and 
translational inhibition.   
 
 
Figure 2-1. The canonical pathway of miRNA biosynthesis 
 
Non-canonical (intronic) miRNA synthesis 
Although the majority of human miRNA genes are found in non-coding regions of the 
genome, approximately 37% of miRNA are ‘intronic’ coded for within the introns of pre-
mRNA.(100) Such miRNA are regulated by the same promoter regions as their corresponding 
protein coding genes and are therefore often co-expressed. Under the regulation of the 
promoter region of the associated gene, intronic pri-miRNA is transcribed in the cell nucleus 
by RNA polymerase II. In the majority of instances, intron splicing then occurs, mediated by 
the splicosome, which excises the pri-miRNA from its associated exons and simultaneously 
releases the spliced continuous exon product. The resultant pri-miRNA then enters the same 
canonical pathway as described above, following the same processing steps to form mature 
miRNA which may then go on to regulate mRNA translation (Figure 1-6).(101) Interestingly, 
there is also evidence to suggest that splicing of the pri-miRNA from its attached exons is not 
always necessary for Drosha processing of intronic miRNA to take place. In fact, it seems 
that drosha-DGCR8 may cleave the pri-miRNA directly from the unspliced intron to form 
pre-miRNA and its flanking exons connected by a discontinuous intron. The 5’ and 3’ splice 
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sites on the resultant mRNA are linked by a group of proteins known as the ‘splicing 
commitment complex’ which tethers together the exons allowing for accurate splicing by the 
splicosome even after cleavage of the pri-miRNA. In this way the total mRNA product is not 
affected, even if Drosha cleavage occurs prior to splicing.(102)  
 
 
Figure 2-2. The non-canonical ‘intronic’ pathway of miRNA biosynthesis 
 
MicroRNA clustering 
A number of microRNA genes may exist on close proximity within a single chromosome 
forming a functional ‘cluster’ that may share the same promoter resulting in a polycistronic 
pri-miRNA transcript.(103) These clusters may also be highly conserved between species, 
suggesting evolutionary significance.(104) Although the exact functional implications of 
miRNA clusters is unknown, is thought that the common transcription of these miRNA may 
improve the efficiency of complex cell signalling and have a role in coordinated expression of 
multiple related miRNAs targeting a common pathway.(103, 105) It is therefore important to 
consider functional miRNA clustering when determining the miRNA signature of any given 
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disease process and to determine whether in fact a polycistronic cluster rather than a single 
miRNA may be regulating pathogenesis.  
 
MicroRNA Nomenclature 
The microRNA naming system follows a specific nomenclature allowing the reader to 
distinguish between pre-miRNA, mature miRNA and its subtypes and miRNA originating 
from different species. A summary of the miRNA nomenclature is shown in Table 1-2. 
 
 
 
MiRNA Type Nomenclature Example 
Pre-miRNA 
− Two pre-miRNA at different 
distinct genomic loci leading to 
identical mature miRNA 
Prefix ‘mir’ – number of miRNA mir-223 
Mature miRNA 
 
− Two miRNA with nearly identical 
sequences 
Prefix ‘miR’ – number of 
miRNA 
 
Denoted by lowercase letter after 
number 
miR-223 
 
miR-208a 
 
− Two miRNAs originating from 
opposite arms of the same pre-
miRNA  (known relative 
expression) 
The principal miRNA is written 
as above, the lesser miRNA is 
marked with an asterisk 
miR-24-1 
miR-24-1* 
 
− Two miRNAs originating from 
opposite arms of the same pre-
miRNA (unknown relative 
expression) 
The suffixes ‘5p’ and ‘3p’ are 
used to denote the miRNA 
derived from the 5’ and 3’ ends 
respectively 
miR-483-3p 
miR-483-5p 
 
Species subtypes 
 
The organism species is denoted 
by a three letter prefix 
hsa-miR-223 
(homo-
sapiens) 
*The numbering of miR is sequential in accordance with their discovery. Before designation 
the new gene must be verified by cloning or with evidence of expression and processing. 
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2.1.3	  MicroRNA	  Target	  Interactions	  
The microRNA-mRNA interaction is mediated by a 6-8 nucleotide ‘seed’ region located at 
the 5’ end of the mRNA, and stabilized by several nucleotides outside the seed region also 
binding in a complementary fashion.(86) In plants microRNA usually bind with complete 
complementarity to their target mRNA resulting in degradation, however, in eukaryotic cells 
microRNA-mRNA pairing exhibits partial complementarity in approximately 60% of 
interactions, resulting in bulging or mismatching of nucleotides.(87) 
 
The aforementioned description of miRNA-mRNA interaction may be described as following 
the conventional canonical rules. More recently however, miRNA binding has been shown to 
be increasingly complex, with evidence to suggest binding at the 3’ end with little interaction 
in the 5’ region in up to 18% of pairings.(87) 
 
2.1.4	  The	  role	  of	  microRNA	  in	  Post	  Operative	  Atrial	  Fibrillation	  
A number of miRNAs have been implicated in cardiovascular disease, particularly in cardiac 
hypertrophy (miR-23, miR-208a, miR-133), myocardial ischaemia (miR-214),(106) and 
fibrosis (miR-133).(107) The role of miRNA in arrhythmogenesis is now also becoming 
increasingly apparent, with miRNA targets regulating the energy substrate, structural and 
electrical make-up of the myocardium. MiRNA associated with regulation of cardiomyocyte 
metabolism (miR-208a and miR-223) are likely to regulate the provision of energy substrate 
required to maintain AF,(108-110) whereas miR-328, miR-1, and miR-26 are thought to play 
a central role in electrical remodelling, modulating calcium and potassium currents 
respectively. Likewise, miR-133, miR-590, miR-29b, miR-208, miR-638, have been shown to 
regulate structural changes such as myocardial fibrosis which may promote 
arrhythmogenicity (figure 2-3).(111) 
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Figure 2-3.   Potential roles of microRNA in the regulation of post-operative atrial fibrillation 
	  
2.1.5	  Aims	  
In light of the ever-increasing evidence supporting a role for microRNA in the regulation of 
cardiac arrhythmogenesis, this study aims to:  
1. Ascertain whether microRNA regulation is altered in the atrial tissue of AF naive 
patients developing de novo post-operative AF.    
2. Identify whether post-operative atrial fibrillation is associated with any changes in 
circulating or urinary microRNA expression.  
3. Determine whether any changes in microRNA expression may be detected pre-
operatively and subsequently hold potential to act as a biomarker in post-operative 
AF. 
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2.2.	  Clinical	  Methods	  
2.2.1.	  Regional	  Ethics	  approval	  
The study was approved by the local and regional research ethics committee on 07/05/2009 
(Ref: 09/H0711/23). Following this, substantive amendments were approved to allow for 
intraoperative recording of atrial electrograms, assessment of susceptibility to AF on 
epicardial stimulation (08/10/2010) and the additional intra-operative sampling of epicardial 
adipose tissue (09/11/2010). 
 
2.2.2.	  Study	  Population,	  Inclusion	  and	  Exclusion	  Criteria	  
Between November 2010 and September 2011 thirty-four patients undergoing non-emergent, 
on-pump coronary artery bypass grafting (CABG) at The Hammersmith Hospital, Imperial 
College NHS Trust, were prospectively selected to participate in this study. All patients 
fulfilling these inclusion criteria were approached on arrival for pre-operative assessment. 
Patients were given a full written information pack and allowed a minimum of 24 hours to 
reach a decision regarding participation in the study. Informed consent was obtained on 
arrival the day before surgery. At this time a full medical history and examination was carried 
out and patients were again screened against study exclusion criteria.  
 
Inclusion and Exclusion Criteria 
Emergency cases, those requiring adjunctive procedures (e.g. valve repair or replacement), 
patients with a prior history of atrial or ventricular arrhythmia, thyroid disease, patients taking 
anti-arrhythmic agents, or those undergoing surgery with mini-cardiopulmonary bypass 
(CPB) systems were excluded.  
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2.2.3.	  Power	  Calculation	  
It is not possible to calculate a required sample size using traditional methods, as there are no 
studies currently describing the microRNA profile of post-operative AF. Similarly, only one 
study currently exists reporting the metabolic profile of post-operative AF. Therefore, our 
sample size calculations are based on the prevalence of POAF and the number of on-pump, 
elective CABG cases performed annually at Hammersmith Hospital. With an annual 
prevalence of 18% POAF and a total of 470 consecutive cases per year this equates to 85 
cases. Therefore, the final study sample size will be 160 patients (85+85). Following this 
initial calculation, a pilot study of the first 24 patients will be performed in order to estimate 
the effect size and thus determine the sample size required to adequately power the remainder 
of the study. 
2.2.4.	  Patient	  Groups	  
Patients were grouped retrospectively (on discharge following Holter analysis) according to 
the absence (Group 1) or presence (Group 2) of AF during the post-operative period.  
 
 
Table 2-2. Patient grouping and sampling protocol 
 
2.2.5.	  Assessment	  of	  Cardiac	  Rhythm	  
In accordance with recommendations made by the Heart Rhythm Society,(112) all patients 
underwent continuous Holter (Novocor Vista 5 lead system, 2 channel recording) monitoring 
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from the time of admission to the time of surgery (12-24hrs). Post-operatively, all episodes of 
AF, atrial flutter, or tachycardia of at least 30 seconds duration were documented. Only Atrial 
Fibrillation episodes >30s were categorized as AF positive (group 2) and patients were 
grouped as in Table 2-2.  
 
2.2.6.	  Sample	  collection	  protocol	  
All patients were subjected to a uniform sampling protocol as outlined in Table 2-2.  
 
Blood Samples 
10mls of whole blood was taken into venous blood collection vacutainers (BDTM) and at the 
following timepoints: (i) Pre-operatively on arrival in hospital, (ii) Intra-operatively at the 
point of discontinuation of cardiopulmonary bypass (fully re-warmed), (iii) Post-operative 
day 2, (iv) Post-operative day 4.  Blood samples were immediately taken to the laboratory and 
serum and plasma obtained from whole blood.  
Serum: Whole blood collected into clot activator, silicon coated vacutainers (BDTM) was left 
to clot for 30 minutes at room temperature. Samples were then centrifuged for 8 minutes at 
4500g to separate serum. The supernatant (serum) was removed under Class II conditions and 
aliquoted into three cryovials. These were stored at -80oC until use.  
Plasma: Whole blood collected into lithium heparin vacutainers (BDTM) and immediately 
taken to the laboratory where it was centrifuged for 8 minutes at 4500g to separate plasma. 
The supernatant (plasma) was removed and stored as above. 
 
Urine 
Mid-stream (MSU) or catheter urine samples were taken: (i) Pre-operatively, (ii) Intra-
operatively (CSU), (iii) Day 2 (MSU or CSU), and (iv) Day 4 (MSU) 
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Note: Catheter samples were obtained from tubing rather than bag to ensure sterility and 
timing of sample.  
 
Atrial tissue biopsy: Atrial samples were obtained prior to cardiopulmonary bypass at the 
point of insertion of the right atrial cannula on the free wall of the right atrium (Figure 2-4). 
Immediately following sampling biopsy specimens were divided into 4 and snap frozen in 
liquid nitrogen (-196 degrees Celsius). These were then stored at -80 degrees until use.  
 
 
 
Figure 2-4. Site of Right Atrial Tissue Biopsy 
 
2.3.	  Laboratory	  Methods	  
2.3.1.	  RNA	  Extraction	  
Atrium 
Whole RNA was extracted from atrial tissue using TRIZOL® Reagent as described in the 
manufacturer protocol (113). Briefly, tissue was homogenised with 1ml of TRIZOL® per 
50mg of tissue. Samples were incubated for 5 minutes at 20oC and 0.2mls of chloroform 
added per 1 ml of TRIZOL®. Samples were then shaken and incubated for a further 3 minutes 
at 20oC and centrifuged at 12 000g for 10 minutes at 4 degrees centigrade to allow phase 
47 
 
separation. The aqueous phase was subsequently transferred to a separate tube. 0.5ml 
Isopropyl alcohol was added per 1ml of TRIZOL® and samples were incubated again at 20oC 
for a further 10 minutes, followed by centrifugation at 12 000g for 10 minutes at 4 degrees. 
The supernatant was removed and the pellet washed with 75% ethanol at a ratio of 1ml EtOH 
to 1ml TRIZOL® used for extraction. Pellets were washed by vortexing and then centrifuged at 
7500g for 5 mins at 4 degrees centigrade. The washing step was repeated 3 times to minimize 
TRIZOL® contamination of samples. The supernatant was removed and pellets left open to air 
to dry for 5-10 minutes. The pellet was then re-dissolved in 5µl of RNAase free water 
(Gibco®) and RNA quality and concentrations were checked with the Nanodrop 1000 
spectrophotometer and Agilent 2100 Bioanalyser. All RNA integrity numbers (RIN) were 
>7.5. Where RNA quality or concentrations did not meet required standards, samples were re-
extracted and quality control repeated to ensure improvement.  
 
Serum  
Serum samples were thawed at room temperature and stored on ice. RNA was extracted 
according to manufacturer protocol using the MirVanaTM PARISTM kit (Applied Biosystems). 
Briefly, 250µl of cell disruption buffer and 500µl of denaturing solution was added to an 
aliquot of 250µl serum. Samples were mixed and stored on ice for 10 minutes. 6 µl of 
synthetic C. Elegans miRNA (cel-miR-39) was added at a concentration of 5 fmol/µl to each 
sample to act as a control and enable normalisation of Ct values following qPCR. 1ml of 
Acid:Phenol Chloroform was added to each sample and samples were vortexed for 30 
seconds to mix. They were then centrifuged at 10 000g for 5 minutes at room temperature to 
separate the mixture into aqueous and organic phases. The upper (aqueous) layer was then 
transferred to a new tube (recording the volume) without disturbing the interphase and lower 
phases, which were subsequently discarded. A corresponding volume of Acid:Phenol 
Chloroform was then added to the newly isolated aqueous layer and the process repeated, 
again recording the volume of the aqueous phase removed. A volume of Ethanol was then 
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added corresponding to 1.25x the volume of the aqueous phase and samples were then mixed 
and briefly centrifuged. Supplied filter cartridges were added to new collection tubes and 
700ml of sample transferred onto the filter. The tubes were then centrifuged at 8000 g for 30 
seconds until all liquid had passed through the filter and the filtrate was subsequently 
discarded. 700µl of Wash Solution 1 was added to the filter, the cartridge centrifuged at 
8000g for 20 seconds and the filtrate discarded. 500µl of Wash Solution 2 was added to the 
filter and centrifuged again at 8000g for 20s. After discarding the filtrate this step was 
repeated a further 2 times to reduce contamination and the cartridge-filter assembly spun at 
8000g for 1 minute to remove excess fluid from the filter. Finally, the filter was transferred 
into a fresh collection tube and 100µl of elution solution (pre-heated to 95oC) added to the 
filter. The assembly was spun at 8000g for 30s and the filtrate containing the extracted RNA 
collected and stored at -80oC until use.  
 
2.3.2.	  MicroArray	  Analysis	  
Extracted RNA was diluted to a total concentration of 50ng/µl. 2µl of RNA was added to 2µl 
of prepared Calf Intestinal Phosphatase (CIP) master mix (0.4µl 10xCIP Buffer, 1.1µl 
labeling spike in solution, 0.5µl CIP) per reaction. After mixing, samples were incubated at 
37oC for 30 minutes to allow dephosphorylation to occur. 2.8µl of Dimethyl Sulphoxide 
(DMSO) buffer was then added to each sample, and samples were denatured by incubation at 
100oC for 5 minutes before being immediately transferred into an ice water bath.  MiRNA 
was ligated by adding 4.5µl of ligation master mix (1.0 µl 10x Ligase Buffer, 3.0µl cyanine 3-
pCp, 0.5µl T4 RNA ligase) to reach a total sample volume of 11.3µl. Samples were then 
mixed and incubated at 16oC for 2 hours to allow the labeling reaction to occur. This reaction 
labels the miRNA with cyanine dye (pCp-Cy3) at its 3’ end to create miRNA with an 
additional 3’ cytidine and one cyanine dye on the 3’ end. Labeled miRNA was dried in the 
Speed Vacuum volume concentrator for 2-3 hours until pellets were dry.  
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To prepare for hybridization each dried RNA sample was re-suspended in 17µl of RNase free 
water (Gibco®). 1µl of pre-prepared hybridization spike in solution was added to each sample 
along with 4.5µl of GE blocking agent and 22.5µl of hi-RPM hybridization buffer. Samples 
were then incubated at 100oC for 5 minutes on the vortex mixer and immediately transferred 
to an ice water bath for 15 minutes to prevent re-annealing.  
 
A total sample volume of 45µl was loaded into the corresponding gasket wells and Agilent 
MicroArray slides (8x60k) placed on top to prepare the final gasket assembly. Wells were 
checked for air bubbles and where then hybridized using the Agilent Sure-hyb hybridization 
chamber on for 20hrs at 55 degrees centigrade.  
 
Following completion of hybridization slides were washed 3 times according to manufacturer 
protocol. Slides were immediately scanned using the Agilent G2505C MicroArray Scanner 
and feature extraction performed using the Agilent Feature Extraction Software version 
10.7.3.1. Analysis was performed using Agilent GeneSpring software GX11.0. 
 
2.3.3.	  Real	  Time-­‐	  Quantitative	  Polymerase	  Chain	  Reaction	  (RT-­‐qPCR)	  
Atrium 
MiRNA levels were quantified using specific TaqManTM assays based upon the results of 
atrial microarray analysis (Applied Biosystems, Foster City, CA, USA). Briefly, 4 miRNAs 
of interest were selected from the 16 differentially expressed miRNAs identified by 
microarray analysis. These included hsa-miR-483-5p (most up-regulated), hsa-miR-208a 
(most down-regulated), hsa-miR-1202 and hsa-miR-223 (clinically interesting miRNA based 
upon previous literature). 
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Extracted RNA samples were thawed at room temperature, briefly mixed by pipetting and 
centrifuged at 2000 rpm for 30 seconds. RNA was subsequently diluted to a concentration of 
2 ng/µl and 5µl aliquots of each sample transferred into pre-labeled PCR tubes.  
 
Reverse Transcription (RT): Reverse transcription (RT) master mix was made up according 
to the number of samples to be analysed. This comprised of: 0.15µl dNTP (2'-
deoxynucleoside 5'-triphosphate), 1.0µl RT Enzyme, 1.5µl 10x RT Buffer, 0.19µl RNase 
inhibitor, 4.16µl water) and 3µl of TaqMan RT primer per sample. A total of 10µl of RT 
master mix was then added to each sample. For each study primer (e.g. hsa-miRNA-483-5p) 
an identical RT reaction was prepared for hsa-miR-186, which acted as a control for analysis. 
This control microRNA was chosen based upon the results of previous microarray analysis, 
which demonstrated miR-186 to be the most conserved miRNA between the AF and non-AF 
groups.  
 
After addition of the RT master and primer mix, samples were mixed by pipetting and 
centrifuged at 2000 rpm for 30 seconds. Samples were then transferred to the thermocycler 
and incubated according to the manufacturer’s protocol (HOLD 30 mins at 16 degrees, 
HOLD 30 minutes at 42 degrees, HOLD 5 mins at 85 degrees, HOLD ∞ at 4 degrees). After 
incubation, resultant cDNA was either used immediately for PCR reaction or stored at -80oC 
until use. 
 
PCR Reaction: Into new PCR tubes 2.4µl of sample cDNA (RT product) was added to 32µl 
of PCR Master Mix (17.25µl of TaqMan fast universal PCR master mix, 1.725µl of qPCR 
probe, 13.23µl of RNAse free water). For each study probe an identical control PCR reaction 
was also carried out.  
 
Samples were mixed by pipetting and centrifuged at 2000g for 30 seconds. 10µl of qPCR 
sample mixture was then added to each well of a 96-well PCR plate. Three technical 
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replicates were performed for each of the samples and controls. Plates were then centrifuged 
at 500g for 30s prior to being placed into the Applied Biosystems 7500 fast Real-Time PCR 
System for qPCR reaction. The PCR reaction was carried out in accordance with the 
manufacturers protocol (114): Hold at 50oC for 2 minutes, Hold at 95oC for 20s, Cycle (40 
cycles) 95oC for 3s, Hold at 60oC for 30 seconds. Amplification plots were examined for 
adequate amplification and successful PCR reaction. Baseline settings were checked to ensure 
appropriateness according to the amplification curve. A delta Rn threshold value of 0.2 was 
set to ensure comparability across plates, however this was checked to ensure it was within 
the exponential phase of amplification prior to analysis. Ct values were recorded for both 
samples and controls and compared using the ΔΔCt method. 
 
Serum 
RT-qPCR of serum samples was performed according to the protocol outlined above. 
Analysis of serum samples differed from atrial tissue RNA only in that synthetic cel-miR-39 
was spiked in at equal concentrations during serum miRNA extraction to enable its use as a 
control for these experiments. This therefore replaced the has-miR-186 control described 
above. 
 
2.4.	  Results	  
2.4.1.	  Clinical	  Study	  
Between November 2010 and April 2011 34 patients undergoing non-emergent, on-pump 
coronary artery bypass grafting (CABG) at The Hammersmith Hospital, Imperial College 
NHS Trust were recruited to participate in this study. Of these 21 patients did not develop 
POAF and were classified into Group 1. The remaining 13 patients developed POAF and 
were classified into Group 2. The mean time to onset of AF was 2.5 days.   
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Pre-operative Demographics 
A summary of the pre-operative demographics is shown in Table 2-3. Patients in Group 2 
were significantly older than those in Group 1. However no differences were observed in 
gender, pre-operative risk stratification score (logEuroSCORE) or other recognised pre-
operative cardiovascular risk factors such as diabetes, hypertension, previous MI/TIA/Stroke, 
renal dysfunction, peripheral vascular disease, hypercholesterolaemia or family history.  
 
 
 
Table 2-3. Pre-operative Demographics 
	  
2.4.2.	  MiRNA	  microarray	  
24 samples (12 AF, 12nAF) determined to have an RNA integrity number (RIN) >7 were 
selected for miRNA microarray analysis. Results were analysed using Agilent’s GeneSpring 
software. Initial analysis parameters were set to detect miRNA with a >2 fold change 
difference in signal intensity between AF and non-AF groups at a level of significance <0.05. 
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This did not reveal any significant differences in miRNA profile between the disease and 
control groups. Repeat analysis was therefore performed using a fold change significance of 
>1.5, again at the p<0.05 significance level. 16 miRNA were subsequently found to be 
differentially expressed between the group 1 and 2 (Figure 2-5; Table 2-4.). Of these, hsa-
miR-483-5p was found to be the most up-regulated (FC = 1.804) and hsa-miR-208a to be the 
most down-regulated (FC = 2.458).  
 
Targeted analysis was selected based on microarray results. In addition to the 2 
aforementioned miRNA, literature review highlighted hsa-miR-223, hsa-miR-1202 and hsa-
miR-29b to be of particular clinical interest in the study of atrial fibrillation and as such these 
miRNA were selected for further targeted analysis.(109, 115, 116)  
 
 
Table 2-4: Significance analysis set to a fold change cut-off of 1.5 and a p-value cut off of <0.05 
demonstrating 16 differentially expressed miRNA between AF and nAF groups.  
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Figure 2-5. Volcano Plot demonstrating 16 differentially expressed miRNA (red) between AF and nAF 
groups 
 
2.4.3.	  Atrial	  tissue	  RT-­‐qPCR	  	  
In order to validate the microarray findings described above, atrial tissue RNA extract was 
also examined using targeted RT-qPCR for the following miRNA: hsa-miR-208, hsa-miR-
483-5p, hsa-miR-1202 and hsa-miR-223. Although results demonstrated the same general 
trend in expression between AF and non-AF groups as observed by microarray these results 
did not reach statistical significance (Figure 2-6). 
 
2.4.4.	  Targeted	  serum	  RT-­‐qPCR	  
Based on the results of the atrial tissue microarray findings, targeted RT-qPCR of serum 
samples was performed for miR-223, miR-483-5p and miR-1202. miR-208a is a 
cardiomyocyte specific miRNA that is known not to be readily detectable in human serum 
unless in the presence of concomitant myocardial injury.(117) RT-qPCR confirmed that miR-
208a was undetectable in the serum of both AF and non-AF groups.  
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Figure 2-6. Atrial RT-qPCR validation of microarray findings. Targeted atrial RT-qPCR was unable to 
show significant differences between AF and non-AF patients when atrial tissue biopsies were 
analysed. Statistical analysis was performed using non-parametric independent samples Mann-Whitney 
testing at a level of significance of p<0.05. 
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 Pre-operative Serum: No differences were observed in the relative levels of miR-223 or 
miR-1202 between AF and non-AF groups. However, hsa-miR-483-5p was found to be 
significantly higher in the pre-operative serum of patients subsequently developing post-
operative AF (Group 2) as shown in Figure 2-7. 
 
 
 
 
 
Figure 2-7: RT-qPCR of pre-operative serum. No significant difference was observed in miR-223 or 
miR-1202 between Groups 1 and 2. However, miR-483-5p was expressed at significantly higher levels 
in Group 2 when compared to Group 1. Statistical analysis was performed using non-parametric 
independent samples Mann-Whitney testing at a level of significance of p<0.05 
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2.4.5.	  Temporal	  changes	  in	  serum	  miR-­‐483-­‐5p	  after	  surgery	  
In light of the observed pre-operative differences in miR-483-5p between the AF and non-AF 
groups, the expression of miR-483-5p was determined at 48 and 96hrs post operatively by 
means of RT-qPCR. No significant difference in miR-483-5p expression was seen between 
the AF and nAF groups at either time point (Figure 2-8). However, a trend was observed 
towards a more significant reduction in miR-483-5p expression in AF than non-AF patients 
between pre-operative and 96-hour time points (Figure 2-9). 
 
 
 
 
 
 
Figure 2-8. Expression of miR-483-5p at: (a) 48hrs after surgery, and (b) 96hrs after surgery. 
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Figure 2-9. (a) Box plot demonstrating the change in ΔCt between pre-operative and 48hr time points 
(p=0.196); (b) Box plot demonstrating a trend towards a greater reduction in ΔCt between pre-
operative and 96hr samples in AF vs. non-AF patients (p=0.075); (c) Change in ΔCt between 48 and 
96hr time points (p=0.481); (d) Results on independent samples non-parametric Mann-Whitney U 
significance testing. 
	  
2.4.6.	  Developing	  a	  serum	  test	  for	  post-­‐operative	  AF	  	  
Receiver operating characteristics (ROC) analysis was used to determine the diagnostic 
accuracy of pre-operative miRNA-483-5p as a diagnostic biomarker for post-operative AF. 
Comparing patients developing POAF to those that did not, the area under the curve (AUC) 
(i.e. the probability that a randomly selected positive has a higher test value than a randomly 
selected negative) was 0.78. Using 1.262 as a relative fold change cut off for the expression 
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level of miRNA-483-5p, the sensitivity and specificity were 77.78 and 77.27 respectively 
with a likelihood ratio of 3.422 (Figure 2-10). 
 
 
	  
Figure 2-10. Receiver operating characteristics curve of pre-operative has-miR-483-5p as a biomarker 
for post-operative AF. 
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2.5.	  Discussion	  
The results of this study provide the first documented insights into the microRNA signature of 
de novo human post-operative atrial fibrillation. Sixteen microRNA exhibit significant 
differential expression in the atria of POAF of which miR-208a is the most down-regulated 
and miR-483-5p is the most up-regulated. Beyond this, I have shown that not only is miR-
483-5p detectable in the serum of human patients, but also that pre-operatively it is expressed 
at significantly higher levels in those patients going on to develop POAF at a mean of 2.5 
days after surgery. Furthermore, the expression of this miRNA appears to become more 
similar in all patients in the post-operative period, with POAF patients demonstrating a trend 
towards a significant reduction in miR-483-5p expression by 96 hours after surgery. 
	  
2.5.1	  The	  atrial	  microRNA	  signature	  
This work has identified pre-existing microRNA dysregulation in patients subsequently 
developing POAF, particularly demonstrating under-expression of miR-208a in the right 
atrium and over-expression of miR-483-5p in both the right atrium and pre-operative serum.  
 
As previously described, atrial fibrillation is a multi-system disease with a complex 
underlying pathophysiology. A number of structural changes have been proposed to take 
place in the myocardium which when combined with changes in the extracellular 
environment, intracellular ion flux, and the systemic circulation provide a pro-arrhythmogenic 
substrate.(19) Many of the structural and electrical changes associated with chronic atrial 
fibrillation have been characterised by changes in gene expression. For example, suppression 
of CACNA1C gene expression results in reduced L-type calcium channel production, giving 
rise to a fall in the L-type calcium current, resulting in decreased action potential duration 
(APD) and increased re-entry. Similarly, increased expression of the genes KCNN1-3 (SK1, 
SK2 and SK3) encoding calcium activated potassium channels may reduce APD by 
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shortening atrial repolarization.(118) Furthermore, changes in intracellular conductance may 
be altered by modified gap junction function through a reduction in connexin 40 and 43 
encoded by the GJA5 and GJA1 genes respectively.  
 
As previously described, microRNA are short, non-coding RNA molecules which act to 
inhibit gene expression. This may occur either through inhibition of translation (through 
incomplete complementarity in miRNA-mRNA binding) or through mRNA degradation 
(complete complementarity of miRNA-mRNA interaction).  As such, this post-transcriptional 
regulation forms a novel mechanism though which both cellular homeostasis and disease 
processes may be regulated, giving rise to an exciting and rapidly evolving field of molecular 
research. 
 
miR-208 
MicroRNA-208 is an intronic, cardiomyocyte specific microRNA encoded for and co-
expressed with the α-Myosin Heavy Chain (α-MHC/Myh6) gene. It shares near sequence 
identity with miR-208b, similarly encoded for and co-expressed with the β-MHC (Myh7) 
gene, and together these miRs are thought to be involved in the development of cardiac 
hypertrophy and fibrosis.(116) Over-expression of miR-208a in a transgenic mouse model has 
been shown to result in hypertrophic growth along with up-regulation of the ‘slower’ isoform, 
β-MHC, subsequently resulting in loss of myocardial contractility and fibrosis. Similarly, loss 
of β-MHC transcript and protein expression has been noted in a miR-208-/- knockout mouse 
model suggesting its regulation by miR-208a.(116)  
 
Both the miR-208a over-expression transgenic mouse and the miR-208-/- knockout mouse 
demonstrate cardiac conduction defects despite not displaying any macroscopic 
morphological anomalies. However, in their 2009 work, Callis et al. demonstrated an 
increased PR interval and heart block in mice over-expressing miR-208a, and detected atrial 
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fibrillation in 80% of miR-208a-/- knockout mice.(116) The mechanistic role through which 
miRNA-208 may modulate atrial fibrillation is likely to be multifactorial, as this microRNA 
is likely to contribute to both the regulation of cardiomyocyte energy homeostasis and 
connexin expression.  
 
miR-483-5p 
MicroRNA 483-5p is a 22-nucleotide (AAGACGGGAGGAAAGAAGGGAG) mature 
microRNA formed from cleavage of the 76-nucleotide stem-loop pre-mir-483 by the enzyme 
Dicer. Its counterpart miR-483-3p is a distinct mature microRNA originating from the 
opposite arm of the pre-mir-483 stem-loop sequence.  Although the majority of human 
microRNA are intergenic, miR-483-5p forms one of the 37% (n=408) of ‘intronic’ 
microRNAs coded within the intron of its host gene, IGF2, located on chromosome 
11p15.5.(100) Situated within intron 2 of IGF2, hsa-miR-483-5p is co-expressed with IGF2 
and has also been demonstrated to play a feedback role, itself regulating IGF2 
expression.(100) MiR-483-5p has been isolated in several human tissue types including 
myocardium, hepatic and brain tissue as well as in blood serum.(100, 119) At present 
however, miR-483-5p remains relatively poorly studied. Its role is much less well 
characterised than that of miR-208 and the mechanism by which it regulates or is modulated 
by the clinical phenotype of POAF remains undetermined. A detailed discussion as to the 
potential target genes affected by both miRNA-483-5p and miRNA-208 can be found in 
chapter 3 where these cellular pathways will be assessed in more detail through formal 
pathway analysis and target validation. 
 
miR-1202 
MicroRNA 1202 is a 21-nucleotide (GUGCCAGCUGCAGUGGGGGAG) mature micro 
RNA. In their 2011 study, Xiao et al. examined the miRNA signature of right atrial biopsies 
taken from mitral stenosis patients undergoing surgical valve replacement (n=9AF; 4 non-
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AF). When comparing AF to non-AF, microRNA-1202 was found to be the most 
differentially up-regulated microRNA, however no further mechanistic information was 
available from this patient cohort and this miRNA was not included in subsequent pathway 
analysis.(115) More recently, in their study of end-stage heart failure receiving left ventricular 
assist device (LVAD) support, Morley-Smith et al. have identified a correlation between 
baseline (prior to LVAD) miRNA-1202 expression and response to LVAD therapy at 3 
months as measured by NT-proBNP levels. Furthermore, measurement of baseline miR-1202 
allowed for accurate prediction of patient response to LVAD therapy.(120) Interestingly, this 
study also identifies that LVAD implantation is associated with a significant and sustained 
up-regulation of miR-483-3p (derived from the opposite arm of the same pre-miRNA (stem-
loop) sequence as miR-483-5p) in both the myocardium and in the plasma, a finding that 
appears to mirror the observed concomitant reduction in NT-proBNP levels. Combined with 
the recognised relationship between elevated pre-operative plasma proBNP levels and de 
novo post operative AF,(121) these findings suggest a link between circulating miRNA-483, 
pro-BNP and AF which requires further investigation to ascertain its biological significance 
and any potential connective mechanism. 
 
mir-223 
mir-223 is a 21 nucleotide microRNA (TGTCAGTTTGTCAAATACCCC) found on the X 
chromosome at location Xq12. Although mir-223 has been reported to be involved in a 
number of cellular processes from the endothelial cell activation(122) to variations in 
individual patient responses to antiplatelet agents,(123) of significance in cardiac 
arrhythmogenesis is its role in control of cellular glucose uptake. Over-expression of mir-223 
has been observed in the myocardium of patients with type 2 diabetes mellitus and in vitro, 
increases in mir-223 are associated with cellular glucose uptake in the absence of insulin 
stimulation, via increased glucose transporter (Glut4) expression.(109) Indeed, via directly 
targeting the Glut4 gene, miR-223 plays a homeostatic role to reduce Glut4 and thus glucose 
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uptake. Reduced glucose transporter (Glut3) expression has also been associated with de novo 
POAF.(124) As a result, subsequent impaired glucose availability can induce electrical 
instability during hypoxic states such as myocardial re-perfusion after coronary bypass 
grafting and thus pre-dispose to AF.(125) Therefore in our patients, the elevated miR-223 
levels observed in AF may result in reduced Glut4 expression, impaired glucose uptake and a 
subsequent increased risk of post-operative arrhythmogenesis. 
 
miR-29 
Recently there has been increasing evidence surrounding the role of miR-29 in human AF. 
My microarray results demonstrated a significant reduction in miR-29 expression (fold 
change -1.76, p=0.0298) in patients developing POAF. This is similar to that observed in the 
work by Dawson et al.(126), who noted an approximately 50% reduction in miR-29b 
expression in chronic AF patients when compared to controls. MiR-29 has been shown to 
regulate the expression of extracellular matrix proteins including collagen 1 and fibrillin 1, 
and down regulation of miR-29 has been associated with the pro-fibrotic atrial substrate 
associated with heart failure in canines.(127, 128) Furthermore, miR-29 itself is 
downregulated by increases in the cytokine TGF-β, which in turn has been shown to be 
upregulated in chronic AF. Interestingly, increases in TGF-β have also been observed in 
patients with longstanding AF (>6months) who developed AF recurrence after surgical 
radiofrequency maze procedures when compared to those patients who maintained sinus 
rhythm(129). These observations were coupled with increases in the collagen type 1 volume 
fraction and although miR-29 levels were not measured in this study, these findings suggest 
that AF recurrence following surgical ablation may be mediated through miR-29. 
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2.5.2.	  MicroRNA	  as	  circulating	  biomarkers	  in	  POAF	  
 
The potential for MicroRNA to act as non-invasive molecular biomarkers of systemic disease 
is of great interest owing to their high level of stability in a many different biofluids including 
serum, plasma and urine.(130) As such, by means of a simple blood test performed at the time 
of routine patient assessment, quantitation of a single or cluster of microRNAs may provide a 
novel avenue for detection and risk prediction of systemic disease with minimal disturbance 
to the patient.  
 
Several microRNA have been implicated in the regulation of cardiovascular disease and 
microRNA expression in chronic atrial fibrillation is an ever-expanding area of research 
(Table 2-5). Nevertheless, much of the work to date examines miRNA expression in right or 
left atrial tissue and there remains a paucity of evidence surrounding circulating microRNA in 
human AF. Recent work by 2 groups has however begun to address this question.(126, 131)  
Liu et al. identified circulating microRNA-150 to be significantly under-expressed in the 
serum of 60 prospectively collected patients with both paroxysmal (n=30; FC~17) and 
persistent AF (n=30; FC~20) when compared to healthy controls (n=30), demonstrating miR-
150 to be an independent predictor of AF (OR 1.96; 95% CI [1.5, 3.57]; P<0.001). It is 
notable however, that in this study miRNA-150 levels were not able to differentiate 
paroxysmal from persistent AF (OR 1.02; 95% CI [0.82, 1.13]; P = 0.61).(131)  
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Table 2-5: MicroRNAs implicated in human and animal models of atrial fibrillation. AF- atrial 
fibrillation; pAF – paroxysmal atrial fibrillation; nAF – non-AF; VTP – ventricular tachypacing; RAA 
– right atrial appendage; LAA – left atrial appendage; SR – sinus rhythm; FC – fold change; APD – 
action potential duration.  
 
miRNA	   Type	  of	  AF	  
Tissue/	  
Biofluid	  
(Species)	  
Target	  Gene(s)	   Direction	  of	  regulation	  
Signalling	  
Pathways/channels	  
Implicated	  
Inflammation/Structural	  Remodeling	  
miR-133 
miR-590 
(132) 
Tachypacing + nicotine 
animal model persistent 
Left and right 
atria (Canine) 
TGF-β1, TGF-
βR2 
Down-regulated (FC 
dependent on nicotine 
dose: miR-133~0.8-0.4; 
miR-590 ~0.7-0.5) 
Removal of inhibition 
of TGF-β1, TGF-βR2 is 
pro-fibrotic. Stimulates 
fibroblast proliferation 
and adhesion.  
miR-150 
(131) 
Paroxysmal 
Persistent 
Serum 
(Human) 
EIF4E, EIF4B, 
ARRB2, MAPK9, 
MAPK2K4, 
PAK1, 
PRKAR1A, SP1, 
CAMK2G, 
PRKCA, IRAK1, 
CAST, KCNIP1, 
TMP3. 
Down regulated 
(paroxysmal: FC~17; 
persistent: FC~20) 
 
Inflammation: mTOR, 
MAPK, Insulin, TGF-β, 
ErbB, Wnt and 
apoptosis signalling 
pathways.  
 
Calcium channels  
Fibrosis 
 
miR-29 
(126) 
Mixed 
AF±CHF  
(Serum: n=30SR, 
33AF) 
(RAA: n=19SR, 9 pAF, 
8 chronic AF) 
 
Tachypacing animal 
model (n=32 cont.; 5 
sham; 19 VTP 24hr; 16 
VTP 1wk, 22 VTP 2wk)  
Serum and 
Right Atrial 
Appendage 
(Human) 
 
Left Atrium 
(Canine) 
COL1A1, 
COL3A1, FBN 
Canine: Down-regulation 
of miR-29b (87% at 
24hrs). 
Down-regulation of miR-
133a and 133b  
 
Human: Down-regulation 
of miR-29b in plasma 
~50%; also down-
regulation of plasma miR-
21 in AF vs. control. 
Down-regulation 29b in 
RAA 40% in pAF and 
54% chronic AF 
Increased atrial fibrosis 
due to increased 
collagen production.   
Ion	  Channel	  Remodelling	  
miR-499 
(133) 
 
Permanent 
(n=4 SR; 4AF) 
Right atrial 
appendage 
(Human) 
KCNN3 Up-regulated (FC=2.33) 
Repression of SK3 ion 
channel expression. 
Effects on APD and 
repolarization. 
miR-26 
(134) 
Persistent 
(n=5AF; 5nAF) 
Right atrial 
appendage 
(Human) 
KCNJ2 Down-regulated; (FC~0.4 miR-26a) 
Subunit of 
acetylcholine-sensitive 
potassium channel. 
Regulates APD and 
resting membrane 
potential. 
miR-328 
(135) 
Tachypacing animal 
model persistent AF 
(n=7 AF; 7nAF) 
Left atrial 
appendage 
(Canine) 
CACNA1C 
CACNB1 
Up-regulated (FC=3.5-
3.9) 
Inhibits genes encoding 
α1c and β1 subunits of 
L-type calcium channel. 
Leads to reduction of 
ICaL and increase in 
APD 
miR-1 
(136) 
Persistent (n=31 AF; 31 
SR for target analysis, 
n=7AF; 8SR miRNA 
analysis) 
LA (AF 
patients with 
MVD); RA 
from SR 
patients 
(Human) 
KCNJ2 
GJA1 
Down-regulated 
(FC~7; relative 
expression 100±29 nAF 
vs. 14±7 AF) 
Subunit of 
acetylcholine-sensitive 
potassium channel. 
Regulates APD and 
resting membrane 
potential. GJA1 
encodes connexin 43, 
altering cell-cell 
conduction 
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More recently, Dawson et al. have also demonstrated a significant down-regulation of miR-
29b in both the plasma (n=30SR, 33 AF) and right atrial appendage tissue of patients with 
paroxysmal (n=9) and chronic atrial fibrillation (n=8). The subsequent reduction in 
suppression of fibrillin (FBN) and the collagen (COL1A1 and COL3A1) mRNA transcripts is 
thought to promote atrial fibrosis thus promoting structural remodelling and increasing 
susceptibility to re-entry and atrial fibrillation.(126)  
 
The results of this study demonstrate significant increase in miR-483-5p in the pre-operative 
serum of POAF patients. Furthermore, ROC analysis reveals an area under the curve of 0.78 
when this biomarker is used to predict patients developing POAF. At present, there is no 
further evidence surrounding the use of circulating miR-483-5p as a serum biomarker. 
However, as previously discussed, an acute and sustained increase in circulating mir-483-3p 
has recently been isolated in heart failure patients after LVAD insertion, not only highlighting 
the ability for microRNA cleaved from the mir-483 stem loop sequence to be detected in the 
plasma, but also how this serum miR may vary alongside changes in cardiac stress. 
 
2.5.3	  Limitations	  
When interpreting the results of this study, it is also important to consider a number of 
limitations that may impact on these findings. Firstly, although the rigorous nature of this trial 
provides a robust definition of POAF with prospectively collected data, the numbers of 
patients recruited remain relatively small. Secondly, AF is a complex, multifactorial 
arrhythmia and microRNA dysregulation alone is unlikely to be the sole regulatory 
mechanism underlying the pathogenesis of post-operative atrial fibrillation. Third, although 
every attempt was made to match for environmental disparities, confounding factors such as 
electrolyte imbalance, post-operative sepsis (clinical or sub-clinical) and pharmacological 
therapies may all influence the relative expression of microRNA and the regulation of 
subsequent biological pathways.  
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2.6	  Conclusions	  
This work has identified pre-existing microRNA dysregulation in patients subsequently 
developing POAF, particularly demonstrating under-expression of miR-208a and over-
expression of miR-483-5p in the right atrium of POAF patients. In order to understand the 
significance of these changes it is now pertinent to clarify the potential mechanisms by which 
these miRNA may regulate cardiac conduction. 
 
In addition, this study has provided the first documented description of circulating microRNA 
profile in POAF patients. Indeed, the observed differential expression of miRNA-483-5p in 
both the right atrial tissue and circulating plasma of these patients supports the hypothesis of a 
pre-existing atrial or systemic inflammatory substrate to this condition, highlighting the 
potential for biomarker development. Given these findings, it is now necessary to address the 
potential mechanisms behind these changes, and validate these findings as will be addressed 
in Chapter 3. Finally, prospective, targeted validation of these results in a larger patient cohort 
is required in order to determine the reliability of circulating microRNA-483-5p as a 
biomarker for POAF.  
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Chapter	  3	  
Genomic	  mechanisms	  in	  POAF	  pathogenesis	  
 
3.1	  Background	  
Following the recent advances in sequencing technology, there has been an exponential 
expansion in the number of microRNAs recorded in the literature from only 218 in 2002 to 
over 35 000 today (Figure 3-1). At publication in June 2014, the comprehensive microRNA 
database miRBase (Release 21, 26 June 2014; http://www.mirbase.org) listed 35828 mature 
miRNA and 28645 hairpin precursor miRNAs, across 223 species.(137)  
 
 
 
Figure 3-1. The exponential growth in recorded miRNA sequences as documented in the miRBase 
database. This is particularly notable after 2009 where the advent of more universally available 
sequencing technologies allowed for the more rapid discovery of novel miRNA species. 
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In order to determine the biological and clinical significance of these microRNAs it is vital to 
understand how they interact with their target genes. In light of the ever expanding numbers 
of miRNA and the fact each miRNA may target several hundred genes it is not possible to 
experimentally validate every potential miRNA-mRNA interaction and a robust method of 
target prediction is therefore required in order to guide researchers to mRNA targets likely to 
be relevant to the experiment or disease process being studied. In order to go about this a 
number of online target prediction packages have been developed. Each of these differs 
slightly in its layout and the way in which potentially functional targets are scored/ weighted, 
however for all, the initial basis for target prediction begins with determining target sites 
whereby there is complete or partial seed pairing of nucleotides 2-8 at the 5’ end of the 
miRNA.  
 
Until 2007, complete complementarity of these first 8 nucleotides was thought to be vital for 
miRNA-mRNA binding.  However, it is now acknowledged that target mRNA knockdown 
requires more than simply seed region pairing. miRNA may bind with incomplete seed 
complementarity, and some miRNA-mRNA interactions may even be mediated outside of the 
seed region.(138) Furthermore, a given microRNA may have multiple binding sites on a 
particular gene, some of which may bind with perfect seed complementarity and others that 
bind only partially. Conversely, it has also been observed that where there is complete 
complementarity of 7mer or 8mer sites with the miRNA seed region, complete knockdown of 
the target mRNA does not always occur.(138) As a result, different target prediction 
algorithms rely on different degrees of seed pair binding with some even allowing a single 
base pair mismatch or bulging in the miRNA-mRNA duplex. 
 
In fact, outside of the seed region, notably at nucleotides 12-17 (138), the remaining miRNA 
may bind with variable degrees of complementarity. The strength of this outside seed region 
binding may act to stabilize the miRNA-mRNA interaction and may even compensate for 
imperfect seed pairing.(138, 139) Furthermore, target genes may contain multiple binding 
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sites for a single miRNA, particularly where there is a biological advantage to being able to 
achieve close to complete knockdown a given gene. In this case, miRNA may act at multiple 
binding sites to produce more marked suppression of the target. In fact, where sites are close 
together, there appears to be a synergistic effect resulting in even more marked suppression 
than that of combining individual site binding.(139) 
 
In order to determine whether a given mRNA target has biological significance and warrants 
further experimental validation in the disease or cellular process being studied, it is pertinent 
to determine whether the miRNA-target interaction is likely to be functional or not. There are 
a number of observations accounted for in the common prediction algorithms that enable us to 
score the likelihood of target functionality (Figure 3-2). Described in detail by Grimson et 
al(138) these include: (1) Position in relation to the 3'UTR of the target gene: Binding sites 
are more likely to be effective if they reside close to the ends of the 3'UTR of the target gene, 
however they become less effective if they fall within 3'UTR sites that are within 15 
nucleotides of the stop codon; (2) AU enrichment: Functional binding sites are more likely to 
be those surrounded by nucleotides enriched in AU bases; (3) Degree of interspecies 
conservation: 3’UTR targets sequences that are highly conserved between species are more 
likely to be functionally active; (4) Proximity to target sites for co-expressed miRNAs: 
Efficacious sites are more likely to be those in close proximity to co-expressed miRNAs. 
Indeed, in order to maximise the suppressive effect of a miRNA there may be multiple target 
sites within the same 3’UTR of a given mRNA.  
 
Each of these factors may act independently to increase the likelihood of a target being a 
functional site. Therefore, instead of solely relying on seed region complementarity, target 
prediction algorithms now use a number of other methods to identify microRNA response 
elements (functional target sites) in target genes.  
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Figure 3-2: Mechanisms for determining the likelihood of microRNA target functionality beyond 
simple seed region pairing 
 
 
 
Target	  Prediction	  Algorithms	  
There is a wide range of miRNA-mRNA target prediction algorithms available. These 
include: TargetScan, miRanda, PITA, RNA22, miRDB, RNAhybrid, PICTAR and Diana-
microT. Of these, TargetScan, miRanda and PITA incorporate a cross section of the different 
features described above and are discussed in more detail below.  
 
TargetScan 
The TargetScan algorithm works by searching for seed pairing regions in 3’UTR alignments 
that are conserved between 28 vertebrate species.(140) Seed matching is based on 7mer 
binding (sites that match nucleotides 2-7 in the seed region as well as nucleotide 8 outside the 
seed region), and 8mer binding (sites that match the nucleotides 2-8 coupled with an A at 
position 1). In addition, potential binding sites are also reported where there is only partial 
complementarity in the seed region but 3’ pairing is conserved. The efficacy of miRNA-
mRNA pairing is given by the context+ score. This is designed to predict the accessibility of a 
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target site to a given miRNA by analysing both the sequence complementarity and the 
surrounding 3'UTR environment. 
 
miRanda  
MiRanda uses the aforementioned methods of target prediction and also provides a score to 
denote the likelihood of mRNA down-regulation when bound by a given miRNA. This score 
is known as the miRSVR score and is based upon a regression model incorporating both 
sequence complementarity and other local features that affect the likelihood of miRNA 
binding, including match and mismatch scores for base pairs, gap penalties and a secondary 
measure of the free energy of formation of the miRNA:mRNA duplex.(141) In addition to the 
miRSVR score, miRanda also provides a measure of conservation across mammalian 
genomes known as the PhastCons score. A score above 0.57 confers high degree of 
interspecies conservation.(141)  
 
PITA 
PITA (Segal Lab; http://genie.weizmann.ac.il/pubs/mir07/mir07_prediction.html) uses an 
algorithm based on seed sequences from nucleotides 2-8 without allowing for mismatches or 
loops. For non-annotated genes, approximation is made of the 3'UTR. As with miRanda, the 
site conservation between mammalian species is also noted. In addition to these features, 
PITA focuses on the energetics of the microRNA-mRNA target interaction including the 
hybridization energy, the energy required to make the target accessible and the combined 
interaction energy.(142) 
 
Although TargetScan and miRanda are the most commonly used in isolation, there is now an 
increasing trend towards a pooled approach to target prediction, with web-based programs 
such as miRWalk allowing the results of the main prediction algorithms to be viewed side by 
side and target genes selected for experimental validation based on their prediction by 2 or 
74 
 
more individual algorithms. However, although this approach is widely used within the 
published literature,(143-145) there is no protocol as to how the results of these algorithms 
should be weighted, and this approach may still yield several hundred to thousands of 
potential targets. Furthermore, the process of target prediction is made more complex by the 
functional nature of miRNA-mRNA interaction. It should also be remembered that the degree 
of binding may be related to the functional state of the cell, the expression of other miRNA, 
and the concentration of the miRNA in the cytoplasm.(140) Furthermore, the availability of 
regulatory proteins such as Argonaute may add even more complexity to the extent by which 
miRNA may knockdown their gene targets.(140)   
 
Given the larger number of potential targets for a single miRNA the aim of target prediction 
in this study is to generate a clinically relevant list of potential genes for further experimental 
validation. The miRWalk program will be used to examine the aforementioned prediction 
algorithms in combination in an attempt to reduce the number of false positives. Given that 
miRNA do not result in 100% knockdown of their target mRNA, the degree of mRNA 
expression will also be experimentally validated. Finally, the effect this modulation of 
messenger RNA has on protein expression will ultimately be determined in order to provide a 
mechanistic understanding of the downstream impact miRNA changes may have on cellular 
function and ultimately disease pathogenesis. 
 
3.1.1	  Pathway	  Analysis	  	  
The role of pathway analysis subsequent to miRNA target prediction is to provide an 
overview of how changes in gene and protein expression may affect cellular function. Given a 
list of differentially expressed miRNA, we are able to establish a likely list of gene expression 
changes as previously mentioned. Subsequent to this, these genes may be inputted into a 
number of pathway prediction tools that examine the degree of enrichment of these genes in 
known pathways. These findings may then be correlated with the disease process of interest 
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and a mechanistic model of disease pathogenesis may be proposed. As with miRNA target 
prediction, a number of pathway tools are available, each with its advantages and 
disadvantages. These include Ingenuity Pathway Analysis (IPA) (http://www.ingenuity.com), 
DIANA-miRPath (http://diana.imis.athena-innovation.gr),(146) Kyoto Encyclopedia of 
Genes and Genomes (KEGG) (http://www.genome.jp/kegg/pathway.html) and Reactome 
(http://www.reactome.org) which provide a combination of commercial and free databases 
with independently curated pathways for a wide range of cellular processes and disease states. 
This study will use a combination of these methods in order to examine upstream and 
downstream regulation in post-operative atrial fibrillation as well as providing a visual 
representation of estimated perturbations in cellular signaling.  
 
3.1.2	  Aims	  
The aim of this chapter is to establish how microRNA changes may play a mechanistic role in 
altering gene and subsequent protein expression in post-operative AF. Online target 
enrichment resources and comprehensive bioinformatics databases will be used to predict 
potentially clinically relevant mechanisms for the microRNA changes described in Chapter 2. 
These pathways will then be systematically investigated from the transcriptome to protein 
level in order to establish whether they are likely to be involved in the pathogenesis of de 
novo post-operative atrial fibrillation.  
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3.2	  Methods	  
3.2.1.	  RT-­‐qPCR	  of	  target	  mRNA	  
Reverse Transcription (RT): Universal reverse transcription (RT) master mix (No 
AmpErase® UNG (Uracil N-Glycosylase); Applied Biosystems) was made up according to 
the number of samples to be analysed. This comprised of: 2.0µl 10x Reverse Transcription 
Buffer, 2.0µl 10x Random Primers, 1.0µl MultiScribe Reverse Transcriptase (50U/µl), 0.8µl 
25x dNTP Mix (100mM), 1.0µl Nuclease free water, and 3.2µl RNAse free water per sample. 
A total of 10µl of RT master mix was then added to each sample.  
 
After addition of the RT master and primer mix, samples were mixed by pipetting and 
centrifuged at 2000 rpm for 30 seconds. Samples were then transferred to the thermocycler 
and reverse transcription was carried out according to the manufacturer’s protocol (HOLD 10 
mins at 25 degrees, HOLD 120 minutes at 37 degrees, HOLD 5 minutes at 85 degrees, HOLD 
∞ at 4 degrees). After incubation, resultant cDNA was either used immediately for PCR 
reaction or stored at -80oC until use. 
 
PCR Reaction: Into new PCR tubes 2.4µl of universal sample cDNA (RT product) was added 
to 32µl of PCR Master Mix (17.25µl of TaqMan fast universal PCR master mix, 1.725µl of 
TaqMan gene expression assay, 13.23µl of RNAse free water). For each study probe an 
identical control PCR reaction (U6) was also carried out.  
 
Samples were mixed by pipetting and centrifuged at 2000g for 30 seconds. 10µl of qPCR 
sample mixture was then added to each well of a 96-well PCR plate. Three technical 
replicates were performed for each of the samples and controls. Plates were then centrifuged 
at 500g for 30s prior to being placed into the Applied Biosystems 7500 fast Real-Time PCR 
System for qPCR reaction. The PCR reaction was carried out in accordance with the 
manufacturers protocol (114): Hold at 50oC for 2 minutes, Hold at 95oC for 20s, Cycle (40 
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cycles) 95oC for 3s, Hold at 60oC for 30 seconds. Amplification plots were examined for 
adequate amplification and successful PCR reaction. Baseline settings were checked to ensure 
appropriateness according to the amplification curve. A delta Rn threshold value of 0.2 was 
set to ensure comparability across plates, however this was checked to ensure it was within 
the exponential phase of amplification prior to analysis. Ct values were recorded for both 
samples and controls and compared using the ΔΔCt method. 
 
3.2.2	  Protein	  Extraction	  
Protein was extracted from atrial tissue using RIPA buffer (SIGMA) without the addition of 
phosphatase inhibitor as the phosphorylation states of target proteins were not to be examined 
in this experiment. 30-40µg of tissue was homogenised in a solution of 500µl cell disruption 
buffer and 5µl protease inhibitor and kept cool on ice to ensure maximal homogenisation. The 
homogenised samples were then centrifuged at 12 000g for 5 minutes and the supernatant 
discarded. 400µl of RIPA buffer was then added to the pellet containing the protein extract 
and samples were vortexed to ensure mixing. Samples were then placed in a sonicade at 4oC 
for 30 minutes to maximise tissue disruption. The samples were then spun at 12 000g for 20 
minutes to pellet out the cell debris. The supernatant containing soluble protein was then 
transferred to a fresh sample tube and concentration of extracted protein assessed using the 
bicinchoninic acid (BCA) assay. 
 
3.2.3	  Protein	  Bicinchoninic	  Acid	  (BCA)	  quantification	  
The concentration of extracted protein was determined using the Pierce® protein assay kit and 
absorbance measured using the BMG FluoStar Galaxy microplate reader. This principle of 
this method is that the Cu+ product of the Biuret reaction (Cu2+   Cu+ by protein in the 
presence of alkali) is chelated with two molecules of BCA forming a purple-coloured end 
product. Experiments were carried out in accordance with the manufacturers protocol. 
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Standard stock solutions were first prepared producing a range from 25-2000 µg/mL. The 
BCA working reagent was then prepared by mixing BCA reagent A (sodium carbonate, 
sodium bicarbonate, bicinchoninic acid and sodium tartrate in 0.1M sodium hydroxide) with 
BCA reagent B (4% cupric sulfate) at a ratio of 50:1. The microplate was prepared by adding 
25µl of each standard and study sample to separate wells. All standards and samples were 
repeated in duplicate. 200µl of working reagent was then added to each well, samples mixed 
on a plate shaker for 30s and the plate incubated at 37oC for 30 minutes. After cooling to 
room temperature, the absorbance of each sample was recorded at a wavelength of 562nm. By 
measuring the absorbance of known standard assays, Microsoft Excel was used to create a 
standard graph from which the protein concentration of test samples could then be 
extrapolated. 
 
3.2.4	  Western	  Blotting	  	  
Prior to commencing western blotting, protein concentrations were determined by BCA assay 
as above. The volume of protein required to load 30mg of protein was calculated and 
aliquoted accordingly. RNAse free water was then added to protein aliquots sufficient to 
reach a uniform loading volume of 20µl. 5µl of loading buffer mixed with β-mercaptoethanol 
(1:20 mix) was then added to each sample, samples were denatured for 5 minutes at 95oC and 
centrifuged at 10 000 rpm for 5 minutes. Samples and ladder markers were then loaded onto a 
pre-prepared, 10 or 15 well, 8% SDS-PAGE gel. For analysis of smaller proteins (<30kDa) 
12% SDS-PAGE was used in order to obtain better separation at this range of molecular 
weight. This was run at 60V for 15-20 minutes (until stacked) followed by 100V for 1.5-2 hrs 
or until the protein had passed three quarters of the way through the gel. Once complete, the 
gels were carefully lifted out of the apparatus and removed from the slides.  
 
Proteins were transferred onto a 0.45µm Protran® membrane by running in a transfer tank at 
150V and 400mA for 1.5 hours. Successful protein transfer was confirmed with Ponceau S 
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stain and the membrane subsequently de-stained by washing three times in PBS-T (Phosphate 
Buffered Saline/Tween at a ratio of 1000ml:1ml) buffer for 5 minutes. The membrane was 
then blocked for 1 hour with 20ml of 5% milk protein blocking buffer and subsequently 
washed with PBS-T as previously described. The membrane and primary antibody were 
finally mixed with milk protein blocking buffer (1:10) and incubated overnight at 4oC.  
 
The following day, the primary antibody was removed and the membrane washed again in 
PBS-T. The membrane was then incubated with the secondary antibody (anti-β-Actin) (with 
added anti-biotin (1:1000) to detect the biotynylated ladder) for 2 hours at room temperature. 
Following repeat wash the membrane was stained using 2mls of Luminata™ Forte Western 
HRP Substrate (Millipore) and scanned using the ChemiDocTM MP imaging system (BioRad 
technologies) Chemiuminescence scanner to detect the presence of protein bands.  
 
In order to detect β-Actin as a loading control the membrane was then re-blocked for 1 hour 
in blocking buffer. After repeat washing, the membrane was incubated in primary mouse β-
Actin for 1 hr followed by washing and incubation in goat-anti-mouse secondary antibody for 
1 hour. Finally, the membrane was washed, stained with chemiluminescence stain, and 
control bands measured as described above. Where required for repeat analysis membranes 
were stripped using ReBlot Plus Strong Antibody Stripping Solution, 10x (Millipore) (diluted 
1:10) for 10 minutes prior to repeat blocking and incubation with the required antibodies. 
Quantitation of protein concentrations was preformed using Kodak Image Station 2000M 
analysis software.  
3.2.5	  Enzyme	  Linked	  Immuno-­‐Sorbant	  Assay	  (ELISA)	  
A solid phase sandwich ELISA technique was used to quantify the concentration of VCAM1 
target protein (Abcam®). ELISA was carried out according to the manufacturers protocol. 
Serum samples were first diluted 1:50 and reagents prepared as per protocol. All samples, 
blanks, controls and standards were run in duplicate. Standard dilutions were made by 
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pipetting 200µl of standard into wells A1 and A2 and 100µl standard diluent into wells B1-F1 
and B2 to F2. 100µl of liquid was transferred from A1 to B1 and mixed by pipetting. This 
was repeated from B1 to C1, C1 to D1, etc… until a series dilution from 50-1.56 ng/ml was 
formed (Table 3-1). Control and blank samples were added to H1/H2 and G1/G2 respectively 
and 100µl of sample was added into all remaining sample wells. 50µl of biotynylated 
monoclonal antibody specific for VCAM1 was added to each well and the plate incubated for 
1hr at room temperature (RT). All wells were then emptied and washed 3 times with 300µl of 
wash buffer. After washing, 100µl of streptavidin-peroxidase enzyme was added to each well 
and the plate incubated again for 30 minutes at RT. After incubation, the plate was again 
washed 3 times with 300µl wash buffer to remove all unbound enzyme. 100µl of chromogen 
TMB substrate solution was then added to all wells, which then acts on the bound enzyme 
resulting in a coloured reaction proportional to the concentration of VCAM1 present in the 
well. After a dark incubation period of 12-15 mins at RT the reaction was stopped with 100µl 
sulphuric acid (H2SO4) and the absorbance read immediately using a spectrophotometer set to 
a primary wavelength of 450nm. 
 
 
Table 3-1: ELISA well plate layout 
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3.2.6.	  Target	  Identification	  and	  Verification	  
Gene	  Ontology	  pathway	  enrichment	  
In order to determine the pathways potentially affected by the dysregulated miRNA profile 
associated with POAF, the 16 differentially expressed miRNA were input into the DIANA-
miRPath web-server. DIANA-miRPath is a miRNA pathway analysis tool which utilises 
targets either experimentally validated in the TarBase database or predicted by the DIANA-
microT-CDS algorithm based on their 3'UTR sequence homology to the miR seed 
region.(146) Resultant pathways were displayed where p<0.05.  
 
Selection	  of	  clinically	  relevant	  target	  proteins	  
Based on the results of the above RT-qPCR analysis potentially clinically relevant gene 
targets were assessed for hsa-miR-483-5p and hsa-miR-208. The miRWalk 
(http://www.umm.uni-heidelberg.de/apps/zmf/mirwalk/index.html) database was used in 
order to determine the list of potential and validated target genes.(147) As previously 
discussed, the miRWalk database examines miRNA-target interactions as produced by 8 
miRNA prediction programs based upon the 3' UTRs of all known human genes. This 
includes the following databases: RNA22, miRanda, miRDB, TargetScan, RNAhybrid, 
PICTAR and Diana-microT. All targets identified for hsa-miR-483-5p (Appendix 1) and hsa-
mir-208 (Appendix 2) by more than 2 of the 8 databases were manually examined for clinical 
significance. A literature search was then performed of all potentially clinically relevant 
targets to determine any previous association with atrial fibrillation. For non-validated 7mer 
and 8mer seed matched targets, the likelihood of functionality was determined according to 
the degree of conservation of the target (PhastCons score), the miRSVR score and the context 
score using the and miRanda (microrna.org) and TargetScan algorithms respectively (see 
Chapter 3.1 for a detailed description of the basis of these target prediction programs). As a 
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result, 4 clinically relevant targets were selected for further investigation and potential 
significance. 
 
Targeted pathway analysis was secondarily performed using Ingenuity Pathway Analysis 
(IPA) software (http://www.ingenuity.com/products/ipa) to detect relevant target genes 
associated with human Atrial Fibrillation. In addition, canonical pathways relevant to the 
genes of interest were examined using the IPA, KEGG and Reactome databases. Finally, a 
systematic literature search was performed using the PubMed 
(http://www.ncbi.nlm.nih.gov/pubmed) and NCBI Gene (http://www.ncbi.nlm.nih.gov/gene/) 
databases in order to detect any further clinically relevant targets not previously identified. 
These were then cross-referenced with my dataset and subsequent pathway maps. 
 
83 
 
3.3	  Results	  
	  
3.3.1.	  Gene	  Ontology	  Pathway	  Enrichment	  
Gene ontology (GO) analysis predicted a number of enriched pathways as shown in Figure 3-
3.  A full summary of enriched pathways along with the miRNA and gene targets implicated 
is shown in Table 3-2. Of particular interest included the calcium signaling pathway (4 
miRNA: miR-19a-3p; miR-19a-5p; miR-3679-5p; miR-4298), the TGFβ signaling pathway 
(4 miRNA: miR-301a-3p, miR-150-3p, miR-150-5p, miR-638), gap junction function (4 
miRNA: miR-483-5p, miR-301a-3p, miR-19a-3p, miR-3679-5p), insulin signaling pathway 
(4 miRNA: miR-301a-3p, miR-19a-3p, miR-150-5p, miR-3679-5p), phosphatidylinositol 
signaling system (3 miRNA: miR-301a-3p, miR-19a-3p, miR-4928) mTOR signaling 
pathway (2 miRNA: miR-301a-3p, miR-19a-3p) and the PI3K-Akt signaling pathway (miR-
150-5p, miR-29b-3p, miR-29b-1-5p, miR-483-5p). Other pathways potentially clinically 
relevant to AF pathogenesis include extracellular matrix signaling, Ubiquitin mediated 
proteolysis, protein digestion and absorption and focal adhesion. Notably however, although 
all differentially expressed miRNA were input, the resultant DIANA-mirPath pathway 
analysis miR-did not include any of the predicted target sites from miR-208a. 
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Figure 3-3: Results from DIANA-mirPath pathway analysis: Enriched pathways incorporating target 
genes of the 16 differentially expressed miRNA between the atrial tissue of POAF vs. non-POAF 
patients.  
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Table 3-2: A summary of significantly enriched pathways in POAF vs. non-POAF patients. The microRNA with and their gene targets in each pathway are shown. 
Highlighted columns denote pathways with clinical relevance in AF pathogenesis.  
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3.3.2	  Specific	  Target	  Identification	  and	  Verification	  
Generalised pathway analysis provides an overview of the signaling cascades potentially 
affected as a result of the dysregulated miRNA profile observed in our patient cohort. These 
findings represent a measure of the over-representation (or enrichment) of the gene targets for 
my differentially expressed miRNAs within each signaling cascade. However, these tools 
have a number of limitations not only in the algorithms used to predict potential miR targets, 
but also in the number of signaling cascades represented in the database, and the 
completeness of our understanding of each of the individual genes and proteins involved in 
each of these pathways.  
 
As a result, for a more complete study of the mechanism by which these miRNA regulate AF 
pathogenesis, I combined this with a targeted approach of individual clinically relevant genes 
identified using the miRWalk database. Two clinically relevant targets were studied in detail 
for the most under-expressed and over-expressed miRNA in POAF patients when compared 
to those maintaining sinus rhythm. 
	  
(a)	  hsa-­‐miR-­‐483-­‐5p:	  
The miRWalk database lists 17 validated targets for hsa-miR-483-5p (Appendix 1a). Based 
on a search restricted to miRNA binding at the 3’UTR, producing a list of all gene transcripts 
with a minimum seed length of 7 bp and a probability of distribution of random matches of a 
subsequence in the given sequence of p=0.05, miRWalk lists 4985 predicted targets of miR-
483-5p of which 999 were predicted by 3 or more databases. (Appendix 1b and 1c) 
 
MAPK3 (ERK1/2): This extracellular signaling kinase is well recognised to play a key role 
in a number of cell signaling processes including cell differentiation and proliferation. 
Increased MAPK3 expression has been previously identified in patients with chronic AF and 
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atrial fibrosis.(148) MAPK3 was found to be a predicted target of hsa-miR-483-5p with a 7 
bp seed length (sequence: AGACGGG) at a p value of 0.0495.  The MirSVR score for the 
miR-483-5p/MAPK interaction was found to be ‘good’ (>-0.1) at -1.0996,(149) with a 
PhastCons score of 0.5875 (>0.57) demonstrating good conservation across mammalian 
genomes.(141, 150) 
 
KCNE5 (KCNE1L): KCNE5 forms part of a group of regulators (KCNE1-KCNE5) of the 
voltage gated potassium channel responsible for the slow inward rectifying potassium current 
(IKs). Its gene product, MiRP4, is a membrane spanning protein thought act as a down-
regulator to the α-subunit KCNQ1 resulting in suppression of IKs. Reduced IKs within the 
atrial myocardium shortens the refractory period giving rise to the potential for macro re-
entrant circuits to develop leading to atrial fibrillation.(151) KCNE5 was found to be a 
potential target for miR-483-5p by 3 of the 8 prediction programs (miRanda, TargetScan and 
PITA), however this target is yet to be validated. The MirSVR score for the miR-483-
5p/KCNE1L interaction was found to be -0.0408, with a PhastCons score of 0.6923 again 
demonstrating good conservation across mammalian genomes. 
 
(b)	  hsa-­‐miR-­‐208a:	  
The miRWalk database lists 15 validated targets (Appendix 1d) and 4688 predicted targets 
for miR-208a, of which 1994 were predicted by 3 or more databases (search criteria as 
described above).  
 
MED13: MED13 is a validated target of hsa-MiR-208a with significant potential clinical 
relevance in the study of AF. It has been identified to both be involved in the cardiac control 
of systemic energy metabolism (108) and in stress-dependent cardiac growth and 
fibrosis.(152). Target analysis of the miR-208a/MED13 interaction reveals 4 potential binding 
sites on the MED13 mRNA beginning at the following sites from the 5’end: (1) Base 499 (2) 
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Base 551 (3) Base 775 (4) Base 2981. MirSVR scores for the interaction varied from a lowest 
of -0.0220 (‘not good’, site (3)) to -1.2116 (‘good’ site (2)). PhastCons scores demonstrated 
good conservation across mammalian genomes for all target sites (Figure 3-4). 
 
 
 
 
Figure 3-4: Potential binding sites for hsa-miR-483-5p with MED13 mRNA 
(http://www.microrna.org). 
 
 
GATA4: The GATA4 gene encodes a zinc-finger transcription factor protein that is thought 
to be essential for normal cardiac development. Mutations in the GATA4 gene have not only 
been associated with congenital structural abnormalities, but have also been identified in 
idiopathic AF.(153) GATA4 was predicted as a target for miR-208a by 3 of the 8 databases 
(MiRanda, PICTAR5 and TargetScan). The MirSVR score for the miR-208a/GATA4 
interaction was found to be -0.0546, with a PhastCons score of 0.6439 again demonstrating 
good conservation across mammalian genomes. 
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3.3.3	  Assessment	  of	  target	  mRNA	  
Expression of target atrial mRNA was assessed by RT-qPCR using universal RT primers. As 
discussed above, the following targets were evaluated:  
• miR-483-5p: KCNE5 and MAPK3 
• miR-208a: GATA4, MED13 
 
No significant difference was observed in atrial mRNA expression of GATA4, MED13, 
KCNE5, or MAPK3 between AF and non-AF groups (Table 3-3). However, despite not 
reaching statistical significance, the expression of KCNE5 mRNA tended to be lower in the 
AF group suggesting that the presence of increased levels of miR-483-5p may be producing a 
modest degree of knockdown of this predicted target (Figure 3-5). Furthermore, the standard 
deviation appeared much greater in the AF group than in patients maintaining sinus rhythm 
suggesting that the degree of variation in target knockdown may be high between individuals. 
This finding would in fact be expected in a complex, multifactorial disease process such as 
post-operative atrial fibrillation and the expression of KCNE5 protein will therefore examined 
in more detail (Section 3.3.4).  
 
 
 
Table 3-3: Mann-Whitney U test to assess the significance of differences in fold change of target 
mRNA expression between AF and non-AF groups. No significant differences were observed in any of 
the target mRNA identified.  
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Figure 3-5: Differential expression of KCNE5 mRNA in AF vs. non-AF groups. 
 
3.3.4	  KCNE5	  protein	  expression	  
Missense mutations in KCNE5 (KCNE1L) have been associated with non-familial or 
acquired AF. Mutant KCNE5 protein is thought to exert a lesser suppressive effect on the 
KCNQ1 subunit, resulting in a gain of function of the inward rectifier potassium channel, 
shortening of action potential duration and increased susceptibility to re-entrant 
tachyarrhythmia.(151) 
 
KCNE5 (KCNE1L) protein levels were evaluated in the atrial tissue of a subgroup of 4 POAF 
and 5 non-POAF patients. Patients developing POAF were identified to have a significantly 
higher level of KCNE5 protein in atrial tissue samples taken at the time of surgery when 
compared to non-POAF patients (p=0.0317) (Figure 3-6).  
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Figure 3-6: Western blot analysis of KCNE5 protein levels in atrial tissue biopsies of POAF vs. non-
POAF patients 
 
 
3.3.5	  MiR-­‐483-­‐5p,	  systemic	  inflammation	  and	  cellular	  adhesion	  in	  POAF	  
Based on the significant miR-483-5p upregulation in the pre-operative serum and intra-
operative atrial tissue of POAF patients, further pathway analysis was carried out on the 
predicted targets of this miRNA. The DIANA-mirPath and DAVID bioinformatics databases 
(http://david.abcc.ncifcrf.gov) (154, 155) were used to predict KEGG pathways significantly 
enriched by targets predicted using the miRWalk program as previously described. These 
results highlighted significant enrichment of 'focal adhesion' and 'cellular adhesion molecules 
(CAMs)' pathways (Figure 3-7) (p=0.00055 and p=0.0037 respectively).  
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Figure 3-7: KEGG pathway for 'focal adhesion' and 'cellular adhesion molecules (CAMs)' showing potential targets of miR-483-5p highlighted in red.
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Local and systemic inflammation is well recognised to play a role in both the triggering and 
maintenance of AF. Furthermore, recent evidence suggests a role for vascular cell adhesion 
protein VCAM1 as a potential pre-operative serum biomarker of post-operative AF.  
 
As shown in Figure 3-8, through detailed exploration of the current literature, two potential 
regulatory mechanisms linking the derangement in miRNA profile seen in this POAF patient 
cohort and perturbation in the vascular cell adhesion molecule VCAM-1 can be observed:  
(1) MiR-483-5p may bind with target mRNA thus negatively regulating RhoA gene 
expression. RhoA protein is noted to decrease the expression of VCAM1 protein as 
mediated by the P2Y2R protein. It may therefore follow that increased pre-operative 
expression of mir-483-5p may reduce expression of RhoA thus giving rise to an 
increase in serum VCAM1 protein expression.  
(2) MiR-483-5p may bind with its MAPK3 gene target and subsequently reduce MAPK3 
gene expression. MAPK3 can be observed to have a negative effect on VCAM1 gene 
expression, therefore a reduction in MAPK3 may result in increased VCAM1 protein 
levels.  
94 
 
 
Figure 3-8: Pathway analysis of possible links between hsa-miR-483-5p and cellular pathways 
identified to play a role in human atrial fibrillation. Possible pathway links between VCAM1 in human 
serum and miR-483-5p gene expression are shown in blue. 
	  
3.3.6	  Serum	  VCAM-­‐1	  expression	  is	  increased	  in	  POAF	  patients	  
Following cardiac surgery, both surgical trauma and cardiopulmonary bypass result in the 
activation of cytokines and leukocyte trafficking producing a local and systemic 
inflammatory response. The link between inflammation and post-operative atrial fibrillation 
has been confirmed by a number of epidemiological studies, and increased levels of IL-6 and 
IL-2 have been associated with an increased incidence of post-operative AF.(156) More 
recently, the soluble vascular endothelial cell adhesion molecule VCAM-1 has been found to 
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be significantly higher in the pre-operative plasma of patients developing post-operative atrial 
fibrillation compared to those that do not, suggesting the existence of a pre-existing pro-
inflammatory state. (157)  
 
Serum VCAM-1 was significantly increased in the pre-operative serum of patients developing 
post-operative atrial fibrillation when compared to controls (p=0.022) (Figure 3-9). This 
confirms the results observed by Verdejo et al. and highlights the potential role of serum 
VCAM-1 as a pre-operative biomarker of POAF.(157) 
 
ELISA evaluation of serum VCAM-1 concentration at 48 hours (Figure 3-10(a)) and 96 
hours (Figure 3-10(b)) post-operatively did not reveal any difference between the POAF and 
non-POAF groups, however a significant reduction in serum VCAM-1 concentration was 
observed between the pre-operative and 48hr post-operative time points in the AF group 
when compared to non-AF (Figure 3-11).  
 
 
 
Figure 3-9: Concentration of pre-operative serum soluble VCAM-1 in AF vs. non-AF patients 
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Figure 3-10: Concentration of serum soluble VCAM-1 in AF vs. non-AF patients at: (a) 48hrs post-
operatively; (b) 96hrs post-operatively.  
 
 
 
 
 
Figure 3-11: Change in concentration of serum soluble VCAM-1 in AF vs. non-AF patients between: 
(a) Pre-operative and 48hrs after surgery; (b) Pre-operative and 96hrs after surgery and (c) 48hrs and 
96hrs after surgery.  
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3.4.	  Discussion	  
 
Based on the results of microarray and real-time quantitative PCR experiments discussed in 
Chapter 2, systematic bioinformatic target prediction and subsequent experimental validation 
has identified a potential interaction between miR-483-5p and the voltage gated potassium 
channel regulator subunit KCNE5, which in turn may play a role in the pathogenesis of de 
novo post-operative atrial fibrillation.  However, similar analysis was not able to identify any 
changes in mRNA expression of the predicted miR-208a targets selected for experimental 
validation, and further investigation is required to validate the mechanistic role of this 
microRNA.  
 
Second, this work has identified significantly higher levels of VCAM-1 in the pre-operative 
serum of AF patients and protein/gene network analysis has revealed a potential link between 
serum VCAM-1 and microRNA-483-5p. As such, I have identified not only two potential 
pre-operative serum biomarkers for POAF, but also a second potential mechanism whereby 
miRNA-483-5p may be involved in the pathogenesis of this arrhythmia. 
 
3.4.1	  MicroRNA	  dysregulation:	  A	  pre-­‐existing	  atrial	  substrate	  for	  POAF?	  
As previously discussed, a wide variety of electrical and structural factors are likely to 
contribute to the triggering and maintenance of atrial fibrillation in the human heart. In 
patients undergoing cardiac surgery with no prior history or recognisable risk factors for the 
condition, approximately 1 in 3 will develop de novo post-operative atrial fibrillation, and 
although a proportion of these may be in part accounted for by aberrations in electrolyte 
balance or post-operative infection, others display no discernable predictors for the 
arrhythmia. Similarly, not all patients with temporary electrolyte disturbances or post-
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operative infections will go on to develop POAF and thus it is hypothesised that a sub-clinical 
substrate for AF propagation and maintenance exists in these individuals.  
 
In order to understand the significance of microRNA dysregulation in the complex 
pathogenesis of this arrhythmia this chapter has utilised several database and bioinformatics 
tools to identify potential mechanisms and pathways through which these miRNA may 
regulate cardiac conduction. For miR-483-5p a total of 4985 predicted and 17 validated 
targets were identified, with 4688 predicted and 15 validated target genes found for miR-
208a.  
 
3.4.2	  MiR-­‐208a	  
MicroRNA-208 is an intronic, cardiomyocyte specific microRNA encoded for and co-
expressed with the α-Myosin Heavy Chain (α-MHC/Myh6) gene. Over the past 5-10 years 
this microRNA has received particular attention in field of cardiovascular research, especially 
in the regulation of cardiac energy homeostasis,(108, 152) hypertrophy and fibrosis.(116, 158, 
159) In animal models, both the miR-208a over-expression transgenic mouse and the miR-
208-/- knockout mouse demonstrate cardiac conduction defects despite not displaying any 
macroscopic morphological anomalies. In their 2009 work, Callis et al. demonstrated an 
increased PR interval and heart block in mice over-expressing miR-208a, and detected atrial 
fibrillation in 80% (n=10) of miR-208a-/- knockout mice.(116) Further analysis identified a 
significant reduction in the protein levels of the miR-208a target GATA4, itself a 
transcriptional regulator of the homeodomain-only protein (Hop) transcription factor that 
when suppressed results in a loss of Connexin 40 expression. By verifying this sequence of 
regulation from miR to connexin expression, this detailed study identified a likely mechanism 
by which suppression of miR-208a may result in atrial fibrillation.(116) It is also notable that 
GATA4 transcript levels remained unchanged despite suppression of GATA4 protein, a 
finding which may correlate with the results seen in my human study. These observations are 
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therefore consistent with post-transcriptional suppression of GATA4 activity by miR-208a, 
and further experimental validation of GATA4 protein suppression in human atrial tissue is 
now required to verify this pathway in human POAF pathogenesis. 
 
In addition to its confirmed actions on GATA4, miR-208a has also been shown to directly 
regulate the thyroid hormone receptor protein-1 (THRAP1 or MED13), a component of the 
mediator complex which itself regulates thyroid hormone related transcription.(108) The 
mediator complex (MED) is a transcriptional co-activator complex recruited by 
transcriptional activators or nuclear receptors to induce gene expression.(160) It is thought 
that MED interacts with RNA polymerase II and thus promotes the formation of a 
transcriptional pre-initiation complex. The role of thyroid hormone receptor protein-1 in this 
complex is in forming the kinase sub-module, a sub-complex with MED12, cyclin dependent 
kinase-8 (CDK8) and Cyclin C, which in turn negatively regulates MED transactivation.(108, 
160) Several studies have verified the role of miR-208a in regulating THRAP1 expression. 
Indeed, transgenic miR-208 overexpression mice express significantly lower levels of 
THRAP1 protein, and miR-208-/- knockout mice express significantly higher levels of 
THRAP1 protein than wild-type littermates, without associated changes in THRAP1 
transcript levels, again suggesting post-transcriptional regulation by miR-208a.(116)  
  
At birth, thyroid hormone signaling regulates cardiac contractility by controlling a switch 
from the slow myosin heavy chain (β-MHC) to the fast twitch α-MHC isoform. Conversely, 
β-MHC is up-regulated in response to cardiac stress such as pressure overload. MicroRNA-
208a has been shown to regulate this β-MHC stress response, and by binding to THRAP1 
may thus increase β-MHC expression (Figure 3-12). Indeed, cardiac expression of both 
THRAP1 and miR-208a have been found to be involved in the control of systemic energy 
expenditure, diet induced obesity and metabolic syndrome,(108) and the hearts of miR-208-/- 
mice demonstrate similarities to hyperthyroid hearts, with up-regulation of stress response 
genes and increases in fast-twitch skeletal muscle expression.(152) THRAP1 therefore 
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represents a potential target whereby miRNA-208a may regulate human atrial fibrillation. 
Decreased expression of mir-208a removes translational inhibition on THRAP1 and thus 
reduces β-MHC expression, particularly in response to stress. It is therefore possible that the 
reduction in miR-208a observed in the right atrial biopsies of POAF patients produces an 
increased susceptibility to AF due to a relative up-regulation of fast-twitch α-MHC isoforms, 
particularly in response to stressful stimuli such as cardiopulmonary bypass, as a result of an 
under-expression of β-MHC and a hyperthyroid phenotype.  
 
 
Figure 3-12: The role of miR-208 in regulating THRAP1 and thyroid hormone signaling pathways. 
Down-regulation of miR-208a results in an increase in THRAP1 protein and inhibition of the mediator 
complex. This inhibits T3 signaling, producing a relative increase in α-MHC and decrease in β-MHC. 
This effect is particularly notable in response to cardiac stress where β-MHC would usually be up-
regulated.  
 
Most recently, microRNA-208a has also been found to be down-regulated in the right atrium 
of human patients with chronic and paroxysmal atrial fibrillation undergoing CABG and or 
valvular surgery.(161) This study also highlighted an increased maximal mitochondrial 
respiration rate in AF vs. non-AF samples, suggesting that AF correlates with a perturbation 
of mitochondrial function; however the relationship between miR-208a dysregulation and 
mitochondrial function is yet to be investigated. 
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MiR-208 is usually undetectable in the circulating blood. However, its release into blood 
plasma/serum has been associated with ischaemic injury, both in the form of angina pectoris 
and in acute myocardial infarction.(162) MiR-208 was un-detectable in the pre-operative 
serum of both sinus rhythm (SR) and post-operative AF (POAF) patients included in this 
study (by RT-qPCR, Ct >34; results not shown) suggesting that although all patients had 
confirmed diagnosis of significant coronary artery disease requiring surgical 
revascularization, acute ischaemia and cardiomyocyte damage prior to surgery was equivalent 
in both groups.  
 
3.4.3	  MicroRNA	  483-­‐5p	  (hsa-­‐miR-­‐483-­‐5p)	  
 
Hsa-miR-483-5p has received relatively little attention when compared to other more widely 
studied microRNA; however, over recent years research into this miR is gaining momentum. 
In 2011, Qiao et al. demonstrated over-expression of mir-483-5p to be associated with an 
inhibition of wound healing and angiogenesis in a mouse model, and Soon et al. observed a 
poorer prognosis in patients with adrenocortical adenocarcinoma overexpressing miR-483-
5p.(119, 163) Conversely, Wang and colleagues observed suppression of glioma cell 
proliferation and induced G0/G1 arrest in patients overexpressing hsa-miR-483-5p, and by 
identifying ERK1 as a direct target of this microRNA, provided evidence for its role as a 
glioma tumor suppressor.(164) More recently, hsa-miR-483-5p has been shown to play a role 
in regulation of human fetal neuronal development via modulation of methyl-CPG binding 
protein 2 (MeCP2) and the MeCP2-interacting corepressor complexes HDAC4 and 
TBL1X.(165) Of particular interest is the work by Wang et al, which demonstrated 
overexpression of serum hsa-miR-483-5p to be an independent predictor of 28-day mortality 
in their cohort of 214 sepsis patients admitted to the intensive care unit (univariate OR 1.08 
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95%CI (1.01, 1.15), p=0.007; multivariate OR1.29 (95% CI: 1.08–1.55) p=0.006), suggesting 
a potential role for this microRNA as a predictive biomarker of poor outcome.  
 
The role of hsa-miR-483 in the heart currently remains largely undetermined. Recent Illumina 
Sequencing results published by Hsu et al (166) identified increased expression of hsa-miR-
483-5p in left atrial biopsies when compared to samples taken from the right atrium of human 
patients (Atrial concentration (based on the average fraction of total mapped miRNA reads in 
the left and right atria)= 1.10E-03; Absolute FC =1.56; p=0.0092; False discovery rate 
(FDR)= 7.92E-02). However, this study was not designed to correlate these differential 
expression profiles with any particular pathology. Ward et al. identified a significant 
reduction in hsa-mir-483-5p expression in the blood plasma of patients with evolving 
NSTEMI as determined by increased plasma troponin-I 6 hours after arrival in the emergency 
department.(167) 
 
3.4.3.1	  A	  mechanistic	  role	  for	  Mir-­‐483-­‐5p?	  
 
Analysis of potential targets for miR-483-5p implicates both electrical and structural 
remodeling pathways. This work has demonstrated a significant increase in the expression of 
atrial KCNE5 protein in the right atrial tissue of patients subsequently developing POAF 
when compared to those maintaining sinus rhythm (p=0.0317). These results therefore 
highlight a mechanism for miRNA-483-5p in atrial electrical remodeling present prior to the 
onset of the clinical arrhythmia.  
 
KCNE5 forms part of a group of regulators (KCNE1-KCNE5) of the voltage gated potassium 
channel responsible for the slow inward rectifying potassium current (IKs). Its gene product, 
MiRP4, is a membrane spanning protein thought act as a down-regulator to the α-subunit 
KCNQ1. Down-regulation of KCNQ1 subsequently results in the suppression of IKs, which 
may in turn shorten action potential duration.  
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Missense mutations leading to a loss of function of KCNE5 have been associated with non-
familial or acquired AF. Mutant KCNE5 protein is thought to no longer exert the same 
suppressive effect on the KCNQ1 subunit, resulting in a gain of function of the inward 
rectifier potassium channel, shortening the action potential duration and increased 
susceptibility to re-entrant tachyarrhythmia.(151)  
 
Upregulation of miR-483-5p may therefore also act to increase IKs through suppression of 
KCNE5, reduced MiRP4 and a loss of inhibition of KCNQ1. This up-regulation of IKs within 
the atrial myocardium would subsequently lead to shortening of the refractory period giving 
rise to the potential for macro re-entrant circuits to develop leading to increased susceptibility 
to atrial fibrillation.(151) As such, these findings now require further investigation with larger 
sample numbers to validate the level of KCNE1L protein expression and in vitro studies to 
confirm the KCNE1L/miR-483-5p interaction. 
 
3.4.3.2	  miR-­‐483-­‐5p	  and	  MAPK	  signaling	  
 
In addition to its role in regulating cardiac conduction through voltage gated potassium 
channel function, bioinformatic target prediction has highlighted the MAPK signaling 
pathway as a target site for miRNA-483-5p. Extracellular-signal-regulated kinases (ERK1/2) 
otherwise known as mitogen-activated protein kinases (MAPK3) are part of a family of 
intracellular signaling protein kinases that regulate a wide range of cellular processes 
including cell growth, proliferation, differentiation and apoptosis.(168) In the atrial 
myocardium, MAPK3 may be activated (phosphorylated) as a result of angiotensin II binding 
with AT1 receptors, resulting in stimulation of transcription factor activation and induction of 
expression of pro-fibrotic gene expression resulting in fibroblast differentiation, extracellular 
matrix accumulation and subsequent increased susceptibility to arrhythmia.(148) Indeed, both 
MAPK3 mRNA and protein expression has been found to be up-regulated in the right atrial 
appendage of patients with rheumatic heart disease and either chronic or paroxysmal AF 
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when compared to sinus rhythm.(148) MAPK3 has however also been implicated in the 
systemic inflammatory response, with leucocyte adhesion and transendothelial migration also 
being mediated by MAPK3 signaling pathways. Up-regulation of MAPK3 may therefore 
stimulate endothelial activation thus contributing to inflammatory pathways underlying AF 
pathogenesis.(169)  
 
MiR-483-5p demonstrates good interaction with its predicted MAPK3 target with a MirSVR 
score of -1.0996. It is therefore possible that binding of miR-483-5p with the MAPK3 target 
results in a reduction in MAPK3 protein expression altering the myocardial response to ATII 
signaling as well as acting on systemic inflammatory pathways and endothelial leukocyte 
recruitment. Given this multifaceted network of MAPK3 signaling, it is likely that the miR-
483-5p/MAPK3 interaction mediates POAF pathogenesis by a number of mechanisms, and 
detailed further study both in vitro and in vivo are now required to elucidate its role in the 
pathogenesis of this multifactorial arrhythmia. 
 
3.4.3.3	  MicroRNA	  483-­‐5p	  and	  cellular	  adhesion	  in	  POAF	  
Vascular cell adhesion molecule 1 (VCAM-1) is an 81 KDa sialoglycoprotein expressed by 
cytokine activated vascular endothelium, dendritic and macrophage-like cells. It is a member 
of the immunoglobulin superfamily, with 6 or 7 extracellular Ig domains, capable of 
interacting with the integrins α4β1 (VLA4), α4β7, and αdβ2 present on eosinophils, basophils, 
mast cells, monocytes and other lymphocytes in order to mediate signal transduction and/or 
cell adhesion and transendothelial migration (Figure 3-13).(170) This binding also relies on 
the activation state of the integrins and co-expression of other factors such as CD24 and 
Galectin-3.  
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Figure 3-13: Leukocyte adhesion: The role of VCAM-1 and other mediators of transendothelial 
migration. 
 
 
VCAM-1 expression is regulated by a number of factors including inflammatory cytokines 
such as TNF-α, IL-1β, and stimulation of toll like receptors on endothelial cells, fibroblasts 
and dendritic cells. Furthermore, VCAM-1 gene expression is regulated by the NFκB 
transcription factor, which may be activated by TNF-α and reactive oxygen species such as 
superoxide radicals generated by sheer stress and microbial stimulation. Soluble VCAM-1 
(sVCAM-1) may be released into the plasma by cleavage involving metalloprotease and 
disintigrin. Release of sVCAM-1 has not only been associated with a number of 
cardiovascular disease processes including human post-operative atrial fibrillation,(157) but is 
also observed as early as 3 hours after routine cardiopulmonary bypass alongside increased 
endothelial cell E-selectin expression.(171) It has been shown that this soluble VCAM-1 may 
have a direct chemotactic effect on leucocytes as well as stimulating inflammation and 
angiogenesis in nearby endothelial cells in a paracrine manner.(172) However, it has also 
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been postulated that such soluble VCAM-1 may actually act to dampen down leukocyte 
adhesion by binding to cell surface receptors of circulating leukocytes and preventing 
adhesion.(173)  
 
Binding of leucocyte integrins to endothelial VCAM-1 not only results in leucocyte adhesion 
but also stimulates a number of downstream processes mediated through Rac1 and reactive 
oxygen species (ROS). Upon binding to VCAM-1, Rac1 signaling cascades are activated and 
there is a rapid release of intracellular calcium through verapamil sensitive calcium channels. 
This in turn leads to the activation of NADPH oxidase and generation of the reactive oxygen 
species superoxide (O.) and hydrogen peroxide (H2O2), which subsequently activate p38-
membrane associated protein kinase (p38MAPK), matrix metalloproteases (MMPs) and 
protein kinase C (PKCα). This ‘outside-in’ signaling is not only crucial for trans-endothelial 
leucocyte migration (mediated by ROS) but also produces a conformational change in 
endothelial cell structure by altering intracellular actin structure allowing the formation of 
gaps between cells of the endothelial monolayer (figure 3-14).(174)  
 
 
As previously discussed, inflammation plays a key role in the pathogenesis of both de novo 
and post-operative atrial fibrillation. Interestingly, my results have verified findings by 
Verdejo et al. demonstrating that increased levels of circulating serum VCAM-1 predict 
POAF in patients with sinus rhythm undergoing CABG where there is no prior history of the 
arrhythmia.(157) These findings support the suggestion that POAF is associated with a pre-
existing atrial substrate or systemic inflammatory state whereby this arrhythmia may be 
predicted prior to cardiac surgical intervention. Interestingly, pre-operative serum VCAM-1 
appears to be a more reliable predictor of POAF than other markers of systemic inflammation 
such as hsCRP and IL-6, which are often confounded by age and other medical co-
morbidities.(36) As VCAM-1 more specifically reflects endothelial cell activation, it has been 
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suggested that endothelial dysfunction and thus susceptibility to CPB related ROS generation, 
may be a key factor underlying the pathogenesis of POAF.(157)  
 
	  
Figure 3-14: VCAM-1 signaling in endothelial cells and its regulation in inflammation 
	  
 
In light of my observed concomitant serum changes in the expression profile of microRNA-
483-5p in this POAF, and the potential for this microRNA to regulate a number of 
inflammatory signaling cascades, I proceeded to investigate whether miRNA-483-5p may in 
fact regulate VCAM-1 expression and thus play a role in endothelial cell dysfunction.  
 
Pathway analysis using Ingenuity Pathway Analysis (IPA) software 
(http://www.ingenuity.com/products/ipa) (Figure 3-8) identified two potential regulatory 
mechanisms linking hsa-miR-483-5p and VCAM-1 expression. As previously discussed, 
VCAM-1 signaling is in part mediated by the Rac signaling pathway with involves a number 
of small GTPase proteins including Ras homologue gene family, member A (RhoA) (Figure 
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3-15). RhoA is identified as a potential target of hsa-miR-483-5p with its binging site at base 
158 from the 5’ end of the RhoA mRNA. This binding site is well conserved with a 
PhastCons score of 0.7483 and shows moderate complementarity with a miRSVR score of -
0.5121 (Figure 3-16).  
 
 
Figure 3-15: The Rac signaling pathway (courtesy of Ingenuity Systems inc.) 
 
 
Figure 3-16: Binding of hsa-miR-483-5p with RhoA mRNA. 
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Inhibition of RhoA by miRNA-483-5p may increase activity or expression of the nuclear 
receptor ligand-activated transcription factor peroxisome proliferator-activated receptors 
(PPAR), which may in turn suppress NF-kB and AP-1-mediated gene activation, down-
regulating VCAM-1.(175) Interestingly, this mechanism of action may also be shared by 
HMG-CoA Reductase inhibitors (or ‘Statins’), a class of drug which although originally 
identified for their lipid lowering effects and subsequent role in cardiovascular disease 
prevention, also possess a number of “pleiotropic” properties, and are associated with a 
reduction in post operative atrial fibrillation.(176, 177) By inhibiting cholesterol synthesis, 
statins may themselves also inhibit RhoA activity by depleting isoprenoid production, 
preventing RhoA anchoring to the plasma membrane and thus rendering it inactive.(178) 
Through this and other mechanisms, statins increase endothelial nitric oxide synthesis, reduce 
paracellular permeability and reduce ROS generation thus improving endothelial function and 
reducing vascular inflammation.(179)  
 
A second potential mechanism by which hsa-miR-483-5p may regulate VCAM-1 expression 
is via inhibition of the membrane associated protein kinase complex MAPK3 (or ERK1/2). 
This extracellular signaling kinase is involved in a number of cell signaling processes 
including cell differentiation and proliferation, and increased MAPK3 expression has been 
previously identified in patients with chronic AF and atrial fibrosis.(148) Furthermore, 
MAPK3 has been previously validated by luciferase assay to be a direct target of hsa-miR-
483-5p.(164) There are several proposed mechanisms by which expression of VCAM-1 may 
be altered by changes in MAPK3 (or ERK1/2) signaling. Firstly, as previously discussed, 
binding to VCAM-1 stimulates a signaling cascade involving NADPH oxidase, protein kinase 
C alpha and protein tyrosine phosphatase 1B (PTP1B). VCAM-1 associated production of 
PTP1B has subsequently been shown to result in activation of MAPK3, which in turn acts to 
regulate leucocyte adhesion and transendothelial migration. In fact, VCAM-1 mediated 
transendothelial migration may be blocked by inhibition of MAPK3.(180) It is therefore 
possible that these observed increases in circulating hsa-miR-483-5p levels form part of a 
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systemic response to inflammation, acting to inhibit MAPK3 and thus dampen the cellular 
response to increased VCAM-1 expression. Conversely however, phosphorylation of MAPK3 
(ERK1/2) stimulates binding of the transcription factors NFkB, AP-1 and SP-1, all of which 
regulate cytokine dependent induction of VCAM-1 expression.(174, 181, 182) Binding of 
hsa-miR-483-5p to MAPK3 may therefore reduce transcription factor activity, thus resulting 
in a down-regulation of transcription factor related VCAM-1 expression and a fall in soluble 
VCAM-1 shed from circulating endothelial cells.  
 
In order to investigate these theoretical mechanisms correlating hsa-miR-483-5p expression 
with soluble VCAM-1 levels detected in human serum mechanistic studies into the relative 
changes in MAPK3 and RhoA protein expression are now required. Unfortunately, it was not 
possible to evaluate RhoA expression in the atrial tissue owing to insufficient sample 
available for protein extraction, and, as an intracellular signaling protein, RhoA is not present 
in the circulating serum at sufficient levels to allow for quantitative analysis. Furthermore, the 
interaction between hsa-miR-483-5p and its predicted target RhoA must be validated and its 
functional significance tested.  
 
3.4.3.4	  MiRNA-­‐483-­‐5p	  and	  RhoA	  signaling	  	  
RhoA is a small GTPase protein belonging to the Ras superfamily involved in cell migration, 
transcription regulation and organization of the actin cytoskeleton (Figure 3-17). In the 
cardiovascular system, increased levels of activated RhoA (GTP bound) have been associated 
with protection against ischaemia-reperfusion injury,(183) and RhoA signaling has been 
identified to play a key role in cardiac hypertrophy, particularly in response to stretch.(184, 
185) Furthermore, several studies utilizing C3 exoenzyme blockade of RhoA signaling have 
also demonstrated the importance of this pathway in promoting integrin dependent leukocyte 
adhesion (186) and de-adhesion.(187) By acting on the actin cytoskeleton, activation of the 
RhoA pathway prevents neutrophil spreading on the endothelial cell membrane, reducing the 
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affinity of integrin binding and thus promoting de-adhesion and preventing transendothelial 
migration.(187) 
 
 
Figure 3-16: The RhoA signaling pathway (courtesy of Ingenuity Systems inc.) 
 
It therefore follows that miR-483-5p post-transcriptional regulation of RHOA gene 
expression may play a key role in endothelial cell function and regulation of the systemic 
inflammatory response.  Furthermore, as suppression of RhoA may also suppress NF-kB and 
AP-1-mediated gene activation, this small GTPase may also explain the observed changes in 
VCAM-1 expression.  
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3.4.4	  Limitations	  
This work demonstrates exciting novel findings in the field of atrial fibrillation biomarker 
research. However, several limitations should also be considered when interpreting these 
results. Firstly, the proposed interactions between microRNA-208 and microRNA-483-5p and 
their respective clinically relevant targets are based on previously published data and have not 
yet been validated either in this patient cohort or within the wider literature. Secondly, no 
single target prediction tool is perfect in determining the functional target sites for a given 
miRNA. Although most tools now incorporate a combination of seed pairing, target 
conservation and thermodynamic favourability into their prediction algorithms, in some cases 
functional sites may still be missed, and non-functional sites may be over represented. For 
example, the reliability of thermodynamic energy calculations remains under debate, and 
there is evidence to suggest that non-conserved binding sites in the 3'UTR may indeed be 
functional and thus missed by conventional prediction algorithms.(188, 189) Third, although 
prediction tools provide species specificity, there is little focus on tissue specificity and the 
functional nature of a mRNA:miRNA interaction may vary according to tissue type, and 
subtype as well as the functional state of the cell.(189) Finally, pathway enrichment analysis 
is reliant on the availability of published gene and protein interactions, and is thus limited by 
the degree of experimental data currently available. As such, subsequent experimental work 
may in future alter the way in which these cellular signaling pathways are understood and 
represented, thus changing the way in which the results of this study may be interpreted. 
 
3.5	  Conclusions	  
This work has utilised a comprehensive bioinformatic target prediction and network analysis 
to identify the potential mechanisms by which miRNA dysregulation may produce the 
downstream cellular changes that result in a post-operative atrial fibrillation.  
Firstly, the predicted targets for the 16 differentially expressed miRNA evaluated in Chapter 2 
were used to determine the cellular pathways that may be involved in AF pathogenesis. This 
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exposed the significant enrichment of cellular adhesion molecule pathways in patients over-
expressing hsa-miR-483-5p, and for the first time revealed a potential link between this 
miRNA and the vascular endothelial adhesion molecule VCAM-1. Evaluation of serum 
VCAM-1 in this patient cohort corroborated previous findings that patients developing POAF 
express higher levels of pre-operative VCAM-1 than those maintaining sinus rhythm, and in 
addition showed a significant fall in VCAM-1 expression within 48hrs post-operatively. 
These findings together support the hypothesis of a systemic inflammatory substrate for this 
arrhythmia and highlight the potential for biomarker development both in miR-483-5p and 
VCAM-1.  
 
Secondly, a focused assessment of clinically relevant miRNA target sites identified a 
potential interaction between miR-483-5p and KCNE5, which in turn may result in a loss of 
inhibition on the voltage gated potassium channel regulator subunit KCNQ1, resulting in a 
gain of function of the inward rectifier potassium channel, shortening of action potential 
duration and increased susceptibility to atrial fibrillation. This is the first study to evaluate 
this pathway in atrial fibrillation patients and subsequent investigation now requires 
validation of this finding in a larger patient cohort. In addition, the miR-483-5p:KCNE5 
target interaction must now also be validated both in vitro and in subsequent small animal 
models in order to confirm the predicted functional disruption of the downstream cellular 
pathways that ultimately regulate cardiac conduction.  
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Chapter	  4	  
Structural	  and	  Electrical	  remodeling:	  Dedifferentiation	  and	  
aberrant	  calcium	  handling	  	  
 
4.1	  Background	  
4.1.1	  Gene	  expression	  in	  atrial	  fibrillation	  
Chapters 2 and 3 highlight a number of potential microRNA, gene targets and subsequent 
pathways that may be perturbed in the atrial myocardium of patients developing post-
operative atrial fibrillation. Together these findings add weight to the hypothesis that prior 
atrial substrate changes pre-dispose to POAF, which encompasses aspects of both structural 
and electrical remodeling. These findings appear to mirror many observations in both 
paroxysmal and chronic AF, further suggesting that rather than ensuing as a result of post-
surgical inflammation and disordered electrolyte balance, POAF forms part of a common 
spectrum of pro-arrhythmogenic modifications also observed in paroxysmal and persistent 
forms of this condition. 
 
Over the past decade, there has been growing evidence to suggest that both structural and 
electrical remodeling occur at a transcriptional level. In their study of 30 patients (10 
permanent AF, 20 SR), Barth et al.(190) identified 1434 genes differentially expressed 
between the atria of AF and SR patients. GO analysis of these genes highlighted a general 
downregulation of transcription factor activity particularly implicating calcium-dependent 
signaling pathways through reduced expression of calcineurin Aα, NFATc3, MAPK and 
CaMK.  
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In fact, a number of gene expression studies now implicate intracellular calcium signaling as 
a key mediator of chronic AF pathogenesis, both directly through reduced SR reuptake and/or 
increased Ca2+ release, and indirectly through inflammatory and oxidative pathways. Firstly, 
reduced SERCA2A gene expression may produce cytosolic calcium overload through 
decreased SR reuptake.(191-193) Second, upregulation of genes encoding a splice variant of 
the ryanodine receptor (RYR3) channel may promote calcium loading by increasing release 
from the SR.(190) Conversely however, AF associated gene expression changes may also act 
to increase SR calcium re-uptake and restore calcium homeostasis. Sarcolipin (SLN), an 
inhibitory regulator of SERCA, may be downregulated in chronic AF, thus leading to 
increased SERCA activity.(194) Furthermore, reduced RYR gene expression and RyR 
receptor activity (measured through the maximal number of RYR 3H binding sites) has also 
been observed in chronic AF associated with mitral valve disease, likely at least in part as a 
consequence of mechanical volume overload.(193) Indirectly, dysregulation of RhoC 
signaling may promote AF pathogenesis through both perturbation of ROCK signaling 
pathways as discussed in Chapter 3, and through MAPK and PI3K signaling which in turn 
may alter sarcoplasmic reticulum calcium uptake.(195) Similarly, increased expression of the 
pro-oxidant monoamine oxidase B may produce intracellular Ca2+ overload through 
generation of H2O2, mitochondrial damage and increased mitochondrial Ca2+ release.(64) 
 
Further to changes in genes regulating myocyte calcium homeostasis, a number of studies 
have demonstrated dysregulation of inflammatory, oxidative and cell signaling pathways in 
chronic AF.(64, 190, 191) Upregulation of NF-κB, SMAD3, SMAD5, VEGF, NF-IL-6, and 
macrophage migration inhibitory factor (MIF) emphasise the pro-inflammatory 
transcriptional changes associated with chronic AF.(190) Increased expression of pro-
oxidative proteins such as monoamine oxidase B, in combination with a concomitant 
downregulation of anti-oxidant genes such as glutathione peroxidase, also highlight a state of 
increased oxidative stress in the atria of AF patients.(64) Furthermore, significant increases in 
reactive oxygen species and dysregulation of genes encoding glutathione-S-transferase, 
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thioredoxin, haeme oxidase, peroxiredoxin, cytochrome p-450, and xanthine dehydrogenase 
have been observed in post-CABG atrial fibrillation, implicating increases in mitochondrial 
derived oxidative stress as a central mediator in POAF pathogenesis.(64) Finally, idiopathic 
AF has also been associated with dysregulation of GJA5 and GJA1 genes encoding connexins 
40 and 43 respectively.(127, 196) As such, in addition to disrupted calcium signaling, 
oxidative stress and activation of pro-inflammatory mediators, gene expression mediated 
alterations in cell-cell coupling may add additional contribution to electrical remodeling 
through production of a conduction block that promotes both the setting-up and maintenance 
of re-entrant circuits.  
 
 
 
 
Figure 4-1: A summary of the gene expression changes observed in human atrial fibrillation. This 
incorporates upregulation of inflammatory pathways, mitochondrial oxidative stress, sarcoplasmic 
calcium channel remodeling, dysregulation of intracellular signaling and conduction block through 
dysregulation of gap junction connexins. 
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Together these gene expression changes demonstrate the complexity of signaling pathways, 
intra- and extra- cellular stimuli regulating AF pathogenesis through both electrical and 
structural remodeling (Figure 4-1). When combined with the network of post-transcriptional 
regulation through microRNA discussed in chapters 2 and 3, these findings highlight the 
intricacy of the genomic control of cardiac conduction, both in causation and in response to 
arrhythmia.  
 
4.1.2	  The	  role	  of	  epicardial	  adipose	  in	  atrial	  fibrillation	  pathogenesis	  
Epicardial adipose tissue (EAT) can be defined as the layer of fat between the epicardium and 
the visceral pericardium. It is embryologically derived from the splanchnopleuric mesoderm 
and retrieves its blood supply directly from the coronary arteries. It differs distinctly from 
pericardial adipose (PAT), which is located outside of the visceral pericardium and is not in 
direct continuity with the myocardium.(197) The role of the epicardial fat in post-operative 
atrial fibrillation was first evaluated in a 2004 study by Cummings et al, in which it was 
shown that preservation of the anterior fat pad between the pulmonary artery and the aorta 
may reduce the incidence of AF after coronary bypass surgery.(198) Since this time, there has 
been increasing focus on epicardial fat in both chronic and POAF pathogenesis with 
suggestion that adipose tissue may have a regulatory effect on cardiomyocytes through local 
paracrine signaling (Figure 4-2). Furthermore, neural plexi have since been identified within 
specific regions of EAT that provide direct autonomic regulation of cardiac conduction. In 
addition, increases in the volume of EAT have been shown to correlate positively with the 
severity of AF (199) and are associated with higher rates of AF recurrence after catheter 
ablation.(200) 
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Figure 4-2: A summary of the mechanisms by which EAT may modulate cardiomyocyte conduction 
and the onset and maintenance of atrial fibrillation. 
	  
EAT	  and	  inflammation	  	  
Epicardial adipose cells exist in close proximity to cardiomyocytes, and the lack of any 
defined fascial layer gives rise to a direct continuity between these two tissue types. This 
allows for paracrine mediators secreted by adipose cells to alter the cellular environment of 
the cardiomyocyte. One of the key factors thought to influence the pathogenesis of both lone 
and post-operative atrial fibrillation is the presence of a pro-inflammatory substrate that is 
evident through increases in the interleukins (IL)- 2, 6, 8, as well as TNFα and CRP. This in 
turn may stimulate electrical and structural remodeling that promotes re-entry and the 
triggering and maintenance of AF. Furthermore, it has recently been suggested that pro-
inflammatory mediators from the EAT may pre-dispose to increased incidence of POAF 
through promoting right ventricular dysfunction.(201, 202)  
 
The EAT is well recognised to secrete both pro- and anti-inflammatory cytokines and thus 
alteration in the balance of these factors may allow changes in the EAT secretome to 
predispose to AF. Indeed, upregulation in the secretion of pro-inflammatory cytokines such as 
Interleukin-6 (IL-6), tumor necrosis factor-α (TNFα), plasminogen activator inhibitor-1 (PAI-
1), monocyte chemoattractive protein-1 (MCP-1), nuclear factor NfkB, resistin and nerve 
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growth factor (NGF) have all been shown to be associated with AF.(203, 204) Through 
breakdown of triglycerides, the EAT is also able to release free fatty acids (FFAs) that act as 
an energy reserve for the myocardium in states of fasting. However, these FFAs present 
within the secretome may also activate JNK (c-Jun N-terminal kinase) and TLR (toll-like 
receptor)-2 and TLR-4 signaling pathways promoting inflammation and cellular insulin 
resistance.(205)  
 
Activin A, a member of the TGFβ superfamily has also been shown to be present in the 
secretome of EAT.(206) Through increases in collagen synthesis and upregulation of 
inflammatory genes encoding matrix metalloproteases (MMPs), vascular endothelial growth 
factor (VEGF) and hypoxia inducing factor (HIF1α),(206) Activin A produced by the EAT 
may induce fibrotic changes within the atrial myocardium that in turn promote regions of 
conduction block and set up a substrate for re-entry.  
 
Similarly, the EAT may also induce an anti-inflammatory substrate through release of 
cytokines such as adiponectin. Adiponectin is a collagen like protein encoded by the APM1 
gene that is produced during adipocyte differentiation. It has a fundamental role in lipid and 
glucose metabolism where it has been shown not only to increase fatty acid oxidation and 
improve muscle uptake and utilisation of FFAs, but also to improve insulin sensitisation and 
reduce insulin resistance.(207) Through a loss of these protective effects, suppression of 
macrophage foam cell formation and inhibition of vascular smooth muscle cell proliferation, 
reduced levels of adiponectin have been associated with type 2 diabetes, metabolic syndrome, 
and atherosclerosis.(207, 208) Similarly, a fall in adiponectin levels may also promote atrial 
remodeling and fibrosis leading to an increased incidence of POAF after CABG surgery.(209) 
Furthermore, lower levels of adiponectin have recently been associated with worse 
cardiovascular outcomes (including stroke, pulmonary odema and acute coronary syndrome) 
in anticoagulated female patients with chronic AF,(210) suggesting that modulation of the 
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EAT secretome may not only affect the presence or absence of AF but also the subsequent 
long term cardiovascular risk profile associated with this arrhythmia.    
 
EAT	  and	  Oxidative	  Stress	  
In addition to release of inflammatory mediators, the EAT secretome has also been shown to 
be a source of reactive oxidative species (ROS) such as superoxide and peroxinitrite and as 
such may promote atrial fibrillation through increases in oxidative stress.(211) Oxidation 
induced calcium entry through the NCX channel and reduction in the L- type calcium current 
(ICa) may result in intracellular calcium overload, producing a compensatory reduction in 
action potential duration (APD) and ERP thus promoting re-entry.(67, 212) Peroxide has also 
been shown to both accelerate activation kinetics and reduce inactivation of voltage gated 
potassium channels, resulting in a reduction in APD and ERP and promoting re-entry.(69) 
Exposure to oxidative stress may also influence cellular Na+ currents both by directly slowing 
inactivation of voltage gated Na+ channels and via secondary messengers such as protein 
kinase C (PKC).(71) Furthermore, peroxide may also enhance the slow inactivating Na+ 
current (INa) (70, 71), promoting diastolic depolarisation, action potential generation and 
arrhythmogenesis. 
 
In the long term, changes in gene expression to restore sarcoplasmic reticulum calcium 
storage and reduce intracellular overload as well as alterations in contractile protein 
expression (for example re-expression of β-myosin heavy chain and reversion to a fetal 
phenotype) may also promote the maintenance of AF.(67) Furthermore, peroxynitrite and 
hydroxyl radicals may also give rise to post-translational modification of myofibrillar proteins 
within atrial myocytes, leading to a reduction in high-energy phosphate supply to myosin 
ATPase.(65, 68). 
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EAT	  and	  neural	  control	  of	  cardiac	  conduction	  
In addition to paracrine signaling the EAT may have direct autonomic effects on cardiac 
conduction. The ganglionic plexi (GP) located within the epicardial fat pads form a key 
component of the autonomic nervous supply to the heart. GP stimulation results in increased 
parasympathetic effects, slowing heart rate and reducing atrial conduction time and refractory 
period. GP ablation is now common practice in the radiofrequency ablation of persistent AF.  
 
4.1.3	  Aims	  
The aim of this chapter was to investigate the relationship between the epicardial adipose 
tissue (EAT) and human post-operative atrial fibrillation. Though evaluation of the gene and 
subsequent protein expression, I aim to test the hypothesis that changes in make-up of the 
epicardial adipose modulate AF pathogenesis. Gene expression microarray techniques will be 
used to identify any differential expression between POAF and non-POAF samples from the 
same patient cohort studied in previous chapters. Any changes will be validated by RT-qPCR 
with subsequent downstream analysis of protein expression.  Where possible I then aim to 
correlate these findings with my previous analysis of atrial tissue in order to provide a more 
comprehensive understanding of the interplay between these two tissue types in POAF 
pathogenesis.  
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4.2	  Methods	  
4.2.1	  Tissue	  Sampling	  
Epicardial adipose tissue (EAT) was defined as adipose located between the myocardium and 
the visceral pericardium. All EAT samples were taken prior to onset of cardiopulmonary 
bypass from the right atrio-ventricular groove. Where possible, diathermy was avoided in 
order to minimise thermal cellular damage that may impact on RNA and metabolite 
extractions. All samples were immediately snap frozen in liquid nitrogen and stored at -80oC 
until further use. 
 
4.2.2	  Lipid	  RNA	  extraction	  
Epicardial adipose samples were kept at -80 degrees until RNA extraction. Extraction was 
performed using the RNeasy Lipid extraction kit (Quiagen) according to the manufacturers 
protocol. Briefly, samples were homogenised in 1ml of QIAzol Lysis Reagent using a pestle 
and mortar and the homogenate left to incubate at room temperature for 5 minutes to promote 
the dissociation of nucleoprotein complexes. 200µl of chloroform was added, the mixture 
vortexed for 15s and left to incubate for a further 3 minutes at room temperature. The tubes 
were then centrifuged at 12 000g for 15 minutes at 4oC to ensure phase separation. The 
aqueous phase was transferred into a new tube, the volume recorded, and the same volume of 
70% ethanol added to the tube prior to vortexing for 15 seconds. 700µl of the mixture was 
then transferred into a tube containing the RNeasy spin column and centrifuged for 15s at 
8000g. The flow through was discarded and this step repeated for any remaining sample. 
700µl of RW1 wash buffer was added to the column and the column centrifuged at 8000g to 
wash the membrane. The column was then transferred to a new tube and 500µl of RPE buffer 
added prior to centrifugation at 8000g. This step was subsequently repeated to ensure no 
ethanol contamination of the final RNA extract. After transferring the RNeasy spin column 
into a final collection tube, 30µl of RNase-free water was added and the tube centrifuged at 
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8000g for 1 minute to elute the RNA contained within the flow-through. The RNA quality 
and concentrations of the eluted RNA were assessed using the Nanodrop 1000 
spectrophotometer and Agilent 2100 Bioanalyser as previously described. All samples with 
RNA integrity numbers (RIN) <6 were re-extracted in an attempt to improve RNA quality. 
Final RNA extractions were subsequently labeled and stored at -80 degrees until further use.  
	  
4.2.3	  Gene	  expression	  microarray	  of	  Lipid	  mRNA	  
Extracted RNA was diluted to a total concentration of 100ng/µl. Agilent gene expression two-
colour microarrays were performed according to the manufacturer protocol. Briefly, 1.5µl of 
RNA was added to 2µl of prepared two-colour diluted spike-in mix (A: Cyanine 3-CTP; 
B:Cyanine 5-CTP). 1.8µl of prepared T7 primer was added to each of the samples and the 
mixture denatured at 65oC for 10 minutes before being placed on ice. 4.7µl of prepared cDNA 
master mix (Per reaction: 2µl 5x first strand buffer, 1µl 0.1M DTT, 0.5µl 10mM dNTP mix, 
1.2µl affinity script RNase block mix) was then added to each tube and the samples incubated 
for 2 hours at 40oC followed by 15 minutes at 70oC to arrest enzyme activity. The 
transcription master mix was then prepared (per reaction: 0.75µl nuclease free water, 3.2µl 5x 
transcription buffer, 0.6µl 0.1M DTT, 1µl NTP mix, 0.21µl T7 RNA polymerase blend 0.24µl 
Cy 3-CTP or Cy 5-CTP) and 6µl of Cy 3-CTP or Cy 5-CTP transcription preparation added to 
the Spike-in A and Spike-in B mixes respectively. The sample mix was then incubated in a 
water bath at 40oC for 2 hours to complete the labeling and amplification reaction. 
 
The labeled and amplified RNA was then purified using the RNeasy mini kit (Quiagen) 
according to manufacturer protocol and the concentration and quality of the resultant cRNA 
assessed using the NanoDrop spectrophotometer as previously described.  
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To prepare for hybridization, for each microarray a fragmentation mix containing the labeled 
cRNA sample (containing: 300ng Cy3 amplified cRNA, 300ng Cy5 amplified cRNA, 5µl 10x 
gene expression blocking agent, 1µl 25x fragmentation buffer, nuclease free water to reach a 
volume of 24µl) was prepared and incubated at 60oC for 30 minutes to fragment the RNA 
before being cooled on ice. 25µl of 2x Hi-RPM Hybridization buffer was then added to 25µl 
of cRNA fragmentation mix and the mixture centrifuged at 13 000g for 1 minute before being 
immediately loaded onto the array.  
 
A total sample volume of 40µl was loaded into the corresponding gasket wells and Agilent 
MicroArray slides (8x60k) placed on top to prepare the final gasket assembly. Five blank 
samples were included as hybridisation controls. Wells were checked for air bubbles before 
hybridization using the Agilent Sure-hyb hybridization chamber at 65oC for 17hrs.  
 
Following completion of hybridization slides were washed according to manufacturer 
protocol. Slides were immediately scanned using the Agilent G2505C MicroArray Scanner 
and feature extraction performed using the Agilent Feature Extraction Software version 
10.7.3.1. Analysis was performed using Agilent GeneSpring software GX11.0. 
 
4.2.4	  RT-­‐qPCR	  of	  atrial	  mRNA	  
Real time- quantitative polymerase chain reaction and subsequent analysis was carried out in 
accordance with the protocol described in Chapter 3 (3.2.1). Universal reverse transcription 
was performed as previously described. TaqMan qPCR gene expression assays were used for 
the following gene targets: SLN, PLN, TRDN, SERCA2A. For each study probe an identical 
PCR reaction was also carried out using ribosomal U6 as a control gene.  
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4.2.5	  Western	  Blotting	  	  
Western blotting was performed according to the methods described in Chapter 3 (Section 
3.2.4) for the following target proteins: Sarcolipin (Anti-SLN, Rabbit polyclonal; #ABT13, 
Millipore UK), Phospholamban (Anti-PLN, Mouse monoclonal 2D12; #ab2865, Abcam), and 
SERCA2A (Anti-SERCA2A ATPase antibody 2A7-A1, Mouse monoclonal; #ab2861, 
Abcam). In order to improve resolution for the small molecular weight proteins SLN and 
PLN, 10-well 10% NuPAGE® Bis-Tris Precast Gels (Life Technologies) were used with 
MES running buffer, made up according to manufacturer recommendations.  
 
4.3	  Results	  
4.3.1	  Gene	  expression	  microarray	  
Quality control highlighted poor integrity of 9 samples with evidence of RNA degradation 
and fragmentation. These samples were therefore excluded from further analysis. 19 samples 
(8 AF, 11nAF) determined to have an RNA integrity number (RIN) >4 were selected for 
miRNA microarray analysis. Results were analysed using Agilent’s GeneSpring software. 
Following normalisation, principle component analysis (figure 4-3) did not identify 
significant clustering of AF and non-AF groups.  
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Figure 4-3: 3D PCA Scores plot showing no clear separation between AF samples (Green) and non-
AF samples (blue) based on then gene expression profile of the epicardial fat. Blank samples are shown 
in red.  
 
Similarly, analysis parameters set to detect genes with a >2 fold change difference in signal 
intensity at a level of significance <0.05 did not reveal any significant differences between 
AF and non-AF groups.  
 
Following these initial results, secondary analysis was performed to detect gene ontology 
(GO) pathways enriched in the complete gene list categorised in order of differential 
expression between AF and non-AF groups.  GO analysis (GOrilla: http://cbl-
gorilla.cs.technion.ac.il) revealed significant enrichment of pathways involved in (i) negative 
regulation of calcium ion transmembrane transporter activity and (ii) regulation of ryanodine- 
sensitive calcium-release channel activity (figure 4-4). A complete list of these genes and 
their GO pathways is show in table 4-2.  
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Figure 4-4: Gene ontology (GO) pathway enrichment of genes ordered by degree of differential 
expression between POAF and non-POAF groups.  
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Table 4-1: Enriched GO terms based on gene list ranked in order of differential expression between 
POAF and non-POAF epicardial fat samples. 'P-value' is the enrichment p-value computed according 
to the mHG or HG model. This p-value is not corrected for multiple testing of 3697 GO terms. 'FDR q-
value' is the correction of the above p-value for multiple testing using the Benjamini and Hochberg 
(1995) method. Namely, for the ith term (ranked according to p-value) the FDR q-value is (p-value * 
number of GO terms) / i. Enrichment (N, B, n, b) is defined as follows: N - is the total number of 
genes; B - is the total number of genes associated with a specific GO term; n - is the number of genes 
in the top of the user's input list or in the target set when appropriate b - is the number of genes in the 
intersection; Enrichment = (b/n) / (B/N). Genes: The list of associated genes that appear in the optimal 
top of the list  for each GO term.(213) 
	  
4.3.2	  RT-­‐qPCR	  of	  Target	  Genes	  
Based on the above findings of the lipid microarray, a number of target genes were 
highlighted that may be clinically relevant to the pathogenesis of POAF. However, it was 
noted that these genes were all muscle specific, and included targets encoding myosin 
isoforms and regulators of sarcoplasmic reticulum proteins (Table 4-1). Although not evident 
on a macroscopic level, it was therefore most likely that these findings represented 
contamination of epicardial fat samples with atrial muscle given the close continuity of 
epicardial fat with the atrial myocardium.  
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As a result of this contamination and the poor quality of RNA extracted from the lipid tissue 
no further evaluation of the transcriptomic signature of epicardial fat was performed. 
However, given the involvement of these muscle specific genes in key arrhythmogenesis 
pathways, RT-qPCR was performed to evaluate the concentration of these mRNA in the atrial 
biopsies of my patient cohort. The following targets were evaluated: Sarcolipin (SLN), 
Phospholamban (PLN), Myosin Heavy Chain 6 (MYH6), Sarcoplasmic reticulum Ca2+ 
ATPase 2a (SERCA2A/ ATP2A2) and Triadin (TRDN). 
 
POAF was found to be associated with a significant reduction in the expression of SLN 
mRNA (p=0.0080) as well as a less significant reduction in MYH6 (p=0.0297) and 
SERCA2A (p=0.0343) gene expression (Figure 4-5). 
 
 
 
Figure 4-5: RT-qPCR results showing 
significantly lower (a) sarcolipin (SLN) 
(p=0.0080); (b) SERCA2A (p=0.0343), 
and (c) MYH6 (p=0.0297) gene 
expression in the right atrial tissue of 
POAF compared to non-POAF. 
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However, no significant difference was observed in the expression of either PLN (p=0.7963) or Triadin 
(p=0.7963) mRNA (Figure 4-6). 
 
 
 
Figure 4-6: RT-qPCR results showing no significant difference in (a) Phospholamban (PLN) 
(p=0.7963) or (b) Triadin (TRDN) (p=0.7963) gene expression in the right atrial tissue of POAF 
compared to non-POAF. 
 
	  
4.3.3	  Western	  Blotting	  
Sarcolipin (SLN) protein levels were evaluated in the atrial tissue of a subgroup of 4 POAF 
and 4 non-POAF patients matched to samples used in the aforementioned RT-qPCR 
experiment. Patients developing POAF had a significantly lower level of SLN protein 
expression in atrial tissue samples taken at the time of surgery when compared to non-POAF 
patients (p=0.0286) (Figure 4-7).  
 
No significant difference was seen in the expression of the regulator protein phospholamban 
(PLN) or in the overall expression of SERCA2a (Figure 4-8 and 4-9). Insufficient atrial 
tissue sample was available to allow for evaluation of atrial myosin heavy chain 6 (cardiac 
muscle, alpha isoform) protein expression in the current study. 
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Figure 4-7: Western blot demonstrating significantly lower sarcolipin (SLN) expression (p=0.0286) in 
the right atrial tissue of patients developing post operative atrial fibrillation (POAF) compared to those 
maintaining sinus rhythm. Red boxes denote samples from POAF patients. 
 
Note: uneven loading secondary to very small quantities of protein available for western blotting. Loading based 
on 10ug of protein per well but estimated as insufficient volume to quantitate with BCA or Bradford assay. 
Recognised band at 13kDa as reported by Millipore. Band at 6kDa not detected possibly due to low starting 
concentration of protein 
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Figure 4-9: Western blot demonstrating no significant difference in the expression of SERCA2A 
protein (p=0.6571) in the right atrial tissue. Red boxes denote samples from POAF patients. 
 
Figure 4-8: Western blot demonstrating no 
significant difference in (a) monomeric 
phospholamban (PLN) (p=0.6095) or (b) 
pentameric PLN (p=0.8952) expression in 
the right atrial tissue of patients developing 
post operative atrial fibrillation (POAF) 
compared to those maintaining sinus rhythm. 
Red boxes denote samples from POAF 
patients. 
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4.4	  Discussion	  
 
4.4.1.	  Structural	  remodelling:	  MYH6	  and	  cardiac	  mechanotransduction	  	  
Muscle myosins are motor proteins that enable muscle contraction through ATP-dependent 
binding with actin. Their structure comprises two heavy chains (MHC), a regulatory light 
chain and an essential light chain. Together the combined heavy chain N-terminals make up 
the motor domain of myosin, that contains both the actin and nucleotide binding sites (Figure 
4-10).(214)  
 
 
Figure 4-10: The myosin motor domain: The purple strand represents the regulatory light chain, the 
yellow the essential light chain. The red, grey and green segments represent the myosin heavy chain 
subfragments at 50kDa, 20kDa and 25kDa respectively. Image taken from Rüegg et al. 2002 Molecular 
Motors: Force and Movement Generated by Single Myosin II Molecules.(215) 
 
 
Two isoforms of myosin exist in cardiac muscle, α-myosin and β-myosin, determined by the 
structure of the globular motor domain made up of the myosin heavy chain proteins.(214) The 
MYH6 gene encodes for the alpha cardiac isoform of the myosin heavy chain 6 protein (α-
MHC), and is found on chromosome 14 at location 14q12. Out of a total of 39 exons 
contained within the MYH6 gene, 37 contain protein coding sequences.(216) In human atrial 
myocardium there is an approximately equal breakdown between α-MHC and β-MHC 
(encoded by the MYH7 gene located 4kb upstream of MYH6 on intron 31 of chromosome 
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14; figure 4-11), however in ventricular tissue the β-MHC isoform is predominant with little 
α-MHC present (notably, the opposite is true in small animals such as mice and rats in which 
ventricular tissue is made up almost exclusively of the α-MHC isoform).(216) The key 
difference between the α- and β-MHC isoforms is their speed of contraction. α-MHC is the 
fast-twitch isoform, and exhibits a myosin cycling time approximately 10 times faster than β-
MHC. This occurs as a consequence of a number of features including a 5-10 fold weaker 
affinity for actin, a 7- to 15-times weaker affinity for ADP, and faster ATP hydrolysis.(214) 
This faster cycle time is also reflected in the difference in energy (ATP) requirement for 
contraction between the two isoforms, and α-MHC demonstrates an approximately 3x higher 
actin activated ATPase activity than β-MHC.(217)  
 
 
 
Figure 4-11: Schematic representation of the locations of the MYH6 gene and its intronic miRNA hsa-
miR-208a 
 
 
Several myocardial disease states including cardiac failure,(218) hypertrophy, 
pressure/volume overload(219) and chronic arrhythmia,(220) result in an MHC class switch 
within the atrial myocardium such that the α-MHC component is replaced with an increased 
proportion of β-MHC slow-twitch muscle.(221) Indeed, in their 2005 study comparing right 
atrial appendage biopsies of chronic AF (>3 months) patients undergoing cardiac surgery to 
those in sinus rhythm, Narolska et al. showed significant switch from the α- to the β-MHC 
isoform in their AF group.(221) Furthermore, a missense arginine to tryptophan mutation at 
position 22,936,019 bp within exon 18 of the MYH6 gene (c.2161C>T), has recently been 
identified in patients with sick sinus syndrome, a condition characterised by brady- and tachy- 
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arrhythmias including atrial fibrillation.(222) Furthermore, although atrial fibrillation was not 
a pre-defined outcome in this study, post-hoc analysis highlighted that individuals carrying 
this mutation also conveyed a significantly greater likelihood of atrial fibrillation (OR 2.03 
95%CI [1.15, 3.58], p=0.015).(222) 
 
These findings are echoed in the results from my patient cohort, whereby a significant 
reduction in MYH6 gene expression was observed in POAF patients when compared to those 
in sinus rhythm. Beyond this, my work is the first to suggest this relative class switch may 
occur prior to the onset of atrial fibrillation rather than as a consequence of it, implying a 
primary role for muscle myosins in the mechanism of structural remodeling in AF 
pathogenesis.  
 
A number of factors may affect the relative concentrations of α- and β- isoforms present in 
cardiac tissue including age, circulating thyroid hormone (triiodothyronine (T3) increases α-
MHC), and adrenergic activity (cAMP mediated increase in expression of α-MHC),(223) as 
well as the expression of the transcription factors GATA4,(224) Nfat3 and FoxP1.(225) 
However, at present the reason for this functional class switch in response to cardiac stress is 
not fully understood and it may indeed occur through a combination of the aforementioned 
mechanisms. It has been postulated that this relative reduction in fast-twitch muscle forms 
part of an adaptive mechanism designed to minimise energy requirement in failing 
myocardium; or in the case of atrial tachyarrhythmias, prevent energy depletion and 
contractile failure through economy of ATP. However, ultimately this class switch is likely to 
prove to be disadvantageous as reduced contractility subsequent to increased β-MHC 
expression may ultimately result in both contractile failure and diastolic dysfunction.(221)  
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MYH6	  and	  miR-­‐208a	  
Interestingly, this fall in MYH6 gene expression in POAF also correlates with the reduced 
expression of miR-208a observed in my patient cohort. MicroRNA-208a is encoded within 
intron 27 of the MYH6 gene (Figure 4-11 and 4-12)(152) and thus reduced transcription of 
the entire MYH6 gene would also be expected to reduce the expression of miRNA-208a as is 
seen in my POAF patient cohort.  
 
 
 
 
Figure 4-12: Regulation of MYH6 by GATA4 and the potential role of miR-208a as a negative 
feedback mechanism in the regulation of MYH6 transcription. 
 
It is therefore possible that this reduced miR-208a expression is in fact a consequence of 
reduced MYH6 expression which, through changes in the relative expression of slow- and 
fast- twitch MHC isoforms, pre-disposes to subsequent atrial fibrillation in the post operative 
period. Indeed, this is supported by the findings of Montgomery and Van Rooj et al. who did 
not observe any electrophysiological changes in the surface ECGs of either rats treated with 
the antagomiR antimiR-208a, or in miR-208-/miR-208- knockout mice.(108, 226) 
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Furthermore, although not demonstrated in my patient cohort (as discussed in chapter 3), it is 
possible that through inhibition of the transcription factor GATA4 which itself promotes α-
MHC expression, miR-208a may produce a negative feedback mechanism acting to maintain 
a balance in MYH6 gene expression (Figure 4-12). 
 
Of note, these findings add further insight into the discussion presented in Chapter 3 in which 
it was postulated that a fall in miR-208a might increase the overall expression of α-MHC 
through removal of translational inhibition on the thyroid hormone receptor protein-1 
(THRAP) and inhibition of triiodothyronine (T3) signaling. In fact, these experimental results 
reveal that miR-208a acts as part of a complex regulatory network that acts to feedback on the 
transcription of both its co-expressed intron MYH6 and its translated protein α-MHC. A 
summary of this network is shown in figure 4-12. 
 
4.4.2	   Electrical	   Remodelling:	   Dysregulation	   of	   cardiomyocyte	   calcium	  
handling	  in	  POAF	  atria	  
 
Another finding observed in my patient cohort was a significant reduction in sarcolipin (SLN) 
gene and subsequent protein expression. Sarcolipin is a small 4kDa, 31 amino acid protein 
(encoded by the SLN gene, location 11q22, chromosome 11), expressed predominantly in 
atria, that acts to inhibit the sarcoplasmic reticulum (SR) ATPase (SERCA) independent to its 
primary regulatory protein phospholamban (PLN). This reduction in SLN protein expression 
correlates with findings in patients with chronic AF as evidenced by Shanmugam et al. who 
observed a similar significant decrease in sarcolipin protein expression.(194, 227) 
Furthermore, my results also corroborate previous findings that this mechanism of SERCA 
regulation in AF occurs independent to the activity of the regulatory protein phospholamban, 
the expression of which remains unchanged.(194) 
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The sarcoplasmic reticulum Ca2+ ATPase, and consequently its regulatory proteins, plays a 
fundamental role in determining the availability of intracellular calcium within the 
cardiomyocyte. During normal contraction, on arrival of an action potential, L-type calcium 
channels are activated resulting in cytosolic calcium influx. This subsequently triggers 
calcium dependent calcium release from the SR through the ryanodine receptor channel 
(RyR2). Through binding with this available free cytosolic Ca2+ Troponin C (TnC) binding 
with Troponin I (TnI) is enabled, removing inhibition of tropomyosin and actin and thus 
triggering myofilament contraction.(228, 229) SR calcium reuptake through SERCA triggers 
dissociation of Ca2+ from TnC and thus results in relaxation (Figure 4-13). One such 
example of reduced SERCA activity can be seen in disease states including diabetic 
cardiomyopathy whereby there is failure of relaxation and subsequent diastolic 
dysfunction.(230)   
 
Through inhibition of SERCA activity, SLN acts to reduce cellular reuptake of Ca2+ into the 
SR. Knockout of SLN removes this inhibition of SERCA2a in cardiac muscle, enhances SR 
Ca2+ reuptake and promotes SR Ca2+ overload.(21, 225) This in turn shortens of the effective 
refractory period and thus may increase susceptibility to AF. Furthermore, increased SR 
calcium load may also lead to diastolic calcium leak giving rise to the potential for delayed 
after depolarizations and thus the triggering of AF(29). Beyond this, SLN may also have 
wider effects on cardiomyocyte calcium homeostasis. In addition to increases in SERCA 
activity, SLN knockout mice also display increases in cardiomyocyte L-type Ca2+ channel 
activity thus increasing Ca2+ influx in response to an action potential. Furthermore, it is 
possible that increases in basal L-type calcium currents may also give rise to prolongation of 
the action potential, stimulation of NCX sodium influx (in exchange for Ca2+) and thus early 
after depolarizations that trigger the initiation of AF.(21)  
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Figure 4-13: A simplified model of cardiomyocyte calcium handling. SERCA2a- sarcoplasmic 
reticulum Ca2+ ATPase; RyR2- ryanodine receptor; TnI- troponin I; TnC- troponin C; SR- 
sarcoplasmic reticulum; NCX- Sodium/calcium exchange transporter. 
 
 
Sarcolipin gene expression has been shown to be modulated by a number of factors including: 
TGFβ,(225) Thyroid hormone,(231) and GREM2 (Gremlin 2)(232). The role of thyroid 
hormone is of particular interest given the common clinical association between 
hyperthyroidism and atrial fibrillation. Furthermore, as mentioned previously free-T3 has the 
ability to increase α-MHC transcription through enhancing binding of the transcription factor 
GATA4 with the MYH6 gene. In the hyperthyroid state, increased T3 has been shown to 
produce post-transcriptional inhibition of SLN mRNA thus subsequently increasing SR 
calcium reuptake through SERCA.(231) Notably, thyroid hormone exerts a similar 
suppressive effect on the other key SERCA inhibitory regulator phospholamban (PLN) 
further increasing SR calcium reuptake. As such, shortening of action potential duration and 
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SR calcium overload is likely to be one mechanism whereby hyperthyroidism is associated 
with tachyarrhythmias and ultimately atrial fibrillation.  
 
Structural	  and	  electrical	  remodeling	  consistent	  with	  an	  AF	  phenotype	  prior	  to	  POAF	  onset	  
 
MHC isoform switch to increase β-MHC is a recognised sign of cardiomyocyte 
dedifferentiation and structural remodeling in chronic lone AF.(21, 233) Along with changes 
in cell size, glycogen storage, connexin expression and mitochondrial size and shape, this 
alteration in MHC composition represents a hallmark of cellular reversion to a fetal 
phenotype.(233) In the setting of chronic lone AF, it has been suggested that this phenomenon 
of dedifferentiation may occur in response to chronic calcium overload and metabolic stress, 
which in turn stimulates structural and electrical remodeling.(233) Indeed, β-MHC isoforms 
have been are less sensitive to intracellular calcium, and require an approximately 50% higher 
intracellular free calcium concentration to achieve half-maximal tension than α-MHC.(234) 
Therefore this MHC class switch may dampen the contractile response to intracellular 
calcium overload and ultimately prevent contractile failure. 
 
In addition, up-regulation of other factors associated with a dedifferentiated fetal atrial 
phenotype such as the heat shock proteins (HSP70 and GRP94), may form part of a 
mechanism to prevent depletion of SR Ca2+ stores through sequestration of Ca2+ within the 
SR.(235) Similarly, the observed reduction in SLN expression in my POAF patient cohort 
may also represent an adaptive mechanism to counter increased intracellular calcium and 
preserve SR calcium stores through removal of inhibition of SERCA2a. Together these 
changes suggest that POAF may be associated with a basal state of cellular calcium overload 
prior to the onset of the arrhythmia. Although the exact mechanism for this remains unclear, a 
number of factors previously associated with AF pathogenesis may be responsible for this 
increase in intracellular Ca2+ including increased oxidative stress, mitochondrial dysfunction 
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and increased cellular glucose concentration.(236) As such, these stimuli may in fact 
represent the underlying causative mechanism behind the atrial remodeling observed in this 
POAF patient cohort. 
 
4.4.3	  Limitations	  
It is important to consider a number of limitations when interpreting the results of this study. 
Firstly, as previously described the study number remains small and further validation of 
these findings is required in a larger patient cohort. Second, as this study was not originally 
designed to examine cellular calcium regulation, although no difference was observed in the 
expression of the SERCA regulator PLN, these results represent only absolute PLN 
expression and the phosphorylation state of PLN was not investigated. Phosphorylation of 
PLN acts to inhibit its binding with SERCA thus removing its inhibitory effect and promoting 
Ca2+ reuptake into the SR. As a result, in order to isolate the effect of SLN down-regulation 
on calcium transport, future studies must ensure both PLN and phosphorylated-PLN levels 
are independently determined. Similarly, a restriction in sample availability did not allow for 
quantification of myosin heavy chain protein or gene expression and therefore relative 
changes in MYH6 (and likewise MYH7) gene expression must now be validated at the 
protein level.(218) Third, it is important to consider other regulatory mechanisms that may 
modulate intracellular calcium such as adrenergic stimulation of protein kinase A (PKA) 
which may not only lead to phosphorylation of phospholamban but also of L-type calcium 
channels, which in turn increase calcium cycling and speeding up SR calcium release.(237) 
Similarly PKA phosphorylation of Troponin I may also act to lower myofilament sensitivity 
to Ca2+ thus reducing the contractile response to intracellular calcium load.(238)  
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4.5	  Conclusions	  
The results of this study highlight a number of exciting novel mechanisms for both electrical 
and structural remodeling in the pathogenesis of atrial fibrillation. Firstly, this work provides 
the first evidence to suggest that a relative class switch in myosin heavy chain protein may 
occur prior to the onset of atrial fibrillation rather than as a consequence of it, implying a 
primary role for muscle myosins in the structural remodeling associated with AF 
pathogenesis. Secondly, this study also provides evidence of pre-existing electrical 
remodeling in POAF atria, as a consequence of increases in sarcoplasmic reticulum calcium 
reuptake through a reduction in inhibitory regulation of the sarcoplasmic reticulum Ca2+ 
ATPase. Together the results from this study suggest that electrical and structural changes 
similar to those observed in chronic AF may also occur in POAF. However, rather than being 
a consequence of chronic atrial tachyarrhythmia, these results suggest that this remodeling 
may actually be a response to increased intracellular calcium concentrations occurring 
secondary to other stimuli such as oxidative stress, mitochondrial dysfunction and cellular 
hyperglycaemia. As such, POAF atrial remodeling may form part of the adaptive response to 
both preserve electromechanical function and restore intracellular Ca2+ homeostasis. 
 
Future work must now focus on validating the findings of this study in a larger patient cohort. 
This must ensure the availability of sufficient atrial tissue to perform a detailed evaluation of 
both MYH6 and MYH7 gene expression along with quantification of α- and β-MHC protein 
levels. Simultaneous assessment of GATA4, miR-208a, miR-208b and the myoMiR miR-499 
may also allow us to better understand the role of microRNA in the regulation and feedback 
control of MHC class switch in POAF atrial myocardium. Secondly, the role of sarcoplasmic 
reticulum calcium reuptake in POAF pathogenesis also requires further experimental 
validation. This requires quantification of not only SERCA and its regulators at both a gene 
and protein level, but also detailed study of cellular calcium signaling and investigation into 
calcium balance within cells cultured from the atrial myocardium of POAF patients. 
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Furthermore, investigation into other key regulators of calcium transport including the 
ryanodine (RyR2) and sodium calcium exchange transporters, is now also required in order 
isolate the impact changes in SLN expression may have on cellular calcium availability in 
vivo.  
144 
 
Chapter	  5	  
Downstream:	  The	  metabolic	  signature	  
 
5.1	  Background	  
5.1.1	  The	  metabolic	  profile	  of	  human	  atrial	  fibrillation	  
The results presented in previous chapters have identified a distinct microRNA and gene 
expression signature in patients developing de novo post-operative atrial fibrillation.  
However, in order to achieve a holistic understanding of AF pathogenesis, it is also pertinent 
to consider the metabolic processes that may contribute to the initiation and maintenance of 
this arrhythmia. In their gene expression analysis, Barth et al. demonstrated four of the twelve 
GO classes dysregulated in chronic AF to be related to upregulation of metabolic functions, in 
addition to downregulation of fatty acid and glycoprotein metabolism.(190) Furthermore, 
through increases in expression of genes encoding inner membrane formation, their results 
also suggest an upregulation of cellular mitochondrial production,(190) supporting the 
hypothesis that electrical and structural remodeling is coupled with an adaptive metabolic 
shift in response to the increasing energy demand of chronic AF.  
 
Under normal conditions, energy provision for cardiomyocyte contraction is usually via 
oxidative phosphorylation of NADH and FADH2 produced by the TCA cycle.(239) The 
mainstay of TCA cycle substrate provision arises from the β-oxidation of fatty acids, with 
glycolysis of glucose contributing between 10 and 40%.(239) The relative proportion of 
energy provision from glucose is variable and is responsive to extracellular glucose 
concentrations. Furthermore, glucose uptake is also sensitive to insulin via its control of the 
GLUT4 transmembrane glucose transporter. Amino acids, ketone bodies and lactate all 
provide additional means of substrate provision for the TCA cycle, however increases in 
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energy provision via these mechanisms are usually in response to starvation, high-energy 
requirement or hypoxia (Figure 5-1).  
 
 
 
Figure 5-1: A summary of the energy substrates for TCA cycle metabolism in cardiomyocytes under 
normal conditions.  
 
 
In chronic AF, results from NMR spectroscopy suggest a change in energy substrate 
provision so as to accommodate for the increasing energetic demand of the fibrillating 
myocardium. Significant increases in β-hydroxybutarate along with the ketogenic amino acids 
tyrosine, leucine and glycine in the right atria of chronic AF patients suggests an increase in 
ketone body metabolism.(110) This metabolic shift is further supported by evidence 
demonstrating increased 3-Oxoacid transferase, an enzyme acting to catalyse ketone body 
utilisation.(240) The ketone body β-hydroxybutarate is converted to acetoacetate and 
subsequently acetoacetyl-CoA, in turn providing a substrate for the TCA cycle upon cleavage 
into acetyl CoA. This delivers a direct source of acetyl CoA for the TCA cycle and provides 
approximately 30% greater energy yield per unit than pyruvate.(239) Whilst they usually 
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contribute only a minor proportion of myocardial energy supply, up-regulation of ketone 
body metabolism in the setting of AF is in keeping with an adaptive response to cellular 
energy deprivation, likely as a result of the increasing metabolic demand. This upregulation 
of ketone body metabolism can also be seen to be coupled with a reduction in glucose 
metabolism as demonstrated by inhibition of a number of intermediaries in the glycolysis 
pathway (Figure 5-2).  
 
 
 
Figure 5-2: A summary of the metabolite changes associated with atrial fibrillation involved in 
glycolysis and the tricarboxylic acid (TCA) cycle. This includes studies of human atrium (right and 
left) along with both chronic and post-operative atrial fibrillation. Pooled results from 5 studies are 
given. References: 1Huang et al.(241);  2Tu et al.(242); 3Kourliouros et al.(243); 4Gourdarzi et al.(240); 
5Mayr et al.(110). Red star indicates upregulation; Green star indicates downregulation. 
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There is also evidence to suggest that post-operative AF is associated with a state of energy 
depletion and inhibition of glycolysis.(243) In their study of 20 patients (10 SR; 10 POAF) 
undergoing CABG surgery, Kourliouros et al. demonstrated a reduction in both pyruvate 
dehydrogenase-β and enolase activity signifying a fall in glucose metabolism.(243) These 
findings suggest that changes in energy provision precede, and may in fact give rise to the 
onset of arrhythmia in post-operative AF. As a result of energy depletion through reduced 
glucose utilisation, the cardiomyocyte may become more susceptible to triggers such as 
inflammation and oxidative stress, leading to degradation and fibrosis.(243) In turn, this may 
result in conduction block and ion channel dysregulation, allowing for both the triggering and 
maintenance of reentrant circuits.  
 
Similar to chronic AF, post-operative AF has also been associated with an upregulation of 
ketone body metabolism as evidenced by increases in β-hydroxybutarate. Furthermore, this 
appears to be coupled to decreases in the availability of glucose and inhibition of glycolysis 
pathways.(110) Indeed, it is important to consider that whilst these processes may occur 
simultaneously through different mechanisms, upregulation of one pathway may in turn 
directly inhibit another. Increases in the concentration of acetyl CoA produced via ketone 
body metabolism may inhibit pyruvate dehydrogenase and reduce conversion of pyruvate to 
acetyl CoA.(110) As such, these metabolite changes should be reviewed together as a global 
shift in cardiomyocyte energy provision rather than as an isolated upward or downward shift 
of a single pathway.  
 
In addition to down-regulation of glycolysis, post-operative AF has also been found to be 
associated with a fall in NADPH-dependent conversion of glucose to sorbitol as demonstrated 
by a reduction in the expression of aldose reductase,(243) the enzyme catalysing the first step 
in polyol pathway of glucose metabolism. Conversely however, alternative energy sources 
such as lipid metabolism show signs of up-regulation as evidenced by increases in the high-
density lipoprotein Apolipoprotein A-I.(243) 
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5.1.2	  Lipid	  metabolism	  	  
In addition to changes in glucose and ketone body metabolism, atrial fibrillation is also 
associated with dysregulation of a number of enzymes and metabolites involved in lipid 
metabolism (figure 5-3). Myocardial energy provision through lipids is mainly via albumin 
bound fatty acids with a smaller proportion from blood lipoprotein triacylglycerols (Figure 5-
1). Albumin bound fatty acids are taken up into the cardiomyocyte either through binding 
with the albumin receptor or via the fatty acid transmembrane transport system, which 
subsequently allow FA to be released directly or indirectly via the cell membrane into the 
cytoplasm.(239) Fatty acids are then transformed to long-chain acyl-CoA by acyl-CoA 
synthase on the mitochondrial membrane before uptake into the mitochondrion via the 
carnitine palmitoyltransferase system, which is regulated by malonyl-CoA. Once inside the 
mitochondrion, acyl-CoA enters β-oxidation.(239)   
 
Chronic atrial fibrillation has been associated with decreases in the expression of fatty acid 
binding proteins and fatty acid syntease suggesting a decrease in fatty acid uptake.(242) 
Furthermore, decreases in mitochondrial very-long-chain (VLC) specific acyl-CoA 
dehydrogenase and the auxiliary enzyme δ(3,5)-δ(2,4)-dienoyl-CoA isomerase are likely to 
limit FA β-oxidation,(241, 242) also reducing the utilisation of those FA that are available for 
energy provision. Conversely however, the final ability for FA to be utilised for energy 
provision appeared to be upregulated in the right atria of patients with chronic AF undergoing 
maze procedures, through increased expression of Acetyl-CoA acyltransferase 2 (ACAA2), 
the mitochondrial enzyme catalyzing the final step in fatty acid oxidation to release acetyl 
CoA.(240) Similarly, other intermediaries of β-oxidation were also increased in this patient 
group including 2,4-Dienoyl CoA reductase-1 precursor, an enzyme that catalyzes the NADP-
dependent reduction of 2,4-dienoyl-CoA to yield trans-3-enoyl-CoA. 
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Figure 5-3: A summary of the lipid metabolite changes associated with Atrial Fibrillation. This 
includes studies of human atrium (right and left) along with both chronic and post-operative atrial 
fibrillation. Pooled results from 5 studies are given. References: 1Huang et al.(241); 2Tu et al.(242); 
3Kourliouros et al.(243); 4Gourdarzi et al.(240); 5Mayr et al.(110)  
 
 
Interestingly, in their subgroup of patients developing de novo post-operative AF, Mayer et 
al.(110) observed decreased atrial levels of acetate when compared to those maintaining sinus 
rhythm. A fall in this end product of lipid metabolism may suggest overall down-regulation of 
lipid as an energy substrate; however, this finding was also coupled with even more 
significant decreases in glucose and the end products of its metabolism alanine and lactate. As 
a result, despite global decreases in both fatty acid and glucose metabolism, a fall in the ratio 
of glucose end products to lipid end products showed good correlation with the development 
of POAF (r=0.66), and in fact was able to correctly classify those patients going on to develop 
POAF in approximately 80% of cases.(110) These findings therefore suggest that 
fundamental metabolite changes not only predate the onset of AF and but play a key role in 
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its pathogenesis. Whilst it is likely that this is primarily a result of impaired glucose 
metabolism, the role of fatty acids remains significant and may indeed play a part in the 
progression to more sustained arrhythmia.  
 
 
5.1.3	  Aims	  
The aim of this chapter is to determine the metabolic signature of post-operative AF in my 
patient cohort. Utilising nuclear magnetic resonance (NMR) and mass spectrometry (MS) 
techniques, the results of metabonomic analysis will be compared to the genomic profile 
outlined in chapters 3 and 4 with the goal of establishing the relationship between gene 
expression and metabolite response. Finally, by combining the results from epicardial adipose 
(EAT) and myocardial tissues, this work also aims to characterise the metabolic interplay 
between these two tissue types.  
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5.2	  Methods	  
5.2.1	  Sample	  Preparation:	  Lipid	  metabolite	  extraction	  for	  Mass	  Spectrometry	  	  
Metabolites were extracted from human epicardial fat using a two-phase tissue extract protocol 
developed on site (Dr. Panagiotis Vorkis).  
 
Aqueous extraction. Tissue samples were homogenised in pre-chilled methanol/water solution 
(1:1) (methanol HPLC gradient grade, Fisher; water LC-MS grade, Fluka). Beginning with a 
maximum of 1.5mL, and reducing proportionally to sample weight, the volume of solution was 
corrected to the weight of the sample. Samples (frozen on dry ice) were loaded onto a bead 
beater (zirconium beads; Bertin Technologies) vibrating at 6500Hz, for 40 seconds. After 2 
cycles the samples were re-frozen on dry ice before a further 2 cycles were performed. Samples 
were centrifuged (Eppendorf, Centrifuge 5417R, Germany) at 13 000 rcf for 20 minutes at 4OC. 
250µL of supernatant was aliquoted into Eppendorf tubes. Samples were spun on a vacuum 
concentrator for 3 hours at 45°C (Eppendorf Concentrator Plus, V-AQ mode) and then stored at 
-40°C until analysis. 
 
Organic extraction. A solution of pre-chilled dichloromethane (MTBE/methanol (3:1) 
(methanol HPLC gradient grade, Fisher; MTBE LCMS grade, Sigma-Aldrich) was added to the 
supernatant from centrifuged aqueous samples, The volume of the solution added was 
proportional to the sample weight as described above. Samples were frozen on dry ice and re-
loaded into the bead beater for 2 cycles of 40 seconds at 6500Hz. Following this, samples were 
centrifuged at 13,000 rcf for 20 minutes, and the organic phase (supernatant) aliquoted into glass 
vials. Samples were allowed to evaporate at room temperature in a fume hood overnight and 
then stored at -40°C for analysis. 
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5.2.2	   Sample	   Processing:	   Magic	   Angle	   Spinning	   (MAS)	   Nuclear	   Magnetic	  
Resonance	  (NMR)	  Spectroscopy	  
 
An aliquot of 20-40mg of atrial tissue sample taken as previously described was prepared for 
high resolution 1H Magic Angle Spinning (MAS) NMR spectroscopy. Samples were packed into 
a zirconium oxide rotor (Bruker Analytische GmbH; Rheinstetten, Germany) measuring 4mm 
diameter. Saline D2O was used as a field lock and 1H NMR spectra were acquired on the 600 
MHz Bruker DRX spectrometer (Rheinstetten, Germany) operating at 600.13MHz using a triple 
resonance MAS probe. The temperature was maintained at 283 K using dry ice and spin rate 
regulated at 5000Hz. Three 1H spectra were acquired for each sample using a 1-D standard, 
Carr-Purcell-Meiboom-Gill (CPMG) and diffusion edited pulse sequences. A spin relaxation 
delay (2nτ) of 200ms was used for the CPMG experiment. The 90-degree pulse length was set to 
10µs. The spectral width was 20ppm, and 128 transients were collected into 32k data points. An 
exponential function was applied to the FID prior to Fourier transformation with a line-
broadening factor of 0.3Hz. 2-D 1H-1H COSY (COrrelated SpectroscopY) and 1H-1H TOCSY 
(TOtal Correlated SpectroscopY) NMR spectra were acquired for all samples for structural 
assessment of metabolites. A total of 80 transients and 256 increments were collected into 2k 
data points with a spectral width of 10ppm. The 1H-1H TOCSY NMR spectra were acquired 
using a MLEV-17 sequence for the spin lock with a spin-lock power of 6kHz. 2-D 1H-1H COSY 
and 1H-1H TOCSY NMR spectra were multiplied by an unshifted sine bell and shifted sine bell 
apodisation function respectively prior to Fourier transform.  
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5.2.3	  Sample	  Processing:	  UPLC-­‐MS	  of	  Lipid	  metabolite	  extracts	  
Hydrophilic	  interaction	  ultra	  performance	  liquid	  chromatography	  (HILIC-­‐UPLC-­‐MS)	  analysis	  of	  
Aqueous	  Extracts	  
Samples were reconstituted in 200µL of solvent mixture of acetonitrile/water (95:5) (LC-MS 
grade, Fisher Scientific, USA), centrifuged for 20min at 13000 rcf, 4°C and then transferred into 
total recovery vials (Waters, USA).  
 
UPLC (Ultra-Performance Liquid Chromatography) separation was conducted with the Acquity 
UPLC System (Waters Corp, USA). An Acquity UPLC BEH HILIC 2.1x100mm, 1.8um, 
column (Waters Corp, USA) was used. The column temperature was set at 35°C, and a 10µL 
injection volume was used for both positive and negative ionization polarity modes. The auto-
sampler was set at 4°C. Mobile phase A consisted of acetonitrile/water (95:5) and mobile phase 
B acetonitrile/water (50:50). Ammonium formate (98%, Fluka, USA) was diluted to 10mM, and 
formic acid (MS grade, Fluka, USA) diluted to 0.1% in both solutions. A summary of the 
chromatographic gradient program is shown in Table 5-1. 
 
Eluting UPLC fractions were detected using a Synapt G2S (Waters MS Technologies Ltd., UK). 
A scan time of 0.20 sec and interscan time of 0.02 sec were used for acquisition. Leucine 
enkephalin was used for lock mass correction. Lock mass data were collected with scan time of 
0.20 sec and scan frequency of 30 sec. Positive mode conditions were as follows: m/z range: 50-
1200, cone voltage 30V, capillary voltage 3KV, Source Temperature 120OC, Desolvation 
Temperature 400OC, Desolvation Gas Flow 800L/Hr. Negative mode conditions were as 
follows: m/z range: 50-1200, cone voltage 30V, capillary voltage 2.5KV, Source Temperature 
120OC, Desolvation Temperature 350OC, Desolvation Gas 800L/Hr. 
 
UPLC-MS analysis was performed using a Quality Control (QC) format. This involved 
preparation of a pooled QC sample of the reconstituted extracts. This sample was then injected 
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10 times to condition the column before beginning the run. Once the run had begun, the sample 
was re-injected 7 times. 
 
Time (min) Flow rate (ml/min) %A %B Curve 
HILIC-UPLC-MS method 
0.0 0.4 99 1 - 
2.0 0.4 99 1 - 
8.0 0.4 45 55 6 
9.0 0.4 1 99 6 
9.1 0.8 1 99 6 
11.0 0.8 1 99 - 
11.1 0.8 99 1 6 
19.0 0.8 99 1 - 
19.1 0.4 99 1 6 
23.0 0.4 99 1 - 
Lipid profiling RP-UPLC-MS 
0.0 0.4 60 40 - 
2.0 0.4 57 43 6 
2.1 0.4 50 50 1 
12.0 0.4 46 54 6 
12.1 0.4 30 70 1 
18.0 0.4 1 99 6 
18.1 0.4 60 40 6 
20.0 0.4 60 40 - 
 
 
Table 5-1: Gradient programs of chromatography of the HILIC-UPLC-MS and the lipid profiling UPLC-
MS methods. 
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Data processing 
Data were processed using XCMS (http://metlin.scripps.edu/xcms/). Analysis incorporated 
peak-picking, grouping, and retention time correction. Results were considered statistically 
significant at a p value of less than 0.05 and a relative fold change above 2. Features were 
accepted where the co-efficient of variation of the control was less than 30%, indicating that the 
feature was reproducible throughout the run. 
 
Data was uploaded to MATLAB (Version R2014a) for further processing. Normalisation was 
performed using median fold change and peak positions were adjusted by recursive segment 
wise peak alignment.(244) Large variability of high intensity peaks was compensated for across 
samples by log-based transformation of mass spectra. This also ensured a consistent noise 
structure for application of multivariate statistical techniques.(245) 
 
Unsupervised analysis of the dataset was performed using principal component analysis (PCA). 
In addition, a recursive maximum margin criterion algorithm (RMMC) and linear discriminant 
analysis (LDA) were used for supervised classification. 
	  
Lipid	  Profiling	  
UPLC-MS analysis. Samples were reconstituted in 200µL of a solvent mixture consisting of 
H2O/isopropanol/acetonitrile (1:2:1) (Optima, LC-MS grade, Fisher Scientific, USA), and 
centrifuged for 20 min at 14 000 rcf, 4°C transferred into Total Recovery vials (Waters, USA). 
 
UPLC separation was conducted using an Acquity UPLC System (Waters Corp, USA). An 
Acquity UPLC CSH C18 2.1x100mm, 1.7um, column (Waters Corp, USA) was used. Column 
temperature was set at 35oC. A 3µL injection volume was used for positive ion mode and a 7µL 
injection volume used for negative ionization mode. The auto-sampler was set at 4°C. Mobile 
phase A consisted of acetonitrile/water (60:40) and mobile phase B Isopropanol/acetonotrile 
(90:10). Ammonium formate (98%, Fluka, USA) was diluted to 10mM, and formic acid (MS 
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grade, Fluka, USA) diluted to 0.1% in both solutions. A summary of the chromatographic 
gradient program is shown in Table 5-1.  
 
Eluting UPLC fractions were detected using a Premier Q-TOF (Waters MS Technologies, UK). 
A scan time of 0.200 sec and interscan time of 0.214 seconds were used for both MS and MSE 
data acquisition. MSE data were collected after ramping of the collision energy from 30 to 40V. 
Leucine enkephalin was used for lock mass correction. Lock mass data were collected with scan 
time of 0.20 sec and scan frequency of 30 sec. Positive mode conditions were as follows: m/z 
range:150-1200, cone voltage 30V, capillary voltage 2KV, Source Temperature 120OC, 
Desolvation Temperature 550OC, Desolvation Gas 900L/Hr. Negative mode conditions were as 
follows: m/z range: 50-1200, cone voltage 30V, capillary voltage 1KV, Source Temperature 
120OC, Desolvation Temperature 550OC, Desolvation Gas 900L/Hr. 
 
UPLC-MS analysis was performed using a Quality Control (QC) format as described for HILIC-
UPLC-MS above.  
 
Data processing 
Data processing was performed as described for HILIC-UPLC-MS above. Results were 
considered statistically significant at a p value of less than 0.05 and a relative fold change above 
2. Features were accepted where the co-efficient of variation of the control was less than 30%, 
indicating that the feature was reproducible throughout the run. 
 
Data was uploaded to MATLAB (Version R2014a) for further processing. Normalisation, 
supervised and unsupervised analysis was performed as described for HILIC-UPLC-MS above.  
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5.3	  Results	  
5.3.1	  Magic	  Angle	  Spinning	  Nuclear	  Magnetic	  Resonance	  Spectroscopy	  
Standard proton spectra were acquired to determine the global profile of metabolites across the 
sample set (figure 5-6). 1D standard proton NMR spectra were also obtained from atrial 
myocardial tissue. The spectral data revealed dominant peaks at 0.83, 0.87, 1.22, 1.57, 2.0, 2.22 
and 5.3 ppm, corresponding to lipid fractions (table 5-2), which, due to their high 
concentrations, prevented further analysis of other metabolites.  
 
 
 
Table 5-2: Chemical shifts corresponding to different lipid fractions identifiable in standard proton mass 
spectra. 
 
 
CPMG pulse sequence was used to filter out the signals from macromolecules. OPLS-DA 
coefficients plot derived from 1H MAS CPMG spectra of atrial myocardial tissue did not reveal 
any significant metabolite differences between POAF vs. non-POAF patients (A, B (Q2Y<0)) 
(Figure 5-4). Similarly, combined CPMG spectra did not reveal any significant metabolic 
discrimination between the groups (Figure 5-5; Blue=POAF (n=10); red=non-POAF (n=16)).  
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Figure 5-4: OPLS-DA loadings plot derived from 1H MAS CPMG spectra of atrial tissue biopsies. The 
predictability Q2Y<0. 
 
 
 
 
Figure 5-5: Combined CPMG spectra obtained from the atrial tissue of AF and non-AF patients. (Blue - 
POAF (n=10); red - non-POAF (n=16)). 
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Figure 5-6: 1D standard proton NMR spectra of heart tissue from an AF patient. Dominant peaks at 1-2 
ppm represent high fat content of atrial tissue samples which precluded further metabolic analysis. 
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5.3.2	  UPLC-­‐MS	  of	  Lipid	  metabolite	  extracts	  
In light of the close anatomical relationship between atrial myocardium and epicardial adipose 
and the high intensity peaks corresponding to lipid fractions within standard proton spectra 
derived from the atrial myocardium, further analysis focused on determining the metabolite 
profiles of epicardial adipose between POAF and non-POAF groups.    
 
UPLC-MS revealed a significant difference in 10 species in positive ion mode and 2 species in 
negative ion mode between POAF and AF groups. In addition, HILIC UPLC-MS analysis 
revealed a significant difference in 21 species in positive ion mode and 6 species in negative ion 
mode between POAF and AF groups. Using published data, a correlation heatmap was drawn 
between these metabolites in order to determine any clusters of metabolites with high correlation 
(Figure 5-7). 
 
Preliminary metabolite annotation was then performed according to mass using the METLIN 
metabolite database (http://metlin.scripps.edu/metabo_search_alt2.php). Positive and negative 
mode IDs were searched using a tolerance of ±30 ppm and charge adducts of M+H/M+Na and 
M-H/M+Cl respectively. Of the 39 metabolites identified, 11 were later excluded where either 
no identification could be found or closer analysis revealed them to be artifact. A further 6 
metabolites were also excluded due to very low peak intensities. In total 22 metabolites were 
positively identified and included in further analyses (Table 5-3).  
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Figure 5-7: Heatmap of correlation matrix between the 39 metabolites differentially expressed between 
POAF and non-POAF patients. 
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Table 5-3: Identification of 22 metabolites identified to be significantly differentially expressed in the 
epicardial adipose tissue of AF patients (p<0.05 and FC>2). Mean intensities POAF and sinus rhythm 
(SR) groups and results of unsupervised model (p values) are also shown. 
 
 
 
Unsupervised principal component analysis (PCA) revealed visible clustering of POAF and 
sinus rhythm groups (Figure 5-8). Linear discriminant analysis (LDA) supervised classification 
revealed similar clustering (Figure 5-9) however in this more stringent model only 12 of the 22 
metabolites previously identified demonstrated statistical significance (Table 5-3).  
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Figure 5-8: Unsupervised model: (a) PCA plot demonstrating clustering of POAF and non-POAF (sinus 
rhythm (SR)) groups. (b) Combined mass spectra of all samples (blue-POAF, red-SR); (c) heat map of 
log10(intensities) of each metabolite in POAF and SR groups.  
 
 
 
 
 
 
 
Figure 5-9: Supervised linear discriminant analysis: (a) PCA plot demonstrating clustering of POAF and 
non-POAF (sinus rhythm (SR)) groups. (b) Combined mass spectra of all samples (blue-POAF, red-SR); 
(c) heat map of log10(intensities) of each metabolite in POAF and SR groups.  
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Finally, leave one out cross validation analysis revealed a 78.6% overall predictability of the 
model to determine the class of a sample given its metabolite profile. Notably, predictability of 
the sinus rhythm class (88.2%) was greater than that for the POAF class (63.6%) most likely as a 
result of (a) the larger variance of POAF samples and (b) the larger number of samples in the SR 
group.  
 
 
 
 
 
Figure 5-10: Leave one out cross validation analysis demonstrating an overall 78.6% ability of the model 
to correctly predict the class of the sample based upon its metabolite profile.  
 
 
 
Of note, review of box plots for metabolites likely corresponding to the long chain molecules 3-
Isopropenylpimelyl-CoA and (3S)-Citryl-CoA revealed two clear clusters within the POAF 
group with very tight clustering of the SR group (Figure 5-11). 
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(a)	  
 
	  
(b)	  
	  
 
 
Figure 5-11: Box plots of specific long chain metabolites identified as: (a) (3S)-Citryl-CoA; and (b) 3-
Isopropenylpimelyl-CoA; demonstrating two clear clusters within the POAF group.  
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5.4	  Discussion	  
 
This chapter has established the metabolic signature of both atrial myocardium and epicardial 
adipose tissue in patients developing AF after coronary artery bypass grafting. Whilst MAS 
NMR metabolomic analysis was not able to discriminate POAF from non-POAF in the atrial 
tissue of my patient cohort, patients could be correctly classified in 78.6% of cases based on 
the metabolic profile obtained from analysis of their epicardial adipose tissue.  
 
5.4.1	  The	  epicardial	  lipidome	  of	  post-­‐operative	  AF	  
These results demonstrated significant decreases in glycerophosphoglycerols, 
glycerophosphoinositols, 18:0-Glc-campesterol, the peptide Isoleucine-Arginine-Glutamate-
Glutamine and the glycerophosphoserine PS(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:1(11Z)). 
Significant increases were seen in triacylglycerols, sphingolipids, glycerophosphates, the 
glycerophosphoserine PS(20:3(8Z,11Z,14Z)/22:0), and the peptides Lysine-Cysteine-Lysine-
Lysine and Arginine-Tryptophan-Arginine-Phenylalanine. Notably two long chain molecules, 
3-Isopropenylpimelyl-CoA and (3S)-Citryl-CoA, were also increased in the POAF group but 
split into two distinct subgroups, one corresponding to that of SR patients and another 
showing a much greater increase in these two molecules (figure 5-11). Although no clear 
reason for this was evident from further analysis of individual patient data, this finding 
demonstrates the spectrum of metabolic derangement in POAF, with evidence of a shift 
towards an 'AF phenotype'. 
 
The condensation reaction of acetyl-CoA and oxaloacetate to form citrate within the TCA 
cycle is catalysed by the enzyme citrate synthase (figure 5-2). In fact, this occurs as part of a 
2-step reaction first characterised by the formation of (3s)-citryl-CoA, which is subsequently 
hydrolysed to citrate and CoA. Through the production of citrate, citrate synthase acts to 
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restock the cytoplasmic pool of acetyl-CoA for lipogenic pathways during surplus energy 
availability. Similarly, a fall in citrate synthease activity is observed in situations of increased 
energy requirement and energy depletion.(246) The increase in (3s)-citryl-CoA observed in 
the epicardial fat of my POAF patient cohort would correlate with an increase in citrate 
production in these patients. This mitochondrial-derived citrate can then subsequently be 
exported into the cytoplasm and converted to Acetyl-CoA for fatty acid synthesis. 
Interestingly, this finding is mirrored in the right atrial myocardium of a porcine model of AF 
presented by Lai et al. whereby citrate synthase gene expression was increased 2.5 fold.(247)   
 
Campesterol is a plant-derived phytosterol that is not synthesised in human cells but is 
naturally present in the diet. Its structure is similar to that of cholesterol and increased 
circulating levels are thought to have a cholesterol lowering effect through competitive 
binding with cholesterol receptors.(248) As such, moderate increases in campesterol are 
thought to lower cardiovascular risk through reducing cholesterol absorption and plaque 
burden. Furthermore, campesterol may also act to increase vascular smooth muscle 
prostacyclin synthesis and subsequently also have a protective effect on the vascular 
endothelium.(249, 250) It is therefore possible that the significantly reduced campesterol in 
my POAF group may signify increased cholesterol storage within the epicardial adipocyte for 
energy provision.(251) Similarly however, a fall in campesterol stored within the EAT may 
also be coupled with a fall in adipocyte and/or the coronary vascular endothelial cell 
prostacyclin synthesis. Reduced prostacyclin may in turn remove its protective effect and 
promote vascular endothelial cell dysfunction, which may in turn increase susceptibility to 
oxidative stress and inflammation thus predisposing to atrial fibrillation. 
 
Adipocytes act as a storage pool for plasma triglycerides (TG), which form a fundamental 
energy reserve in times of fasting or increased metabolic demand. Under these conditions, 
stored TG may be hydrolysed to release glycerol and free fatty acids (FFA) that can in turn be 
taken up by the cardiomyocyte.(252) UPLC-MS analysis revealed a significant increase in 
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both triglyceride (triacylglycerol) classes differentially observed in POAF compared to non-
POAF patients (table 5-2), suggesting either increased storage or decreased metabolism of 
TG in the EAT of these patients. Whilst reduced triglyceride levels may signify a depletion of 
the adipocyte TG store, increased levels may also signify impaired TG utilisation and, as a 
result, reduced FFA availability. Furthermore, breakdown of TG into fatty acids is tightly 
governed by the action of the enzyme hormone sensitive lipase (HSL) which itself is 
regulated (inhibited) by insulin and/or adrenergic stimulation.(253)As both insulin resistance 
and increased adrenergic activity have been associated with increased susceptibility to 
AF,(82, 254) it is possible that these factors may also contribute to impaired TG utilisation 
and cardiomyocyte energy depletion, further enhancing the substrate for arrhythmogenesis.  
 
In addition to triglycerides and cholesterol compounds, the complex lipid profile of EAT also 
contains a number of other glycerophospholipids including glycerophosphoglycerols, 
glycerophosphoserines, glycerophospinositols and glycerophosphates. These compounds 
form part of the fundamental structure of the cell membrane lipid bilayer as well as serving 
both metabolic and signaling functions. This complex functionality leads to difficulty in 
determining the exact role of these lipids in the pathogenesis of post-operative atrial 
fibrillation. However, it is notable that five out of the six lipids identified in my patient cohort 
showed decreased abundance in POAF patients. It is therefore possible that this reflects an 
increase in the utilisation of glycerolipids as an energy substrate for fatty acid production, 
rather than the consumption of triglycerides as described above. In addition, it is notable that 
glycerophospinositols may act as precursors to inositol phosphates. Variations in the 
availability of these lipids may therefore impair the activity of membrane derived intra-
cellular signaling pathways which in turn may play a role in a number of mechanisms leading 
to the pathogenesis of cardiac arrhythmia. 
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5.4.2	  The	  right	  atrial	  metabolome	  of	  POAF	  
The results of this study did not identify any significant difference in the right atrial 
metabolite profile of patients developing POAF when compared to those maintaining SR after 
coronary artery bypass grafting. These findings differ from those of Mayr et al. who 
demonstrated significantly lower concentrations of glucose, beta-hydroxybutyrate, and acetate 
in their cohort of 22 patients (n=11 POAF) developing de novo post-operative AF.(110) 
Similarly, in their proteomic study, Kourliouros et al. demonstrated a reduction in enolase and 
pyruvate dehydrogenase in the atrial tissue of POAF patients, further suggesting a 
downregulation of glycolysis and pyruvate metabolism.(243) Together, these studies add 
weight to the hypothesis that inhibition of glycolysis may pre-dispose to POAF through both 
a reduction in energy provision, which in turn promotes a pro-inflammatory substrate that 
may be more susceptible to oxidative stress.(243) 
 
The exact reason as to why no similar finding was observed in this patient cohort is unknown. 
However, it is pertinent to note that the experimental methods used differ between this and 
previous metabonomic studies of atrial fibrillation. This study utilised magic angle spinning 
(MAS) nuclear magnetic resonance to obtain a solid-state, non-destructive metabolic profile 
of whole atrial tissue biopsies. The advantages of this approach are that it is able to give a 
high sensitivity metabolite profile more representative of in vivo tissue, as well as retaining 
information specific to the tissue compartment.(255) However, at the same time, this 
technique requires precise dissection of the tissue of interest in order to provide a 
homogeneous sample for analysis, and contamination with other cell types results in high 
heterogeneity. The results from this study revealed very intense lipid peaks in the standard 
proton spectra derived from all atrial samples, suggesting a significant degree of lipid 
contamination. Retrospectively, this is unsurprising given the close relationship between the 
atrial myocardium and the epicardial adipose, particularly in the region of the right atrial 
appendage. It is therefore likely that the lack of significant spectral differences between 
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POAF and non-POAF groups is a consequence of the high cellular heterogeneity present 
within the samples studied. The results of this analysis therefore highlight the need for future 
studies to focus on careful sample dissection whilst at the same time minimising the time 
taken for tissue preparation. Where this is not possible, future work should focus on a 
technique of metabolite extraction and 2D NMR analysis (110) in order to reliably determine 
the atrial metabolite profile of these patients. 
 
5.4.3	  Limitations	  
The untargeted methodology utilised in this study confers the benefit of both an unbiased and 
all-inclusive approach to metabolite detection when compared to targeted analysis. However, 
when considering the findings presented here a number of limitations should also be taken 
into account. Firstly, as described above, the high sensitivity and compartmental information 
provided by MAS NMR relies on the provision of a homogenous tissue type for analysis. 
Similarly, whole tissue analysis requires careful tissue handling, minimising the time spent at 
room temperature so as to prevent enzymatic degradation or changes in metabolite profile 
prior to freezing.(255)  
 
These tissue handling requirements also exist for the use of epicardial adipose tissue for 
UPLC-MS analysis. All samples were maintained at room temperature for the shortest 
possible time period, however the exact impact of small variations in tissue handling on the 
EAT metabolite profile is impossible to quantify. Second, the lipid identification presented 
here is the result of preliminary peak annotation performed utilising the Metabolite and 
Tandem MS (METLIN) database (http://metlin.scripps.edu/index.php)(256). This approach 
utilised a 30 ppm tolerance for each peak analysed to maximise metabolite identification 
whilst minimising false positives. However, absolute verification of these metabolites 
requires further MS/MS analysis with comparison to known standards for the metabolites of 
interest and is the focus of ongoing work. Furthermore, although the METLIN database 
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includes over 64 000 structures in its most recent release, this continues to grow and as such 
is not entirely comprehensive. It is therefore possible that future analysis may uncover 
physiologically relevant metabolites that are not identifiable at the present time. Finally, 
whilst variations in chromatography performance were minimised in this analysis through the 
use of QC and internal standards and as a result of the relatively small sample size studied, 
the impact of these factors becomes more significant in larger, multicenter studies and should 
be carefully considered when planning multiple sample runs or when comparing metabolite 
profiles between institutions and instruments. 
 
5.5	  Conclusions	  
This study is the first of its kind to determine the metabolite profile of epicardial adipose 
tissue (EAT) in post-operative atrial fibrillation. Using ultra-performance liquid 
chromatography integrated with XCMS and online database analysis, this study has identified 
a derangement in glycerophospholipids, triglycerides, campesterol and the acyl donors (3s)-
citryl-CoA and Isopropenylpimelyl-CoA. Furthermore, this distinct lipidomic profile was able 
correctly categorize 78.6% of patients at risk of post-operative atrial fibrillation at the time of 
coronary artery revascularization.  
 
Accounting for 60-90% of energy provision under normal conditions, free fatty acids (FFA) 
are particularly essential to maintain adequate energy supply to contracting cardiomyocytes in 
times of increased demand or systemic starvation. The altered metabolite profile of the 
epicardial adipose tissue characterised in this study highlights the plasticity of EAT 
metabolism, and identifies a number of changes which together may play an important role in 
the pathogenesis of AF both through alterations in FFA availability and through increases in 
susceptibility to other triggering factors such as inflammation and oxidative stress. 
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The findings presented here also highlight a number of areas for ongoing work. Firstly, where 
possible it now necessary to compare this mass spectrometry data to that of known authentic 
standards, in order to validate these preliminary metabolite identifications. Second, the 
finding of two distinct subgroups within the metabolite profiles of both acyl donors requires 
further investigation in a larger patient cohort. Whilst it is possible that these results merely 
represent opposite ends of a spectrum of change in POAF, it is also plausible that there are 
distinct characteristics present in this subgroup of POAF patients that may be of clinical 
relevance.  Finally, 2D NMR analysis of extracted atrial metabolites is now required to 
provide a holistic analysis of the atrial tissue in my patient cohort. Together these results will 
complete the most comprehensive analysis of microRNA, gene expression, metabolite and 
lipidomic analysis studied in a single cohort of POAF patients, and offer novel insights into 
the pathogenesis of this arrhythmia not only for ongoing research but also for future clinical 
risk reduction. 
 
 
 
173 
 
Chapter	  6	  
Conclusions	  and	  further	  work	  
 
6.1	  Summary	  and	  discussion	  of	  results	  
Atrial fibrillation (AF) is the commonest sustained disorder of cardiac rhythm, leading to 
increased risk of thromboembolism, stroke and overall mortality.(2) Post-operative AF affects 
approximately one third of people undergoing coronary artery bypass grafting despite no 
previous history of the disease and is a major cause of increased post-operative hospital stay, 
morbidity and even mortality.(74) From genome to metabolome, this research has highlighted 
a number of novel and exciting findings in the pathogenesis of human postoperative atrial 
fibrillation (POAF). Through the application of a diversity of laboratory techniques to both 
tissue and biofluids, the results presented in this thesis have provided a unique overview of 
the transcriptional, post-transcriptional and metabolite changes associated with this common 
arrhythmia. Furthermore, these observations characterise a number of structural, electrical 
and metabolic derangements that together produce an atrial substrate both susceptible to 
external triggers and amenable to the initiation and maintenance of electrical re-entry. 
 
6.1.1	  The	  microRNA	  signature	  of	  POAF	  and	  regulation	  of	  gene	  expression	  
For the first time, this research has identified a distinct microRNA profile in POAF, 
characterized by the differential expression of 16 microRNAs. The most over expressed of 
these is hsa-miR-483-5p and the most under expressed is the cardiomyocyte specific hsa-
miR-208a. Furthermore, microRNA 483-5p was also found to be significantly upregulated in 
the pre-operative serum of patients with POAF, indicating a potential role for this microRNA 
as a clinical biomarker for arrhythmia susceptibility. Based on this microRNA profile, 
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downstream target analysis was performed in order to determine any potential mechanistic 
role for these microRNA in POAF pathogenesis. This established a possible link between 
miR-483-5p and the vascular endothelial adhesion molecule VCAM-1 via the action of the 
intracellular GTPase RhoA. Subsequent analysis confirmed a significant increase in serum 
VCAM-1 in my POAF patient cohort, signifying upregulation of leukocyte adhesion and 
suggesting a systemic pro-inflammatory phenotype in these patients.  
 
Furthermore, based on this microRNA profile, detailed gene ontology and interaction network 
analysis has identified a number of novel gene expression changes in POAF, the diversity of 
which supports the presence of both electrical and structural atrial remodeling prior to the 
onset of arrhythmia. In this patient cohort, it was identified that disrupted potassium and 
calcium handling may play a critical role in cardiomyocyte electrical remodeling increasing 
the risk of arrhythmogenesis. Indeed, target prediction analysis identified KCNE5 
(KCNE1L), a regulator of the KCNQ1 inhibitory subunit of the inward rectifier potassium 
channel, to contain a target site for miR-483-5p. Further analysis demonstrated up-regulation 
of KCNE5 in POAF, suggesting a tendency towards gain of function of the inward rectifier 
channel, which may subsequently contribute to shortening of the action potential duration and 
increased susceptibility to re-entry. Gene ontology analysis also highlighted an enrichment of 
cardiomyocyte calcium signaling pathways, and further gene expression and proteomic 
analysis revealed significant downregulation of the SERCA inhibitor sarcolipin (SLN) in my 
POAF patient cohort.  
 
When considering structural remodeling, this study has provided the first evidence of pre-
existing cardiomyocyte de-differentiation in the atria of POAF patients, characterised by a 
significant decrease in the adult myosin heavy chain subtype MYH6 alongside suppression of 
its intronic miR, miR-208a. Reversion to a slow-twitch, fetal/ventricular phenotype mirrors 
observations documented in chronic lone AF,(21, 233) however this has never before been 
characterised prior to the onset of arrhythmogenesis. In the setting of chronic lone AF, it is 
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suggested that dedifferentiation and MHC class switch results from chronic calcium overload 
and metabolic stress, owing to the reduced sensitivity of β-MHC to intracellular 
calcium.(234) Through dampening the contractile response to intracellular calcium it is 
therefore possible that in both chronic and post-operative AF, down-regulation of MYH6 
expression may represent a protective mechanism that ultimately strives to prevent contractile 
failure where there is cytosolic calcium overload. 
 
Similarly, reduced SLN expression observed in my POAF patient cohort may also represent 
an adaptive mechanism to counter increased intracellular calcium and preserve SR calcium 
stores through removal of inhibition of SERCA2a. Together these changes suggest that POAF 
may be associated with a basal state of cellular calcium overload prior to the onset of the 
arrhythmia, giving rise to a novel hypothesis that requires further targeted scientific 
investigation. At present, the exact mechanism for this remains unclear, however factors such 
as increased oxidative stress, mitochondrial dysfunction and dysregulation of cellular glucose 
metabolism may all promote cytosolic calcium overload and as such are likely to be 
fundamental to a mechanism that incorporates both structural and electrical remodeling.(236)  
 
6.1.2	  The	  role	  of	  the	  epicardial	  adipose	  lipidome	  in	  POAF	  
Beta-oxidation of free fatty acids (FFA) delivers the primary source of acetyl-CoA to the 
cardiomyocyte TCA cycle, accounting for approximately 60-90% of total energy substrate 
provision.(239) Glucose and ketone bodies contribute much smaller proportions of this 
energy supply, however inhibition of glycolysis and upregulation of ketone body metabolism 
have been shown to underlie the metabolic substrate that promotes both chronic and post-
operative AF.(110, 243) Although this study was not able to characterise the metabolic profile 
of atrial myocardium in this POAF cohort, a number of novel findings were identified 
surrounding the role of lipid metabolism within the epicardial adipose tissue (EAT) of these 
patients.  
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Previous studies have indicated that chronic AF may be associated with a fall in 
cardiomyocyte fatty acid uptake and utilisation that contributes to a state of energy 
depletion.(110, 240-243) However, these studies did not examine the impact of FFA 
availability from the surrounding EAT. In this POAF patient cohort, lipidomic analysis of 
epicardial adipose tissue was able to identify a characteristic derangement in 
glycerophospholipids, triglycerides, campesterol and the acyl donors (3s)-citryl-CoA and 
Isopropenylpimelyl-CoA. Furthermore, this distinct lipidomic profile was able correctly 
categorize 78.6% of patients at risk of post-operative atrial fibrillation at the time of coronary 
artery revascularization.  
 
The exact impact that each of these lipids has on AF pathogenesis is difficult to quantify 
given the complexity of the EAT lipidome and the vast array of lipid subtypes present. 
However, it is possible that observed increases in (3s)-citryl-CoA, indicating increased citrate 
production, signify upregulation of fatty acid synthesis within the epicardial adipose of POAF 
patients. Furthermore, impaired storage of the cardioprotective plant sterol campesterol may 
reduce its protective effects on the vascular endothelial cell, increasing susceptibility to 
oxidative stress and inflammation. In addition, dysregulation of triglyceride storage and 
glycero-phospholipid metabolism may not only alter fatty acid availability but also modify 
the activity of membrane bound secondary messengers and subsequent intracellular signaling 
pathways. As such, the altered EAT lipidomic profile characterised in this study demonstrates 
a number of novel changes which together may play an important role in the pathogenesis of 
AF. Furthermore, these findings once again add to the increasing volume of evidence to 
support the dynamic role of the EAT which extends far beyond free fatty acid provision, to 
encompass paracrine control of the local cardiomyocyte environment, and regulate its 
susceptibility to key triggering factors such as inflammation and oxidative stress. 
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6.2	  Unanswered	  questions	  and	  future	  research	  	  	  
Alongside the novel insights this study has provided into the mechanisms of POAF, it has 
also given rise to a number of equally novel questions. It is therefore paramount that these 
findings are considered as a platform on which to continue to address the many unanswered 
questions remaining in the pathogenesis of this complex and multifactorial arrhythmia.  
 
1.	  Validating	  a	  novel	  serum	  biomarker	  
In order to reliably determine the role of circulating microRNA-483-5p as a biomarker for 
POAF, prospective and targeted validation of these results is now required in a larger patient 
cohort. Based on this work, post-hoc analysis estimates that at an effect size of 0.75, a total of 
62 patients would be required to yield 80% power with a Type 1 error rate (α) of 0.05. In 
order to validate these findings it is therefore vital to first ensure reproducibility in a larger 
patient cohort. Beyond this, should results yield a suitably high sensitivity and specificity, the 
next stage in biomarker development would require formal feasibility assessment with 
estimation of both the practicality and cost of upscaling to clinical practice.  
 
2.	  Investigating	  the	  role	  of	  cardiomyocyte	  de-­‐differentiation	  
Characterisation of the relationship between MHC isoform switch and POAF, requires a 
detailed evaluation of both MYH6 and MYH7 gene expression along with quantification of α- 
and β-MHC protein levels in a larger patient cohort. Furthermore, simultaneous assessment of 
the co-expressed intronic microRNAs miR-208a and miR-208b, should be included to 
provide a holistic understanding of the role of microRNA in the regulation and feedback 
control of myosin heavy chain expression in the atrial myocardium.  
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3.	  Determining	  the	  impact	  of	  cytosolic	  calcium	  overload	  in	  POAF	  pathogenesis	  
The results of this work highlight a novel role for intracellular calcium signaling in the 
pathogenesis of post-operative AF through impaired sarcolipin (SLN) regulation of 
SERCA2A sarcoplasmic reticulum calcium reuptake. In order to identify the impact of SLN 
downregulation in vivo, future research must combine the study of SLN gene and protein 
expression with analysis of intracellular calcium balance within cells cultured from the atrial 
myocardium of POAF patients. Furthermore, in order to be fully comprehensive, this analysis 
must also incorporate other key regulators of SR calcium transport including SERCA, PLN, 
TRDN and the ryanodine (RyR2) transporter.  
 
4.	  Combining	  the	  epicardial	  adipose	  lipidome	  with	  the	  myocardial	  metabolome	  in	  POAF	  
Another area for ongoing research highlighted here is the requirement for a united study of 
the metabolic substrate for atrial fibrillation. Adding to the results provided in previously 
published metabolomic and proteomic studies of atrial tissue, this research provides the first 
insight into the epicardial adipose lipidome in post-operative AF. Further work firstly 
necessitates authentication of this lipidomic profile against known standards, in order to 
validate these preliminary metabolite identifications. Beyond this, future direct integration of 
EAT lipidomic and atrial metabolite analysis is required to provide a holistic metabolic map 
of the atrial tissue and the impact of its local environment in POAF.  
 
6.3	  Conclusion	  	  	  
 
In conclusion, the results presented in this thesis have provided a comprehensive analysis of 
the microRNA, gene expression, metabolic and lipidomic signature of a single cohort of 
patients developing new onset post-CABG atrial fibrillation. These findings provide a body of 
evidence to support the existence of a pre-existing atrial substrate in these patients, 
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characterised by structural, electrical and metabolic remodeling. This not only offers novel 
insights into the pathogenesis of atrial fibrillation but also poses many new questions 
surrounding biomarker development and factors such as cardiomyocyte de-differentiation and 
calcium signaling. These findings therefore form a platform on which to build our 
understanding of the pathogenesis of this complex and multifactorial arrhythmia, with the 
ultimate aim to not only reduce clinical risk but also develop novel therapeutic strategies. 
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Appendix	  
Appendix	  1a	  
Validated targets for miR-483-5p according to the miRWalk Database (http://www.umm.uni-
heidelberg.de/apps/zmf/mirwalk/index.html) Last accessed July 2014, last release March 
2011.  
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Appendix	  1b	  
miRWalk search criteria for predicted miRNA targets (http://www.umm.uni-
heidelberg.de/apps/zmf/mirwalk/index.html) 11 March 2013. 
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Appendix	  1c	  
Predicted Targets of hsa-miR-483-5p as listed by the miRWalk database (http://www.umm.uni-
heidelberg.de/apps/zmf/mirwalk/index.html) 11 March 2013. 
 
Gene	   DIANAmT	   miRanda	   miRDB	   miRWalk	   RNA	  hybrid	   PICTAR4	   PICTAR5	   PITA	   RNA22	   Targetscan	  
Total	  
programs	  
predicting	  
target	  
ABCF2	   1	   1	   1	   1	   0	   0	   1	   0	   0	   1	   6	  
CLCN3	   1	   1	   1	   1	   0	   0	   1	   0	   0	   1	   6	  
UGT3A1	   1	   1	   1	   1	   0	   0	   1	   0	   0	   1	   6	  
A2ML1	   1	   1	   1	   1	   0	   0	   1	   0	   0	   1	   6	  
ZNF417	   1	   1	   1	   1	   0	   0	   1	   0	   0	   1	   6	  
ALCAM	   1	   1	   1	   1	   0	   0	   1	   0	   0	   1	   6	  
F2R	   1	   1	   1	   1	   0	   0	   1	   0	   0	   1	   6	  
ANKRD6	   1	   1	   1	   1	   0	   0	   1	   0	   0	   1	   6	  
RUSC1	   1	   1	   1	   1	   0	   0	   1	   0	   0	   1	   6	  
RNF165	   1	   1	   1	   1	   0	   0	   1	   0	   0	   1	   6	  
MRTO4	   1	   1	   1	   1	   0	   0	   1	   0	   0	   1	   6	  
PLA2G5	   1	   1	   1	   1	   0	   0	   1	   0	   0	   1	   6	  
MAPK3	   1	   1	   1	   1	   0	   0	   1	   0	   0	   1	   6	  
MRP63	   1	   1	   1	   1	   0	   0	   1	   0	   0	   1	   6	  
SLC7A3	   1	   1	   1	   1	   0	   0	   1	   0	   0	   1	   6	  
SLC35B4	   1	   1	   1	   1	   0	   0	   1	   0	   0	   1	   6	  
STC2	   1	   1	   1	   1	   0	   0	   1	   0	   0	   1	   6	  
MYOM2	   1	   1	   1	   1	   0	   0	   1	   0	   0	   1	   6	  
M6PRBP1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
COX4NB	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
PCGF3	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
KLF2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
SPON2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
PPIH	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
CRTAP	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
VAT1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
SEMA6C	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
SORBS1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
TGOLN2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
IGF2BP1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
ADCY1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
C1QL1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
LILRB3	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
TRIOBP	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
BTN3A2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
POLR3A	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
SLC2A6	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
PROSC	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
CA5B	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
GPR44	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
TEX261	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
CHRNA4	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	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Gene	   DIANAmT	   miRanda	   miRDB	   miRWalk	   RNA	  hybrid	   PICTAR4	   PICTAR5	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   RNA22	   Targetscan	  
Total	  
programs	  
predicting	  
target	  
CHRNA5	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
GPRIN1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
SMYD4	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
SLAMF6	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
OSBPL7	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
OSBPL10	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
KLHDC3	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
WDR92	   0	   1	   1	   1	   0	   0	   1	   0	   0	   1	   5	  
HSPA12B	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
SFXN4	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
FOXN4	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
PAQR4	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
RAVER1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
ZNF440	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
C19orf39	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
FBXO27	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
PUSL1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
B3GALT6	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
TPRG1L	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
TEDDM1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
COL4A4	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
TBC1D20	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
COL6A1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
C2orf60	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
MBOAT2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
TAF8	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
ICA1L	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
GALM	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
COPA	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
SLC31A1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
SHROOM1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
CPT1A	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
HGSNAT	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
RIMS4	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
KRT72	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
STK35	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
KDELC2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
SPTY2D1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
NOTUM	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
WIPF2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
HIPK4	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
C19orf55	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
PHF13	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
MFSD4	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
AANAT	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
HSCB	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
PNPLA5	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
CYB561	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
PLEKHG4B	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	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   miRWalk	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programs	  
predicting	  
target	  
C6orf151	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
C6orf129	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
ADRBK1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
FAM84B	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
C9orf66	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
CYP7A1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
USP54	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
MGC24039	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
DAPK1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
ZNF114	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
PAQR7	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
DHX8	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
KLHDC6	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
DFFA	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
ADAMTS17	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
DLX1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
DPYSL2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
SLC26A2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
E2F2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
EDA	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
CELSR2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
MEGF9	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
EIF4EBP2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
CC2D1B	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
C1orf69	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
APOBEC3F	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
TRIM65	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
FAM116A	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
TMEM184A	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
LGI3	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
C9orf90	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
EVC	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
EXTL3	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
C10orf56	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
ORAOV1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
DOK6	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
MS4A2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
LOC221091	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
KCTD20	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
SLC29A4	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
RASA3	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
MLXIP	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
NCBP2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
FOXC1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
IGSF9B	   0	   1	   1	   1	   0	   0	   1	   0	   0	   1	   5	  
FAIM2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
UNC13A	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
KIF21B	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
KIAA0082	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	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ARHGAP26	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
KIF1B	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
HIC2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
CAMTA2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
PLXND1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
IQCE	   0	   1	   1	   1	   0	   0	   1	   0	   0	   1	   5	  
SMG6	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
ANKS1A	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
WSCD1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
C22orf9	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
SATB2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
KIAA0323	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
PPP1R13B	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
SRGAP2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
PIP5K1C	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
ICMT	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
TTC9	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
SEC14L2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
CCRK	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
LDOC1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
SGK3	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
MTCH1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
FXN	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
FUT6	   1	   0	   1	   1	   0	   0	   1	   0	   0	   1	   5	  
ZNF620	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
EBF3	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
MSRB3	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
GABRB2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
RIPK5	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
TMEM184B	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
DKFZP434B0335	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
TRIM58	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
INTS7	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
C20orf194	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
GPR124	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
CHD5	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
UBXD7	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
TOR1AIP1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
CCDC9	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
GTPBP5	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
GMEB2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
PLDN	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
TSPAN17	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
MDGA1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
AMFR	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
GFAP	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
CACYBP	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
PDE7B	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
ZNF364	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	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GOLGA3	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
GPR3	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
LOC283331	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
LOC283514	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
C19orf63	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
KLK9	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
FAM83H	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
ZFP41	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
ILDR1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
MKNK2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
ACAD9	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
GRIN1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
GRM4	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
GSK3A	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
OLA1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
GUCA1B	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
REPIN1	   1	   0	   1	   1	   0	   0	   1	   0	   0	   1	   5	  
CCDC106	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
HDAC2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
HUNK	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
ST6GALNAC6	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
CDR2L	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
HIP1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
HNF4A	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
DDX51	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
APOF	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
XIAP	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
CCDC137	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
IRF8	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
IDS	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
STAC2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
IFNAR1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
PDDC1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
NUP43	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
SHROOM2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
IL10	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
AQP2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
IL12B	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
FOXK2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
ILF3	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
IVL	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
CD82	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
KCNA7	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
FAM73A	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
KCNJ5	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
KCNQ1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
LOC388969	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
IER5L	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
LAD1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	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LOC391356	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
LDLR	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
LEP	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
ARHGDIA	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
LIM2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
LMO1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
PHOX2A	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
C10orf132	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
MCM4	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
MEA1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
RAB8A	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
MLLT1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
ACHE	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
MPZ	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
MTHFR	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
NFIX	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
NFKBIL2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
NFYB	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
NKX2-­‐2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
NPTX2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
NTSR1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
ACO2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
PAFAH2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
SERPINE1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
PAX1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
ACOX1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
MRPS16	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
FIS1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
YARS2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
PHF20	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
TMEM69	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
PCSK2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
RBJ	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
TLR7	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
CD320	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
CDC40	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
GALNAC4S-­‐6ST	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
SNX9	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
PRRX2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
PDE6G	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
CTDSPL2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
LARS	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
CXXC5	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
PDGFRA	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
TRIM33	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
TMBIM4	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
SLC26A4	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
PIK3R2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
PLAGL2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	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PLEC1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
PNOC	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
C11orf24	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
CSNK1G1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
PCBP3	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
SMCR7L	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
RNF216	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
DGCR8	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
CCDC93	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
ANKRD16	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
GNL3L	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
HES2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
IL17RD	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
ALKBH4	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
KLHL28	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
ASPN	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
C2orf18	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
PIWIL2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
C20orf12	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
TMEM143	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
QRSL1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
CWF19L1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
RNF121	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
LSG1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
DHTKD1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
ELMOD1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
PLXNA3	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
YEATS2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
IPO9	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
N4BP2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
40787	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
PRKCA	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
LRP2BP	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
HR	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
FOXJ2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
WWC3	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
C1orf183	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
MAPK1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
BARX1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
MAP2K3	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
CRTAM	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
WDR45L	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
PRMT8	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
CYP26B1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
INPP5E	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
BARHL1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
SPHK2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
THAP10	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
NCLN	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	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RGMA	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
JPH2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
ZNFX1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
SLC45A4	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
JPH3	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
AICDA	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
PTGIS	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
CNOT6	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
KIAA1303	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
PTK6	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
SORCS2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
TMEM181	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
PITPNM2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
PTPN1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
GATAD1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
SLC4A5	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
PTPRS	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
PVRL1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
ZNF250	   0	   1	   1	   1	   0	   0	   1	   0	   0	   1	   5	  
RAB3B	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
RAB3IL1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
RAD23B	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
MESDC1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
REL	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
RPS6KA3	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
RSU1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
SALL2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
SCN2B	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
SCN4A	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
SCN4B	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
CCL25	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
NAPB	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
MUTED	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
TNN	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
XPNPEP3	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
ZNF667	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
PRDM16	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
FN3K	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
NOD2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
ZFYVE20	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
PDLIM2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
XPO4	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
ZFP106	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
C5orf28	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
NOM1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
SGTA	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
UNQ338	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
RAI16	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
IPPK	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	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C1orf176	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
MARCKSL1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
ZBTB8	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
SLC7A1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
BMPR2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
LRRC61	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
CHID1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
SMO	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
SNAPC1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
SOX4	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
SOX11	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
AKR1D1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
SSR3	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
STAT3	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
STAT5B	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
STK4	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
STXBP1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
BSG	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
KLF9	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
TBCD	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
TEAD1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
TERT	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
TFAP2B	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
TIMP2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
TPMT	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
C5AR1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
TYRO3	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
UBE2G1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
UPK1B	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
UGDH	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
UVRAG	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
XPC	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
ZKSCAN1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
ZNF70	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
PRRG4	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
FTO	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
FKRP	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
ALDH5A1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
GLB1L	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
FN3KRP	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
C22orf29	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
ZYG11B	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
LIN28	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
CLIP4	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
MAFK	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
TMC5	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
SNX22	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
ADM2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
ADCK4	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	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ZNF556	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
ZC3H12A	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
C4orf29	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
SPSB1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
MUS81	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
OPA3	   0	   1	   1	   1	   0	   0	   1	   0	   0	   1	   5	  
RAB11FIP1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
NUBPL	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
CXorf21	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
PDGFD	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
LRRC27	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
DNAJC5	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
TTYH3	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
ZBP1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
NDEL1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
SNX27	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
TMEM163	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
TRIM7	   1	   0	   1	   1	   0	   0	   1	   0	   0	   1	   5	  
RNF170	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
TRIM56	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
FAHD1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
GDF5	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
RP3-­‐402G11.5	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
CASP6	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
STK40	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
KREMEN1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
MAGT1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
CASP8	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
NICN1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
ING5	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
C10orf58	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
ACBD6	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
C16orf14	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
ARFGAP2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
ZNF594	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
GLIS2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
GPT2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
PIGO	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
CBX2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
CDC42BPA	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
MFSD9	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
RAX2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
C1orf198	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
NFATC2IP	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
ZNF587	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
ZNRF1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
MUM1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
HSH2D	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
RANBP3	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	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C18orf45	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
GCM1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
GAS7	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
BCAS1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
BARX2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
PRIC285	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
FHDC1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
SELI	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
MKNK1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
CAV2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
GTPBP10	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
OASL	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
PNPT1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
MBTPS1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
CBS	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
NAPA	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
PRPF4B	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
BSN	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
CCND2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
CDK5R2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
AP3D1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
SIGLEC10	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
NAV1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
NAV2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
KLHL6	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
KBTBD6	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
C16orf45	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
FAM105B	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
C19orf52	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
LYRM7	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
SYT7	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
DPP9	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
INA	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
KRT75	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
NEURL	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
ANKRD44	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
SLC28A2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
RSAD2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
RASL10B	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
SFRS2IP	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
SNX29	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
RIPPLY1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
DLG5	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
MSC	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
SOCS6	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
CCDC114	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
CIAO1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
ZNF264	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
KCNK6	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	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MAP4K4	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
HAND2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
PCYT1B	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
CHST3	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
ONECUT2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
SPTLC2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
RAB36	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
SH3PXD2A	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
FAM131B	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
SEMA3E	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
KIAA0562	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
IFT140	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
HDAC4	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
KIAA0513	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
KIAA0101	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
PJA2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
RBM19	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
CDC34	   1	   1	   0	   1	   0	   0	   1	   0	   0	   1	   5	  
GNE	   1	   1	   0	   1	   0	   0	   0	   0	   0	   1	   4	  
GNE	   1	   0	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
GJC1	   1	   1	   0	   1	   0	   0	   0	   0	   0	   1	   4	  
GJC1	   1	   0	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
IL18BP	   1	   1	   0	   1	   0	   0	   0	   0	   0	   1	   4	  
IL18BP	   1	   0	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
CDH12	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
WASF2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
ZNF197	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
CD96	   1	   1	   0	   1	   0	   0	   0	   0	   0	   1	   4	  
CD96	   1	   0	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
CDKN1A	   1	   1	   0	   1	   0	   0	   0	   0	   0	   1	   4	  
CDKN1A	   1	   0	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
ADARB1	   1	   0	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
ADARB1	   1	   1	   0	   1	   0	   0	   0	   0	   0	   1	   4	  
RBM14	   0	   1	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
TACC3	   1	   0	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
TRIM38	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
CEACAM5	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
NXF1	   0	   1	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
SLC34A2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
ZNF275	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
RALBP1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
SFRS2B	   0	   1	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
SLC27A4	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
ABHD2	   1	   0	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
ABHD2	   1	   1	   0	   1	   0	   0	   0	   0	   0	   1	   4	  
KLF12	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
TMEM106A	   1	   1	   0	   1	   0	   0	   0	   0	   0	   1	   4	  
GBP4	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
CISH	   1	   1	   0	   1	   0	   0	   0	   0	   0	   1	   4	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LRRC58	   0	   1	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
C20orf108	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
OLIG1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
PRAP1	   1	   0	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
CLCN6	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
TMEM132D	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
C15orf27	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
ZC3H18	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
CD300LB	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
ZFP3	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
GGT6	   1	   1	   0	   1	   0	   0	   0	   0	   0	   1	   4	  
GJD3	   0	   1	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
SHE	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
DMBX1	   0	   1	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
COL4A6	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
COL6A2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
BBS5	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
ADAT2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
SRrp35	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
CREBBP	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
MYO3B	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
ZBTB46	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
SMCR8	   0	   1	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
CRYAA	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
CSK	   1	   1	   0	   1	   0	   0	   0	   0	   0	   1	   4	  
CSK	   1	   0	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
CSN2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
PRIMA1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
C14orf145	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
NCAN	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
C18orf25	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
SLC35F3	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
SLC30A7	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
NFAM1	   0	   1	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
GPR155	   1	   0	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
GPR155	   1	   1	   0	   1	   0	   0	   0	   0	   0	   1	   4	  
ADRA2C	   0	   1	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
PRELID2	   1	   0	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
PRELID2	   1	   1	   0	   1	   0	   0	   0	   0	   0	   1	   4	  
ADRBK2	   0	   1	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
DBN1	   1	   1	   0	   1	   0	   0	   0	   0	   0	   1	   4	  
DBN1	   1	   0	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
KANK4	   0	   1	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
SPATA5	   0	   1	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
MIER3	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
CYB5R3	   1	   1	   0	   1	   0	   0	   0	   0	   0	   1	   4	  
DLX1	   1	   1	   0	   1	   0	   0	   0	   0	   0	   1	   4	  
DVL3	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
B3GNT6	   0	   1	   0	   1	   0	   0	   1	   0	   0	   1	   4	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LOC196993	   0	   1	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
GRAMD2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
ELK1	   1	   1	   0	   1	   0	   0	   0	   0	   0	   1	   4	  
RNF215	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
ERBB3	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
ESRRG	   1	   1	   0	   1	   0	   0	   0	   0	   0	   1	   4	  
ESRRG	   1	   0	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
C10orf27	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
FKTN	   1	   1	   0	   1	   0	   0	   0	   0	   0	   1	   4	  
SDK1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
FOXK1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
NAPEPLD	   1	   1	   0	   1	   0	   0	   0	   0	   0	   1	   4	  
TMEM130	   1	   1	   0	   1	   0	   0	   0	   0	   0	   1	   4	  
FEN1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
FGF2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
AAK1	   0	   1	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
FOXF1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
TPX2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
PCNX	   0	   1	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
KIAA0265	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
FOXO3	   0	   1	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
KIF1B	   1	   1	   0	   1	   0	   0	   0	   0	   0	   1	   4	  
IQSEC2	   1	   1	   0	   1	   0	   0	   0	   0	   0	   1	   4	  
IQSEC2	   1	   1	   0	   1	   0	   0	   0	   0	   0	   1	   4	  
CLASP2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
TTLL12	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
DIP2A	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
FBXL7	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
JMJD6	   0	   1	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
RRS1	   0	   1	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
ZFR2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
ANKRD12	   0	   1	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
VPS39	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
PSD3	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
POFUT1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
NUP62	   1	   1	   0	   1	   0	   0	   0	   0	   0	   1	   4	  
NUP62	   1	   0	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
HSPBP1	   1	   1	   0	   1	   0	   0	   0	   0	   0	   1	   4	  
HSPBP1	   1	   0	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
FXN	   1	   1	   0	   1	   0	   0	   0	   0	   0	   1	   4	  
ALPI	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
FUT6	   1	   1	   0	   1	   0	   0	   0	   0	   0	   1	   4	  
KDSR	   0	   1	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
GABRB3	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
HYPK	   0	   1	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
BACE2	   1	   1	   0	   1	   0	   0	   0	   0	   0	   1	   4	  
MMACHC	   0	   1	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
FBXW2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
TSPAN17	   1	   1	   0	   1	   0	   0	   0	   0	   0	   1	   4	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HS6ST3	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
GNGT2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
GPR1	   1	   1	   0	   1	   0	   0	   0	   0	   0	   1	   4	  
GPR1	   1	   0	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
SPRYD4	   1	   1	   0	   1	   0	   0	   0	   0	   0	   1	   4	  
C12orf61	   0	   1	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
KSR2	   0	   1	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
C14orf24	   1	   0	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
C14orf24	   1	   1	   0	   1	   0	   0	   0	   0	   0	   1	   4	  
C19orf63	   1	   1	   0	   1	   0	   0	   0	   0	   0	   1	   4	  
LOC285382	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
GPX3	   0	   1	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
GRB2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
GRLF1	   0	   1	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
RBM15B	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
SEC61A1	   0	   1	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
HDLBP	   1	   0	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
HDLBP	   1	   1	   0	   1	   0	   0	   0	   0	   0	   1	   4	  
HLA-­‐E	   1	   1	   0	   1	   0	   0	   0	   0	   0	   1	   4	  
ACACB	   0	   1	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
HOXC11	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
TMEM16J	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
ICAM4	   1	   1	   0	   1	   0	   0	   0	   0	   0	   1	   4	  
ARL16	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
KY	   0	   1	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
MYLK4	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
NRBP2	   1	   0	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
NANOS1	   0	   1	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
IFIT3	   1	   0	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
INPP5B	   0	   1	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
ITGA6	   1	   0	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
KIFC3	   1	   1	   0	   1	   0	   0	   0	   0	   0	   1	   4	  
VGLL3	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
SAMD5	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
LAIR2	   0	   1	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
ZNF793	   0	   1	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
FAM102A	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
SNX30	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
ZBTB34	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
HERV-­‐FRD	   0	   1	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
ARR3	   0	   1	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
ARSD	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
MARK3	   1	   1	   0	   1	   0	   0	   0	   0	   0	   1	   4	  
MECP2	   1	   0	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
MEF2D	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
MKLN1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
TRIM67	   0	   1	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
MTM1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
MYO1C	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	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MYO9B	   1	   1	   0	   1	   0	   0	   0	   0	   0	   1	   4	  
MYO9B	   1	   1	   0	   1	   0	   0	   0	   0	   0	   1	   4	  
NDUFS2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
NDUFV3	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
NGFR	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
NHS	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
P4HB	   1	   1	   0	   1	   0	   0	   0	   0	   0	   1	   4	  
NEUROG3	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
PARK2	   1	   1	   0	   1	   0	   0	   0	   0	   0	   1	   4	  
PAX2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
AK3	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
PCM1	   0	   1	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
KLHL5	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
IRAK4	   1	   1	   0	   1	   0	   0	   0	   0	   0	   1	   4	  
ZNF580	   1	   1	   0	   1	   0	   0	   0	   0	   0	   1	   4	  
CHMP1A	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
MGC29506	   0	   1	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
NRN1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
MEX3C	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
CUTA	   1	   1	   0	   1	   0	   0	   0	   0	   0	   1	   4	  
C7orf20	   0	   1	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
ATP6V1A	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
PHB	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
PHF2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
PIK3C2A	   0	   1	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
PANK1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
PLXNA2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
38596	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
POLA1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
EPB41L4B	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
L1TD1	   0	   1	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
PPARA	   1	   1	   0	   1	   0	   0	   0	   0	   0	   1	   4	  
PPARA	   1	   0	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
SLC6A20	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
DNAJB12	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
FAM29A	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
BIVM	   1	   0	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
YTHDF1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
C12orf41	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
PLEKHB2	   0	   1	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
PDPR	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
SRBD1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
DDX19A	   1	   0	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
WDR33	   1	   1	   0	   1	   0	   0	   0	   0	   0	   1	   4	  
PRELP	   1	   0	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
PRELP	   1	   1	   0	   1	   0	   0	   0	   0	   0	   1	   4	  
STAB2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
LUC7L	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
TSR1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
218 
 
Gene	   DIANAmT	   miRanda	   miRDB	   miRWalk	   RNA	  hybrid	   PICTAR4	   PICTAR5	   PITA	   RNA22	   Targetscan	  
Total	  
programs	  
predicting	  
target	  
FAM63A	   1	   0	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
MAPK3	   1	   1	   0	   1	   0	   0	   0	   0	   0	   1	   4	  
UBFD1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
PCDHB9	   0	   1	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
ANKH	   0	   1	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
LMOD3	   0	   1	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
RP5-­‐1022P6.2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
TMPRSS4	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
KIAA1191	   1	   1	   0	   1	   0	   0	   0	   0	   0	   1	   4	  
KIAA1191	   1	   0	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
WDR18	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
NDRG2	   1	   0	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
NDRG2	   1	   1	   0	   1	   0	   0	   0	   0	   0	   1	   4	  
SLC12A5	   1	   0	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
HECW2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
KIAA1549	   0	   1	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
PCDHB16	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
PURB	   0	   1	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
PLEKHA2	   0	   1	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
RGS12	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
RPS6KA2	   1	   0	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
RYR3	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
SC5DL	   1	   0	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
SC5DL	   1	   1	   0	   1	   0	   0	   0	   0	   0	   1	   4	  
ATXN1	   1	   0	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
ATXN1	   1	   1	   0	   1	   0	   0	   0	   0	   0	   1	   4	  
LOC63920	   0	   1	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
GFRA4	   1	   1	   0	   1	   0	   0	   0	   0	   0	   1	   4	  
GFRA4	   1	   0	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
ERAP2	   1	   1	   0	   1	   0	   0	   0	   0	   0	   1	   4	  
ERAP2	   1	   0	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
LOC643641	   0	   1	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
hCG_2040376	   0	   1	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
RABL5	   1	   1	   0	   1	   0	   0	   0	   0	   0	   1	   4	  
BMP3	   0	   1	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
MRPS34	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
SNAP25	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
SP4	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
SPAST	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
SPN	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
STAR	   1	   0	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
STXBP1	   1	   1	   0	   1	   0	   0	   0	   0	   0	   1	   4	  
TMPO	   1	   0	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
TMPO	   1	   1	   0	   1	   0	   0	   0	   0	   0	   1	   4	  
UBA1	   1	   1	   0	   1	   0	   0	   0	   0	   0	   1	   4	  
SLC35A2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
UTRN	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	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VDR	   1	   1	   0	   1	   0	   0	   0	   0	   0	   1	   4	  
WNT7B	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
ZNF19	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
ZNF215	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
ZYX	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
DNALI1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
EVI5	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
CACNB2	   1	   0	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
CACNB2	   1	   1	   0	   1	   0	   0	   0	   0	   0	   1	   4	  
ZNF655	   1	   0	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
ZNF655	   1	   1	   0	   1	   0	   0	   0	   0	   0	   1	   4	  
C7orf26	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
ATG9A	   1	   0	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
ATG9A	   1	   1	   0	   1	   0	   0	   0	   0	   0	   1	   4	  
METT10D	   0	   1	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
C20orf121	   1	   1	   0	   1	   0	   0	   0	   0	   0	   1	   4	  
C20orf121	   1	   0	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
PPP1R3B	   0	   1	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
ZNF669	   0	   1	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
DCAKD	   1	   1	   0	   1	   0	   0	   0	   0	   0	   1	   4	  
DCAKD	   1	   0	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
ZNF212	   0	   1	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
FOXRED2	   1	   1	   0	   1	   0	   0	   0	   0	   0	   1	   4	  
FOXRED2	   1	   0	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
FBXL18	   0	   1	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
ITIH5	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
KIAA1715	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
HM13	   0	   1	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
SLC38A1	   1	   0	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
NDEL1	   1	   1	   0	   1	   0	   0	   0	   0	   0	   1	   4	  
KAZALD1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
TRIM7	   1	   1	   0	   1	   0	   0	   0	   0	   0	   1	   4	  
VANGL1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
SCRT1	   1	   1	   0	   1	   0	   0	   0	   0	   0	   1	   4	  
TMUB1	   1	   0	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
FRMD8	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
PIP5K1A	   1	   0	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
TMPRSS13	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
KATNAL1	   1	   1	   0	   1	   0	   0	   0	   0	   0	   1	   4	  
KATNAL1	   1	   0	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
GPR103	   0	   1	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
RNASEH2C	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
SETD3	   0	   1	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
GPR123	   1	   0	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
L3MBTL3	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
ZNF527	   0	   1	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
SLC12A8	   0	   1	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
FBXL10	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
ATCAY	   0	   1	   0	   1	   0	   0	   1	   0	   0	   1	   4	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DNAJC14	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
TSPYL5	   0	   1	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
KHSRP	   0	   1	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
CAV2	   1	   1	   0	   1	   0	   0	   0	   0	   0	   1	   4	  
JRK	   0	   1	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
OASL	   1	   1	   0	   1	   0	   0	   0	   0	   0	   1	   4	  
CBL	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
STX11	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
SERPINB7	   1	   1	   0	   1	   0	   0	   0	   0	   0	   1	   4	  
SERPINB7	   1	   0	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
RGS11	   1	   0	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
RGS11	   1	   1	   0	   1	   0	   0	   0	   0	   0	   1	   4	  
TNFRSF10A	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
DPM2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
CACNA1I	   1	   1	   0	   1	   0	   0	   0	   0	   0	   1	   4	  
CACNA1I	   1	   0	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
RAB7L1	   1	   0	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
UBE3B	   1	   0	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
UBE3B	   1	   1	   0	   1	   0	   0	   0	   0	   0	   1	   4	  
LIMD1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
ZSWIM1	   0	   1	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
PSTPIP2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
COX19	   0	   1	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
HN1L	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
KIFC2	   0	   1	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
ACVR1B	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
CDKN2AIPNL	   0	   1	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
DCLK1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
ZMYM6	   0	   1	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
C4orf42	   0	   1	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
DLGAP2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
ZNF461	   0	   1	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
LYK5	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
MAPKAPK2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
MGC16385	   0	   1	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
EDG5	   0	   1	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
39873	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
ACCN3	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
C9orf61	   1	   1	   0	   1	   0	   0	   0	   0	   0	   1	   4	  
C9orf61	   1	   0	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
HAND1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
H2AFV	   0	   1	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
MED23	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
GOSR1	   1	   0	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
GOSR1	   1	   1	   0	   1	   0	   0	   0	   0	   0	   1	   4	  
PUNC	   0	   1	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
SOX13	   0	   1	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
ENTPD4	   1	   1	   0	   1	   0	   0	   0	   0	   0	   1	   4	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KIAA0226	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
NOS1AP	   1	   1	   0	   1	   0	   0	   0	   0	   0	   1	   4	  
KIAA0101	   1	   1	   0	   1	   0	   0	   0	   0	   0	   1	   4	  
MAML1	   0	   1	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
TATDN2	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
PLEKHM1	   0	   1	   0	   1	   0	   0	   1	   0	   0	   1	   4	  
NUAK1	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
SRGAP3	   1	   1	   0	   1	   0	   0	   1	   0	   0	   0	   4	  
MED6	   1	   1	   0	   0	   0	   0	   1	   0	   0	   1	   4	  
SFRS14	   1	   1	   0	   0	   0	   0	   1	   0	   0	   1	   4	  
LRRC56	   1	   1	   0	   0	   0	   0	   1	   0	   0	   1	   4	  
ZNF526	   1	   1	   0	   0	   0	   0	   1	   0	   0	   1	   4	  
TMEM45B	   1	   1	   0	   0	   0	   0	   1	   0	   0	   1	   4	  
MOBKL2A	   1	   1	   0	   0	   0	   0	   1	   0	   0	   1	   4	  
SRCRB4D	   1	   1	   0	   0	   0	   0	   1	   0	   0	   1	   4	  
ASB8	   1	   1	   0	   0	   0	   0	   1	   0	   0	   1	   4	  
C20orf151	   1	   1	   0	   0	   0	   0	   1	   0	   0	   1	   4	  
TTL	   1	   1	   0	   0	   0	   0	   1	   0	   0	   1	   4	  
C5orf41	   1	   1	   0	   0	   0	   0	   1	   0	   0	   1	   4	  
DLX2	   1	   1	   0	   0	   0	   0	   1	   0	   0	   1	   4	  
DSG3	   1	   1	   0	   0	   0	   0	   1	   0	   0	   1	   4	  
RHOBTB3	   1	   1	   0	   0	   0	   0	   1	   0	   0	   1	   4	  
SMG1	   1	   1	   0	   0	   0	   0	   1	   0	   0	   1	   4	  
ZC3H4	   1	   1	   0	   0	   0	   0	   1	   0	   0	   1	   4	  
ARHGEF9	   1	   1	   0	   0	   0	   0	   1	   0	   0	   1	   4	  
OTP	   1	   1	   0	   0	   0	   0	   1	   0	   0	   1	   4	  
TRIM29	   1	   1	   0	   0	   0	   0	   1	   0	   0	   1	   4	  
SHPK	   1	   1	   0	   0	   0	   0	   1	   0	   0	   1	   4	  
KIF4A	   1	   1	   0	   0	   0	   0	   1	   0	   0	   1	   4	  
BACE2	   1	   1	   0	   0	   0	   0	   1	   0	   0	   1	   4	  
PNKD	   1	   1	   0	   0	   0	   0	   1	   0	   0	   1	   4	  
KLHL3	   1	   1	   0	   0	   0	   0	   1	   0	   0	   1	   4	  
C1orf107	   1	   1	   0	   0	   0	   0	   1	   0	   0	   1	   4	  
SCARA5	   1	   1	   0	   0	   0	   0	   1	   0	   0	   1	   4	  
TUSC5	   1	   1	   0	   0	   0	   0	   1	   0	   0	   1	   4	  
PNMA3	   1	   1	   0	   0	   0	   0	   1	   0	   0	   1	   4	  
C16orf5	   1	   1	   0	   0	   0	   0	   1	   0	   0	   1	   4	  
PACSIN1	   1	   1	   0	   0	   0	   0	   1	   0	   0	   1	   4	  
ICAM4	   1	   1	   0	   0	   0	   0	   1	   0	   0	   1	   4	  
IL1R1	   1	   1	   0	   0	   0	   0	   1	   0	   0	   1	   4	  
IL13	   1	   1	   0	   0	   0	   0	   1	   0	   0	   1	   4	  
RHOA	   1	   1	   0	   0	   0	   0	   1	   0	   0	   1	   4	  
FLG2	   1	   1	   0	   0	   0	   0	   1	   0	   0	   1	   4	  
SH2D5	   1	   1	   0	   0	   0	   0	   1	   0	   0	   1	   4	  
MLLT6	   1	   1	   0	   0	   0	   0	   1	   0	   0	   1	   4	  
OSM	   1	   1	   0	   0	   0	   0	   1	   0	   0	   1	   4	  
C21orf58	   1	   1	   0	   0	   0	   0	   1	   0	   0	   1	   4	  
MRPS10	   1	   1	   0	   0	   0	   0	   1	   0	   0	   1	   4	  
VPS13D	   1	   1	   0	   0	   0	   0	   1	   0	   0	   1	   4	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PARL	   1	   1	   0	   0	   0	   0	   1	   0	   0	   1	   4	  
CCBL2	   1	   1	   0	   0	   0	   0	   1	   0	   0	   1	   4	  
C12orf5	   1	   1	   0	   0	   0	   0	   1	   0	   0	   1	   4	  
TBC1D24	   1	   1	   0	   0	   0	   0	   1	   0	   0	   1	   4	  
CPNE5	   1	   1	   0	   0	   0	   0	   1	   0	   0	   1	   4	  
PEX19	   1	   1	   0	   0	   0	   0	   1	   0	   0	   1	   4	  
WIZ	   1	   1	   0	   0	   0	   0	   1	   0	   0	   1	   4	  
SORT1	   1	   1	   0	   0	   0	   0	   1	   0	   0	   1	   4	  
UNKL	   1	   1	   0	   0	   0	   0	   1	   0	   0	   1	   4	  
SMARCD1	   1	   1	   0	   0	   0	   0	   1	   0	   0	   1	   4	  
TPM3	   1	   1	   0	   0	   0	   0	   1	   0	   0	   1	   4	  
TREML2	   1	   1	   0	   0	   0	   0	   1	   0	   0	   1	   4	  
ASRGL1	   1	   1	   0	   0	   0	   0	   1	   0	   0	   1	   4	  
CAPZB	   1	   1	   0	   0	   0	   0	   1	   0	   0	   1	   4	  
FAM83A	   1	   1	   0	   0	   0	   0	   1	   0	   0	   1	   4	  
KCNAB2	   1	   1	   0	   0	   0	   0	   1	   0	   0	   1	   4	  
STX16	   1	   1	   0	   0	   0	   0	   1	   0	   0	   1	   4	  
C12orf65	   1	   1	   0	   0	   0	   0	   1	   0	   0	   1	   4	  
C22orf32	   1	   1	   0	   0	   0	   0	   1	   0	   0	   1	   4	  
DSEL	   1	   1	   0	   0	   0	   0	   1	   0	   0	   1	   4	  
SNPH	   1	   1	   0	   0	   0	   0	   1	   0	   0	   1	   4	  
RUSC2	   1	   1	   0	   0	   0	   0	   1	   0	   0	   1	   4	  
KIF14	   1	   1	   0	   0	   0	   0	   1	   0	   0	   1	   4	  
IL18BP	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
B3GALT5	   0	   1	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
B3GALT5	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
B3GALT5	   0	   0	   0	   1	   0	   0	   1	   0	   0	   1	   3	  
ADARB1	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
SPON2	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
SORBS1	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
SORBS1	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
SORBS1	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
SORBS1	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
SORBS1	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
SORBS1	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
ERLIN1	   1	   1	   0	   1	   0	   0	   0	   0	   0	   0	   3	  
ERLIN1	   1	   0	   0	   1	   0	   0	   1	   0	   0	   0	   3	  
FUSIP1	   0	   1	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
LILRB3	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
STON1	   0	   0	   0	   1	   0	   0	   1	   0	   0	   1	   3	  
TRIOBP	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
DIDO1	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
ABCB8	   0	   1	   0	   1	   0	   0	   1	   0	   0	   0	   3	  
PHF21B	   1	   0	   0	   1	   0	   0	   1	   0	   0	   0	   3	  
DTX2	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
PALM2	   0	   1	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
PALM2	   0	   0	   0	   1	   0	   0	   1	   0	   0	   1	   3	  
CISH	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
CLCN3	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	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GGT6	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
DMBX1	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
COL6A2	   1	   1	   0	   1	   0	   0	   0	   0	   0	   0	   3	  
COPA	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
DNAJC21	   1	   1	   0	   1	   0	   0	   0	   0	   0	   0	   3	  
DNAJC21	   1	   0	   0	   1	   0	   0	   1	   0	   0	   0	   3	  
HINT3	   1	   1	   0	   1	   0	   0	   0	   0	   0	   0	   3	  
DNHD1	   0	   1	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
PRICKLE1	   1	   0	   0	   1	   0	   0	   1	   0	   0	   0	   3	  
CYB561	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
CYB561	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
PRELID2	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
C16orf82	   0	   0	   0	   1	   0	   0	   1	   0	   0	   1	   3	  
CYB5R3	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
CYB5R3	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
DIO2	   0	   1	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
DIO2	   0	   0	   0	   1	   0	   0	   1	   0	   0	   1	   3	  
EDA	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
P76	   0	   1	   0	   1	   0	   0	   1	   0	   0	   0	   3	  
ELK1	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
MUC20	   0	   0	   0	   1	   0	   0	   1	   0	   0	   1	   3	  
MUC20	   0	   1	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
EMP2	   0	   1	   0	   1	   0	   0	   1	   0	   0	   0	   3	  
TUBB	   1	   1	   0	   1	   0	   0	   0	   0	   0	   0	   3	  
ESRRG	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
ETV1	   1	   0	   0	   1	   0	   0	   1	   0	   0	   0	   3	  
EXT2	   1	   1	   0	   1	   0	   0	   0	   0	   0	   0	   3	  
CYBASC3	   1	   0	   0	   1	   0	   0	   1	   0	   0	   0	   3	  
ALDH3B1	   0	   0	   0	   1	   0	   0	   1	   0	   0	   1	   3	  
ALDH3B1	   0	   1	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
FKTN	   0	   0	   0	   1	   0	   0	   1	   0	   0	   1	   3	  
TMEM130	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
SLC29A4	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
FHL1	   1	   0	   0	   1	   0	   0	   1	   0	   0	   0	   3	  
ZNF365	   1	   0	   0	   1	   0	   0	   1	   0	   0	   0	   3	  
NCBP2	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
SPEN	   0	   1	   0	   1	   0	   0	   1	   0	   0	   0	   3	  
TNRC6B	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
SULF1	   0	   1	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
FBXO28	   0	   1	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
C22orf9	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
CRTC1	   0	   1	   0	   1	   0	   0	   1	   0	   0	   0	   3	  
BRD4	   0	   1	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
SLC39A14	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
SLC39A14	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
CCRK	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
CCRK	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
RUSC1	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
RUSC1	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	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RUSC1	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
NUP62	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
SGK3	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
SGK3	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
ALOX12B	   0	   1	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
MSRB3	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
TMCO4	   1	   0	   0	   1	   0	   0	   1	   0	   0	   0	   3	  
GABRB2	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
RIPK5	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
BACE2	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
THUMPD3	   0	   1	   0	   1	   0	   0	   1	   0	   0	   0	   3	  
PNKD	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
TSPAN17	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
ABL2	   0	   1	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
ABL2	   0	   0	   0	   1	   0	   0	   1	   0	   0	   1	   3	  
CACYBP	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
GNAO1	   0	   1	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
FLJ35848	   0	   0	   0	   1	   0	   0	   1	   0	   0	   1	   3	  
FAM80A	   0	   1	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
RNF212	   1	   1	   0	   1	   0	   0	   0	   0	   0	   0	   3	  
LOC285908	   0	   0	   0	   1	   0	   0	   1	   0	   0	   1	   3	  
DPY19L4	   0	   1	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
HIPK2	   0	   1	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
GRIN1	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
GRIN1	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
OLA1	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
REPIN1	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
HNF4A	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
7A5	   0	   1	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
ITGA6	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
CD82	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
C1orf95	   0	   1	   0	   1	   0	   0	   1	   0	   0	   0	   3	  
KCNJ16	   1	   1	   0	   1	   0	   0	   0	   0	   0	   0	   3	  
KCNJ16	   1	   0	   0	   1	   0	   0	   1	   0	   0	   0	   3	  
KCNK3	   0	   1	   0	   1	   0	   0	   1	   0	   0	   0	   3	  
KCNQ1	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
KIFC3	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
KIFC3	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
SH2D5	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
LRP3	   0	   1	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
MAFG	   1	   0	   0	   1	   0	   0	   1	   0	   0	   0	   3	  
MAFG	   1	   1	   0	   1	   0	   0	   0	   0	   0	   0	   3	  
MARK3	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
MARK3	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
MARK3	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
MCM4	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
MEF2A	   1	   1	   0	   1	   0	   0	   0	   0	   0	   0	   3	  
NEDD9	   0	   1	   0	   1	   0	   0	   1	   0	   0	   0	   3	  
NPM1	   0	   1	   0	   1	   0	   0	   1	   0	   0	   0	   3	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OAS3	   0	   1	   0	   1	   0	   0	   1	   0	   0	   0	   3	  
PARK2	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
PARK2	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
PAX2	   1	   1	   0	   1	   0	   0	   0	   0	   0	   0	   3	  
ACOX1	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
ZNF580	   0	   0	   0	   1	   0	   0	   1	   0	   0	   1	   3	  
ANKFY1	   1	   1	   0	   1	   0	   0	   0	   0	   0	   0	   3	  
TRIM33	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
CUTA	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
CUTA	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
CUTA	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
CUTA	   0	   0	   0	   1	   0	   0	   1	   0	   0	   1	   3	  
PGR	   0	   1	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
PLEC1	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
PLEC1	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
PLEC1	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
PLEC1	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
PLEC1	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
PCBP3	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
POLH	   0	   1	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
RNF216	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
POU6F1	   0	   1	   0	   1	   0	   0	   1	   0	   0	   0	   3	  
DNAJB12	   1	   1	   0	   1	   0	   0	   0	   0	   0	   0	   3	  
FLJ20184	   0	   1	   0	   1	   0	   0	   1	   0	   0	   0	   3	  
FLJ20309	   0	   1	   0	   1	   0	   0	   1	   0	   0	   0	   3	  
PPP2R5C	   1	   0	   0	   1	   0	   0	   1	   0	   0	   0	   3	  
C17orf85	   0	   0	   0	   1	   0	   0	   1	   0	   0	   1	   3	  
ZNF331	   1	   1	   0	   1	   0	   0	   0	   0	   0	   0	   3	  
ZNF331	   1	   0	   0	   1	   0	   0	   1	   0	   0	   0	   3	  
PARL	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
ELMOD1	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
LUC7L	   1	   1	   0	   1	   0	   0	   0	   0	   0	   0	   3	  
H2AFJ	   0	   1	   0	   1	   0	   0	   1	   0	   0	   0	   3	  
FAM63A	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
HR	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
C1orf183	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
KIAA1191	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
NDRG2	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
NDRG2	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
NDRG2	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
NDRG2	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
NDRG2	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
TMCC3	   0	   1	   0	   1	   0	   0	   1	   0	   0	   0	   3	  
PPM1H	   0	   1	   0	   1	   0	   0	   1	   0	   0	   0	   3	  
BEGAIN	   1	   0	   0	   1	   0	   0	   1	   0	   0	   0	   3	  
C8orf79	   0	   1	   0	   1	   0	   0	   1	   0	   0	   0	   3	  
PTPRS	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
PTPRS	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
GNB4	   0	   1	   0	   1	   0	   0	   1	   0	   0	   0	   3	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RSU1	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
SFRS4	   1	   1	   0	   1	   0	   0	   0	   0	   0	   0	   3	  
C10orf141	   0	   1	   0	   1	   0	   0	   1	   0	   0	   0	   3	  
HIF3A	   1	   0	   0	   1	   0	   0	   1	   0	   0	   0	   3	  
CTAGE1	   0	   1	   0	   1	   0	   0	   1	   0	   0	   0	   3	  
RABL5	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
RABL5	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
PLEKHG2	   0	   1	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
BMPR1B	   0	   1	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
SMARCD1	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
FSCN1	   1	   0	   0	   1	   0	   0	   1	   0	   0	   0	   3	  
SP100	   0	   1	   0	   1	   0	   0	   1	   0	   0	   0	   3	  
SSR1	   0	   1	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
STAR	   0	   1	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
STAT3	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
STAT3	   0	   1	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
BSG	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
BSG	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
SUPT5H	   1	   1	   0	   1	   0	   0	   0	   0	   0	   0	   3	  
SUPT5H	   1	   0	   0	   1	   0	   0	   1	   0	   0	   0	   3	  
SURF6	   0	   1	   0	   1	   0	   0	   1	   0	   0	   0	   3	  
C6orf35	   0	   1	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
UBA1	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
SLC35A2	   1	   1	   0	   1	   0	   0	   0	   0	   0	   0	   3	  
UCK2	   0	   1	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
CACNB2	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
CACNB2	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
CACNB2	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
CACNB2	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
ZNF655	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
FKRP	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
ALDH5A1	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
HMBOX1	   1	   0	   0	   1	   0	   0	   1	   0	   0	   0	   3	  
SH3TC2	   0	   1	   0	   1	   0	   0	   1	   0	   0	   0	   3	  
CXorf36	   1	   1	   0	   1	   0	   0	   0	   0	   0	   0	   3	  
GSTCD	   1	   1	   0	   1	   0	   0	   0	   0	   0	   0	   3	  
GSTCD	   1	   0	   0	   1	   0	   0	   1	   0	   0	   0	   3	  
ST7	   1	   0	   0	   1	   0	   0	   1	   0	   0	   0	   3	  
TMC5	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
TMC5	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
WWC2	   0	   1	   0	   1	   0	   0	   1	   0	   0	   0	   3	  
ASRGL1	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
PDGFD	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
PABPN1	   0	   1	   0	   1	   0	   0	   1	   0	   0	   0	   3	  
TRIM7	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
TRIM7	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
COLQ	   1	   1	   0	   1	   0	   0	   0	   0	   0	   0	   3	  
COLQ	   1	   0	   0	   1	   0	   0	   1	   0	   0	   0	   3	  
DNAL1	   0	   1	   0	   1	   0	   0	   0	   0	   0	   1	   3	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TM2D2	   1	   1	   0	   1	   0	   0	   0	   0	   0	   0	   3	  
CASP6	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
CASP8	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
CASP8	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
CASP8	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
CASP8	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
FBXL10	   1	   1	   0	   1	   0	   0	   0	   0	   0	   0	   3	  
PIGO	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
CDC42BPA	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
ZDHHC12	   0	   1	   0	   1	   0	   0	   1	   0	   0	   0	   3	  
SLC7A3	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
RANBP3	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
RANBP3	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
KCNAB2	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
GAS7	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
GAS7	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
GAS7	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
APOL1	   1	   0	   0	   1	   0	   0	   1	   0	   0	   0	   3	  
PRIC285	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
MKNK1	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
GTPBP10	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
STX16	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
AP3D1	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
NAV2	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
NAV2	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
CCDC149	   1	   1	   0	   1	   0	   0	   0	   0	   0	   0	   3	  
C19orf6	   1	   1	   0	   1	   0	   0	   0	   0	   0	   0	   3	  
ARHGEF2	   1	   0	   0	   1	   0	   0	   1	   0	   0	   0	   3	  
GPR56	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
GPR56	   0	   0	   0	   1	   0	   0	   1	   0	   0	   1	   3	  
ACCN3	   1	   1	   0	   1	   0	   0	   0	   0	   0	   0	   3	  
SNAP29	   0	   1	   0	   1	   0	   0	   1	   0	   0	   0	   3	  
EFTUD2	   1	   1	   0	   1	   0	   0	   0	   0	   0	   0	   3	  
TAOK2	   1	   1	   0	   1	   0	   0	   0	   0	   0	   0	   3	  
RECQL5	   1	   1	   0	   1	   0	   0	   0	   0	   0	   0	   3	  
RECQL5	   1	   1	   0	   1	   0	   0	   0	   0	   0	   0	   3	  
MAP4K4	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
GOSR1	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
ENTPD4	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
CLCA3	   0	   0	   0	   1	   0	   0	   1	   0	   0	   1	   3	  
FAM131B	   1	   0	   0	   1	   0	   0	   0	   0	   0	   1	   3	  
STARD8	   1	   0	   0	   1	   0	   0	   1	   0	   0	   0	   3	  
APPBP2	   1	   1	   0	   0	   0	   0	   1	   0	   0	   0	   3	  
PAICS	   1	   1	   0	   0	   0	   0	   1	   0	   0	   0	   3	  
DIDO1	   1	   1	   0	   0	   0	   0	   0	   0	   0	   1	   3	  
ADAMTS6	   1	   1	   0	   0	   0	   0	   1	   0	   0	   0	   3	  
DTX2	   1	   1	   0	   0	   0	   0	   0	   0	   0	   1	   3	  
DTX2	   1	   0	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
KLHDC7A	   1	   1	   0	   0	   0	   0	   1	   0	   0	   0	   3	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C7orf55	   1	   0	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
DFFA	   1	   1	   0	   0	   0	   0	   0	   0	   0	   1	   3	  
EFNB3	   1	   1	   0	   0	   0	   0	   1	   0	   0	   0	   3	  
CELSR3	   1	   0	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
TMEM16F	   1	   0	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
AKT2	   1	   0	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
NAPEPLD	   1	   1	   0	   0	   0	   0	   0	   0	   0	   1	   3	  
ZHX2	   1	   1	   0	   0	   0	   0	   1	   0	   0	   0	   3	  
TNRC6B	   1	   0	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
OTUD3	   1	   0	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
KIF13B	   1	   1	   0	   0	   0	   0	   1	   0	   0	   0	   3	  
ACSL6	   1	   0	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
NPHP4	   1	   0	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
FRAG1	   1	   0	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
BCL9L	   1	   0	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
C11orf77	   1	   0	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
REPIN1	   1	   1	   0	   0	   0	   0	   0	   0	   0	   1	   3	  
ANXA11	   1	   0	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
HTR4	   1	   1	   0	   0	   0	   0	   1	   0	   0	   0	   3	  
ICAM4	   1	   1	   0	   0	   0	   0	   0	   0	   0	   1	   3	  
IFIT3	   1	   1	   0	   0	   0	   0	   0	   0	   0	   1	   3	  
LCE1B	   1	   1	   0	   0	   0	   0	   1	   0	   0	   0	   3	  
SMAD3	   1	   1	   0	   0	   0	   0	   1	   0	   0	   0	   3	  
MECP2	   1	   1	   0	   0	   0	   0	   0	   0	   0	   1	   3	  
NOTCH2	   1	   0	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
PDE11A	   1	   1	   0	   0	   0	   0	   1	   0	   0	   0	   3	  
FZR1	   1	   0	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
SLC25A39	   1	   0	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
PKD1	   1	   1	   0	   0	   0	   0	   1	   0	   0	   0	   3	  
MTMR12	   1	   1	   0	   0	   0	   0	   1	   0	   0	   0	   3	  
RBM35A	   1	   1	   0	   0	   0	   0	   1	   0	   0	   0	   3	  
UQCC	   1	   0	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
PPP3CB	   1	   0	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
DPYSL5	   1	   1	   0	   0	   0	   0	   1	   0	   0	   0	   3	  
SLC44A2	   1	   1	   0	   0	   0	   0	   1	   0	   0	   0	   3	  
RPS6KA2	   1	   1	   0	   0	   0	   0	   0	   0	   0	   1	   3	  
SP1	   1	   1	   0	   0	   0	   0	   1	   0	   0	   0	   3	  
VAMP1	   1	   1	   0	   0	   0	   0	   1	   0	   0	   0	   3	  
TBL1X	   1	   1	   0	   0	   0	   0	   1	   0	   0	   0	   3	  
TMEM1	   1	   1	   0	   0	   0	   0	   1	   0	   0	   0	   3	  
VDR	   1	   0	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
DERL1	   1	   1	   0	   0	   0	   0	   1	   0	   0	   0	   3	  
C14orf45	   1	   1	   0	   0	   0	   0	   1	   0	   0	   0	   3	  
SLC7A5	   1	   1	   0	   0	   0	   0	   1	   0	   0	   0	   3	  
SLC38A1	   1	   1	   0	   0	   0	   0	   0	   0	   0	   1	   3	  
ELL	   1	   0	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
ARID5B	   1	   0	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
LL22NC03-­‐75B3.6	   1	   0	   0	   0	   0	   0	   1	   0	   0	   1	   3	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KIAA1754	   1	   1	   0	   0	   0	   0	   1	   0	   0	   0	   3	  
AOC3	   1	   1	   0	   0	   0	   0	   1	   0	   0	   0	   3	  
BRSK2	   1	   1	   0	   0	   0	   0	   1	   0	   0	   0	   3	  
RICS	   1	   0	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
RNF144A	   1	   1	   0	   0	   0	   0	   1	   0	   0	   0	   3	  
HS3ST3B1	   1	   1	   0	   0	   0	   0	   1	   0	   0	   0	   3	  
CDH5	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
CTDSP2	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
STX6	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
WDR68	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
ABCC4	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
TRDN	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
CORO2B	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
CDIPT	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
MXD4	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
ZBTB6	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
CPLX1	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
METAP2	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
AKAP13	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
MAN1B1	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
MGAT4A	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
FOXP4	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
LOC116349	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
OSCAR	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
DHRS13	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
CSTB	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
SYT6	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
CYP2B6	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
C9orf97	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
REM2	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
DBT	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
HBEGF	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
DUSP5	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
AHR	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
TET3	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
ANKRD23	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
AK1	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
EPHA4	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
LEMD2	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
TFEC	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
VASH1	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
NMNAT2	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
GARNL4	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
FOSB	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
KCNE1L	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
STXBP4	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
FLJ25778	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
GABRA3	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
USP49	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	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WSB1	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
LRRC32	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
PHGDH	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
TNRC6A	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
GNAT1	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
FLJ39743	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
GSTM5	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
HOXB2	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
AQP6	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
KPNA1	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
ZNF321	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
PIM3	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
MCAM	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
PPP1R12B	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
NCL	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
ORC2L	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
P2RX5	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
PAFAH1B1	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
PALM	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
MRPL30	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
PHF21A	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
KLF13	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
FXYD7	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
DLL4	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
POU4F2	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
C1orf181	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
KIF1A	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
C9orf167	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
TMEM104	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
MAGOHB	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
CDCA8	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
P15RS	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
LGI2	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
SMPD3	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
HIF1AN	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
CENPN	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
AGPAT3	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
CAMK1D	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
MAN1C1	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
PBXIP1	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
CYP20A1	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
REXO1	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
KIAA1377	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
C20orf77	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
RFC3	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
CX3CL1	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
SFRP1	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
SLC1A2	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
SMTN	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	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WNK2	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
SLC8A2	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
PHACTR4	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
TROVE2	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
TEF	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
TGFA	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
TIMP3	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
TNFSF4	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
CLIP2	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
MOBKL2B	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
MAP6D1	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
TRIM45	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
CCDC6	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
EFHD1	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
TRABD	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
ANKRD13C	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
USP48	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
RAB11FIP4	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
PPP1R9B	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
ARHGAP19	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
REPS1	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
SSH2	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
BHLHB2	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
FAM125B	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
CLDN2	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
BCL7B	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
TRIP13	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
CD28	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
TMEM203	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
IER2	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
SPOCK2	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
FARP2	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
TOMM70A	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
TMCC2	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
KBTBD11	   0	   1	   0	   0	   0	   0	   1	   0	   0	   1	   3	  
 
